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Advances in medicine and our understanding of human biology have led to an increase in 
longevity, while the rise of contraceptives has led to a decrease in fertility rates. These two 
factors will lead to an increased proportion of older adults in the world population [1]. While 
longevity is in itself incredibly valuable, increased age is unfortunately often associated with 
health problems. These health problems consist primarily of non-communicable chronic 
diseases, including type 2 diabetes, disability, cancer, cardiovascular disease and cognitive 
decline. As a consequence, the increase in life expectancy is expected to lead to increased 
costs of health care, while the population that can support these health care costs is expected 
to diminish [2]. 
 An important strategy to deal with population aging has been to promote healthy 
aging; not only to prevent mounting health care costs, but also to maintain independence 
and quality of life of older populations for as long as possible. Aging is thought to be 
caused by a gradual accumulation of molecular and cellular damage [3]. However, aging 
is not necessarily a steady decline towards impaired physiological performance due to 
this damage, but rather a gradual decline in the ability to handle stressors and decreased 
reserves to handle cellular and molecular damage [4]. These stressors include for example 
smoking, a large high fat meal, but also physical activity or lack thereof. The healthy aging 
phenotype can be described as not only the absence of disease, but also a preserved ability 
to handle stressors [4]. While healthy aging is partly beyond our control due to for example 
genetic traits, maintaining a healthy lifestyle over the life course, specifically with regard to 
nutrition and physical activity, is a key component of healthy aging [5, 6]. 
Frailty and Sarcopenia
A phenotype that is close to the opposite of the healthy aging phenotype is the frail phenotype 
[4]. Frailty is characterised by a decreased resistance to stressors, leading to increased risk 
of adverse health outcomes, and is prevalent (~9.6–10.2%) among older populations [7, 
8]. Fried et al. defined five characteristics for frailty: unintended weight loss, exhaustion, 
weakness, slow gait speed and low physical activity [9]. While frailty encompasses a wide 
variety of factors, a major component of (physical) frailty is sarcopenia: age-related loss of 
muscle mass. Sarcopenia and frailty overlap; generally frail individuals exhibit sarcopenia 
and sarcopenic individuals are often frail [10]. A related term to sarcopenia is dynapenia, the 
age-related loss of muscle strength [11]. 
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Figure 1.1 – Trajectories of muscle function in the frail and healthy ageing phenotypes. 
 Decreased muscle size and strength, as is the case with physical frailty and 
sarcopenia, has been associated with a wide variety of negative health outcomes, including 
increased risk of hospitalization, physical disability and even death [12-14]. In figure 1.1 
the trajectory associated with the healthy aging phenotype and the frail phenotype are 
contrasted with regard to muscle function. Although muscle mass and muscle strength 
are correlated, it has been argued that loss of muscle strength is a more important risk 
factor among older populations than muscle mass [11, 14]. Various factors are implicated 
in the cause of age-related loss of muscle mass and strength, highlighting the complexity 
of sarcopenia and dynapenia. Contributing factors that have been suggested include 
hormonal changes, physical inactivity, decreased satellite cell counts, insuff icient energy and 
protein intake, vitamin D deficiency, shift s in muscle fibre type proportions, mitochondrial 
dysfunction, inflammation (‘inflammaging’) and decreased response to anabolic stimuli 
(anabolic resistance) [15-17]. 
Muscle atrophy
Repeated periods of muscle disuse due to hospitalization and disease (bed rest) or bone 
fractures (limb immobilization) can also significantly contribute to frailty, sarcopenia and 
dynapenia. Short periods of muscle disuse can lead to rapid losses of muscle mass and 
strength [18]. For example, five days of knee immobilization among young healthy volunteers 
led to a drop of ~3.5% in muscle cross-sectional area and a ~8.5% drop in muscle strength 
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who have a decreased capacity to regain these losses [20-22]. Over the lifetime these losses 
of muscle mass and strength can accumulate, particularly among older individuals [23]. 
Limiting the losses during muscle disuse is of vital importance to manage the aging trajectory 
of muscle function and to maintain muscle health in later stages of life (figure 1.2). 
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Figure 1.2 – Trajectories of muscle function with or without muscle disuse events
 Muscle atrophy occurs when there is an imbalance in muscle protein synthesis 
and muscle protein breakdown. In the case of anabolic resistance, mentioned previously, 
the anabolic response to dietary protein is diminished, leading to a net loss in muscle mass 
over longer periods of time [17]. By contrast, cancer cachexia, the wasting of skeletal muscle 
due to cancer, can lead to a dramatic increase in muscle protein breakdown [24]. Due to 
the diff iculty of measuring the balance between muscle protein synthesis and breakdown 
over prolonged periods of time, some discussion exists which is dominant in muscle atrophy 
due to disuse [25]. Potential mechanisms for muscle protein breakdown include autophagy, 
apoptosis, calpains and ubiquitin mediated proteolysis [26, 27]. Of these mechanisms, 
ubiquitin mediated proteolysis has been the most studied in skeletal muscle. However, each 
of these mechanisms may be involved in muscle atrophy and degree of their involvement 
likely depends on the underlying cause of muscle loss. 
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Preventing muscle loss
Various strategies have been proposed to attenuate muscle losses due to disuse and age. 
Strategies that are effective in enhancing muscle performance and size in athletes may be 
especially useful as countermeasures. Resistance-type exercise training is one of the most 
effective ways of enhancing muscle mass and strength among older populations [28-30]. The 
beneficial effects of resistance-type exercise training are, in general, enhanced when training 
is combined with increased energy and protein intake [31]. Unfortunately, resistance-type 
exercise training is in some cases not an option, such as for example when an individual 
is hospitalized or when a leg is fully immobilized due to a fracture. In these cases, other 
measures are required to prevent muscle losses. Other possible interventions to prevent 
muscle loss include pharmacological interventions, such as anabolic androgenic steroids 
and selective androgen receptor modulators, as well as stimulating muscle contractions 
using neuromuscular electrical stimulation [32]. 
 Possible nutritional strategies to combat muscle loss are protein supplementation 
and supplementation with bioactive compounds (for instance creatine, leucine, β-Hydroxy 
β-Methylbutyrate and ursolic acid) [33, 34]. Undernutrition among older adults is also 
associated with decreased muscle mass and strength [35]. Vitamin D deficiency in particular 
has been studied as a contributing factor to age-related muscle loss. Several observational 
studies have found a link between vitamin D status and muscle function [36-40]. However, it 
is still unclear how vitamin D affects muscle function [41]. In the context of muscle loss due to 
muscle disuse, creatine supplementation has shown promise either by attenuating muscle 
loss during immobilization or by enhancing muscle gain during resistance-type exercise 
training after knee immobilization [42, 43].
Transcriptomics and metabolomics
Age, nutrition and exercise can have a wide range of effects in skeletal muscle at the molecular 
level. Exercise alone can affect various pathways and metabolic processes in the muscle, 
depending on the type, intensity and duration of the exercise [44, 45]. Similar heterogeneity 
can be observed in the processes affected by aging, nutrition and muscle atrophy. The 
use of high throughput ~omics techniques allows for simultaneous investigation of the 
various processes involved by measuring a large amount of genes, proteins or metabolites 
simultaneously. Both transcriptomics and metabolomics will be employed in this thesis.
 Previously, in the case of transcriptomics, activity specific genes were measured 
individually using qPCR or northern blots. Transcriptomic techniques, such as microarrays or 
RNA-seq, measure approximately mRNA of 20.000 human genes in a single sample. Measuring 
the transcriptional activity of (almost) all known genes not only allows for quantification of 
familiar genes, but also to measure the activity of genes not previously associated with a certain 
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affected by a certain upstream regulator (such as a hormone, transcription factor or chemical) 
can shed light on the effect of an intervention or stimulus on larger cellular processes rather 
than individual genes. Transcriptomics has been used in the study of nutrition, exercise and 
pharmacological compounds and has especially proven invaluable in the study of the broad 
but subtle effects of nutrition, due to the maturity of the platforms [46, 47].
 A newer development has been the field of metabolomics. Metabolomics primarily 
pertains to all small molecules and metabolites that occur in human metabolism [48]. These 
metabolites represent a fingerprint of cellular processes.  The tissue metabolome is generally 
closer to the phenotype, allowing for the investigation of cellular processes in more detail, 
particularly energy metabolism, whereas the transcriptome represents the regulatory state 
of a cell or tissue [49]. The development and validation of metabolomics profiling of skeletal 
muscle allows for the application of this technology in in the context of muscle function [50]. 
Thesis outline
 The effect of age, frailty and physical activity on the function and size of skeletal 
muscle is complex. A better understanding of the molecular mechanisms involved can 
provide new insights in potential strategies to maintain muscle function over the life course. 
This thesis aims to investigate these mechanisms and processes that underlie the effects 
of age, frailty and physical activity by leveraging the sensitivity and comprehensiveness of 
transcriptomics and metabolomics. Additionally, two potential nutritional strategies that 
can improve muscle function are investigated using transcriptomics. 
 In chapter 2 and 3 the differences between frail older adults, healthy older adults and 
young individuals in the muscle metabolome and transcriptome are explored. Furthermore, 
the effects of resistance-type exercise on the muscle transcriptome and metabolome serve 
as ‘benchmark’ of a positive influence on muscle function. In chapter 2 the focus is on the 
transcriptome, whereas in chapter 3 the focus is placed on the metabolome. Chapter 4 
explores the effect of knee immobilization on the muscle transcriptome and metabolome. 
Creatine supplementation is evaluated as strategy to attenuate muscle losses during knee 
immobilization. Chapter 5 investigates the effects of vitamin D (calcifediol) supplementation 
as potential strategy to improve muscle function among frail older adults. Chapter 6 
provides a comparison between knee immobilization and bed rest with regard to the muscle 
transcriptome. Furthermore, additional publically available datasets on physical inactivity 
models are explored and compared to identify a human signature of muscle atrophy. Various 
forms of muscle disuse are compared with the signature of frailty (described in chapter 2) to 
identify a potential surrogate model for age-related muscle loss. Lastly, chapter 7 provides 
an overall discussion of the results presented in this thesis, as well as future perspectives.
CHAPTER 1                    
16
GENERAL INTRODUCTION
17
Ch
ap
te
r 1References
1. United Nations, World Population Ageing. 2013: New York.
2. Salomon, J.A., et al., Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for 
the Global Burden Disease Study 2010. The Lancet, 2012. 380(9859): p. 2144-2162.
3. Kirkwood, T.B.L., A systematic look at an old problem. Nature, 2008. 451(7179): p. 644-647.
4. Franco, O.H., et al., Changing course in ageing research: The Healthy Ageing Phenotype. Maturitas, 
2009. 63(1): p. 13-19.
5. Kiefte-de Jong, J.C., J.C. Mathers, and O.H. Franco, Nutrition and healthy ageing: the key ingredients. 
Proc Nutr Soc, 2014. 73(2): p. 249-59.
6. Hamer, M., K.L. Lavoie, and S.L. Bacon, Taking up physical activity in later life and healthy ageing: the 
English longitudinal study of ageing. British Journal of Sports Medicine, 2014. 48(3): p. 239-243.
7. Fulop, T., et al., Aging, frailty and age-related diseases. Biogerontology, 2010. 11(5): p. 547-563.
8. Collard, R.M., et al., Prevalence of Frailty in Community-Dwelling Older Persons: A Systematic Review. 
Journal of the American Geriatrics Society, 2012. 60(8): p. 1487-1492.
9. Fried, L.P., et al., Frailty in Older Adults: Evidence for a Phenotype. The Journals of Gerontology 
Series A: Biological Sciences and Medical Sciences, 2001. 56(3): p. M146-M157.
10. Cruz-Jentoft, A.J., et al., Sarcopenia: European consensus on definition and diagnosisReport of the 
European Working Group on Sarcopenia in Older PeopleA. J. Cruz-Gentoft et al. Age and Ageing, 2010. 
39(4): p. 412-423.
11. Clark, B.C. and T.M. Manini, Sarcopenia≠ dynapenia. The Journals of Gerontology Series A: 
Biological Sciences and Medical Sciences, 2008. 63(8): p. 829-834.
12. Visser, M., et al., Muscle Mass, Muscle Strength, and Muscle Fat Infiltration as Predictors of Incident 
Mobility Limitations in Well-Functioning Older Persons. The Journals of Gerontology: Series A, 2005. 
60(3): p. 324-333.
13. Janssen, I., S.B. Heymsfield, and R. Ross, Low Relative Skeletal Muscle Mass (Sarcopenia) in Older 
Persons Is Associated with Functional Impairment and Physical Disability. Journal of the American 
Geriatrics Society, 2002. 50(5): p. 889-896.
14. Newman, A.B., et al., Strength, But Not Muscle Mass, Is Associated With Mortality in the Health, Aging 
and Body Composition Study Cohort. The Journals of Gerontology: Series A, 2006. 61(1): p. 72-77.
15. Mitchell, W.K., et al., Sarcopenia, Dynapenia, and the Impact of Advancing Age on Human Skeletal 
Muscle Size and Strength; a Quantitative Review. Frontiers in Physiology, 2012. 3: p. 260.
16. Malafarina, V., et al., Sarcopenia in the elderly: Diagnosis, physiopathology and treatment. Maturitas, 
2012. 71(2): p. 109-114.
17. Breen, L. and S.M. Phillips, Skeletal muscle protein metabolism in the elderly: Interventions to 
counteract the ‘anabolic resistance’ of ageing. Nutrition & Metabolism, 2011. 8(1): p. 68.
18. Wall, B., M. Dirks, and L. van Loon, Skeletal muscle atrophy during short-term disuse: implications for 
age-related sarcopenia. Ageing Research Reviews, 2013. 12(4): p. 898-906.
19. Wall, B., et al., Substantial skeletal muscle loss occurs during only 5 days of disuse. Acta Physiologica 
Scandinavica, 2013. 210(3): p. 600-11.
CHAPTER 1                    
18
20. Covinsky, K.E., et al., Loss of independence in activities of daily living in older adults hospitalized with 
medical illnesses: increased vulnerability with age. J Am Geriatr Soc, 2003. 51(4): p. 451-8.
21. Hirsch, C.H., et al., The natural history of functional morbidity in hospitalized older patients. J Am 
Geriatr Soc, 1990. 38(12): p. 1296-303.
22. Visser, M., et al., Change in muscle mass and muscle strength after a hip fracture: relationship to 
mobility recovery. J Gerontol A Biol Sci Med Sci, 2000. 55(8): p. M434-40.
23. English, K.L. and D. Paddon-Jones, Protecting muscle mass and function in older adults during bed 
rest. Current Opinion in Clinical Nutrition and Metabolic Care, 2010. 13(1): p. 34-39.
24. Evans, W.J., Skeletal muscle loss: cachexia, sarcopenia, and inactivity. The American Journal of 
Clinical Nutrition, 2010. 91(4): p. 1123S-1127S.
25. Reid, M.B., A.R. Judge, and S.C. Bodine, CrossTalk opposing view: The dominant mechanism causing 
disuse muscle atrophy is proteolysis. The Journal of Physiology, 2014. 592(24): p. 5345-5347.
26. Bonaldo, P. and M. Sandri, Cellular and molecular mechanisms of muscle atrophy. Disease Models 
&amp; Mechanisms, 2013. 6(1): p. 25-39.
27. Jackman, R.W. and S.C. Kandarian, The molecular basis of skeletal muscle atrophy. American 
Journal of Physiology - Cell Physiology, 2004. 287(4): p. C834-C843.
28. Peterson, M.D., A. Sen, and P.M. Gordon, Influence of Resistance Exercise on Lean Body Mass in Aging 
Adults: A Meta-Analysis. Medicine and science in sports and exercise, 2011. 43(2): p. 249-258.
29. Peterson, M.D., et al., Resistance exercise for muscular strength in older adults: A meta-analysis. 
Ageing Research Reviews, 2010. 9(3): p. 226-237.
30. Aagaard, P., et al., Role of the nervous system in sarcopenia and muscle atrophy with aging: strength 
training as a countermeasure. Scandinavian Journal of Medicine & Science in Sports, 2010. 20(1): 
p. 49-64.
31. Cermak, N.M., et al., Protein supplementation augments the adaptive response of skeletal muscle to 
resistance-type exercise training: a meta-analysis. The American Journal of Clinical Nutrition, 2012. 
96(6): p. 1454-1464.
32. English, K.L., et al., Leucine partially protects muscle mass and function during bed rest in middle-
aged adults. The American Journal of Clinical Nutrition, 2016. 103(2): p. 465-473.
33. Morley, J.E., et al., Nutritional recommendations for the management of sarcopenia. Journal of the 
American Medical Directors Association, 2010. 11(6): p. 391-396.
34. Sakuma, K. and A. Yamaguchi, Novel Intriguing Strategies Attenuating to Sarcopenia. Journal of 
Aging Research, 2012. 2012: p. 11.
35. Morley, J.E., Undernutrition in older adults. Family Practice, 2012. 29(suppl_1): p. i89-i93.
36. Visser, M., D.J.H. Deeg, and P. Lips, Low Vitamin D and High Parathyroid Hormone Levels as 
Determinants of Loss of Muscle Strength and Muscle Mass (Sarcopenia): The Longitudinal Aging 
Study Amsterdam. The Journal of Clinical Endocrinology & Metabolism, 2003. 88(12): p. 5766-5772.
37. Bischoff-Ferrari, H.A., et al., Effect of Vitamin D on Falls: A Meta-analysis. Journal of the American 
Medical Association, 2004. 291(16): p. 1999-2006.
GENERAL INTRODUCTION
19
Ch
ap
te
r 138. Bischoff-Ferrari, H.A., et al., Higher 25-hydroxyvitamin D concentrations are associated with better 
lower-extremity function in both active and inactive persons aged ≥60 y. The American Journal of 
Clinical Nutrition, 2004. 80(3): p. 752-758.
39. Houston, D.K., et al., Association Between Vitamin D Status and Physical Performance: The InCHIANTI 
Study. The Journals of Gerontology: Series A, 2007. 62(4): p. 440-446.
40. Tajar, A., et al., The association of frailty with serum 25-hydroxyvitamin D and parathyroid hormone 
levels in older European men. Age and Ageing, 2013. 42(3): p. 352-359.
41. Ceglia, L. and S.S. Harris, Vitamin D and Its Role in Skeletal Muscle. Calcified Tissue International, 
2013. 92(2): p. 151-162.
42. Johnston, A.P., et al., Effect of creatine supplementation during cast-induced immobilization on the 
preservation of muscle mass, strength, and endurance. The Journal of Strength & Conditioning 
Research, 2009. 23(1): p. 116-120.
43. Hespel, P., et al., Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and 
alters the expression of muscle myogenic factors in humans. The Journal of physiology, 2001. 536(2): 
p. 625-633.
44. Wernbom, M., J. Augustsson, and R. Thomeé, The Influence of Frequency, Intensity, Volume and 
Mode of Strength Training on Whole Muscle Cross-Sectional Area in Humans. Sports Medicine, 2007. 
37(3): p. 225-264.
45. Egan, B. and Juleen R. Zierath, Exercise Metabolism and the Molecular Regulation of Skeletal Muscle 
Adaptation. Cell Metabolism, 2013. 17(2): p. 162-184.
46. van Ommen, B. and R. Stierum, Nutrigenomics: exploiting systems biology in the nutrition and 
health arena. Current Opinion in Biotechnology, 2002. 13(5): p. 517-521.
47. Afman, L. and M. Müller, Nutrigenomics: From Molecular Nutrition to Prevention of Disease. Journal 
of the American Dietetic Association, 2006. 106(4): p. 569-576.
48. Daviss, B., Growing pains for metabolomics: the newest’omic science is producing results--and more 
data than researchers know what to do with. The Scientist, 2005. 19(8): p. 25-29.
49. Fiehn, O., Metabolomics — the link between genotypes and phenotypes, in Functional Genomics, C. 
Town, Editor. 2002, Springer Netherlands: Dordrecht. p. 155-171.
50. Alves, R.D., et al., Global profiling of the muscle metabolome: method optimization, validation and 
application to determine exercise-induced metabolic effects. Metabolomics, 2015. 11(2): p. 271-285.
Chapter 2 - Expression of protocadherin gamma in skeletal
muscle tissue is associated with age and muscle
weakness
Roland W.J. Hangelbroek*
Parastoo Fazelzadeh*
Michael Tieland
Mark V. Boekschoten
Guido J.E.J. Hooiveld
John P.M. van Duynhoven
James A. Timmons
Lex B. Verdijk
Lisette C.P.G.M. de Groot
Luc J.C. van Loon
Michael Müller
*Both authors contributed equally
Published in Journal of Cachexia, Sarcopenia and Muscle (2016)
DOI: 10.1002/jcsm.12099
Omslag Final v2.2.pdf   3   9-11-2017   20:08:42
Chapter 2 - Expression of protocadherin gamma in skeletal
muscle tissue is associated with age and muscle
weakness
Roland W.J. Hangelbroek*
Parastoo Fazelzadeh*
Michael Tieland
Mark V. Boekschoten
Guido J.E.J. Hooiveld
John P.M. van Duynhoven
James A. Timmons
Lex B. Verdijk
Lisette C.P.G.M. de Groot
Luc J.C. van Loon
Michael Müller
*Both authors contributed equally
Published in Journal of Cachexia, Sarcopenia and Muscle (2016)
DOI: 10.1002/jcsm.12099
Omslag Final v2.2.pdf   3   9-11-2017   20:08:42
22
CHAPTER 2
Abstract
The skeletal muscle system plays an important role in the independence of older adults. 
In this study we examine differences in the skeletal muscle transcriptome between healthy 
young and older subjects and (pre-)frail older adults. Additionally, we examine the effect of 
resistance-type exercise training on the muscle transcriptome in healthy older subjects and 
(pre-)frail older adults. 
 Baseline transcriptome profiles were measured in muscle biopsies collected from 
53 young, 73 healthy older subjects and 61 frail older subjects. Follow-up samples from these 
frail older subjects (31 samples) and healthy older subjects (41 samples) were collected after 
6 months of progressive resistance-type exercise training. Frail older subjects trained twice 
per week and the healthy older subjects trained three times per week.
 At baseline genes related to mitochondrial function and energy metabolism were 
differentially expressed between older and young subjects, as well as between healthy 
and frail older subjects. 307 genes were differentially expressed after training in both 
groups. Training affected expression levels of genes related to extracellular matrix, glucose 
metabolism and vascularization. Expression of genes that were modulated by exercise 
training were indicative of muscle strength at baseline. Genes that strongly correlated with 
strength belonged to the protocadherin gamma gene cluster (r=-0.73).
 Our data suggest significant remaining plasticity of ageing skeletal muscle to adapt 
to resistance-type exercise training. Some age-related changes in skeletal muscle gene 
expression appear to be partially reversed by prolonged resistance-type exercise training. 
The protocadherin gamma gene cluster may be related to muscle denervation and re-
innervation in ageing muscle.
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Introduction
The number of people aged above 65 has increased rapidly over the past few decades, and 
is likely to increase progressively [1]. Because senescence is associated with a wide range of 
afflictions, including physical disability, cancer, heart disease and diabetes, the demand for 
care for older people will further increase. The loss of skeletal muscle mass and function with 
aging leads to frailty and results in the loss of independence of older adults. 
 Frailty, and related sarcopenia, are very complex and many factors contribute 
to their aetiology. This includes physical inactivity, malnutrition, hormonal changes and 
changes within the muscle [2-4]. Mitochondrial function decreases with age [5], fast-twitch 
muscle fibres demonstrate a smaller cross-sectional area [6], protein synthesis capacity is 
reduced [7], anabolic signals are less effective [8, 4], and there are fewer satellite cells to 
regulate adaptive responses to stimuli [9]. Muscle cells of older adults can also undergo 
continuous cycles of denervation and reinnervation, which can lead to both weakness and 
loss of muscle mass [10, 11].  
 One of the most effective strategies to improve muscle mass and strength in adults 
is physical exercise [9, 12]. Resistance-type exercise is particularly suitable to curtail muscle 
loss and muscle weakness in older people. In accordance, quality of life is improved after 
participating in resistance-type exercise training [13]. Some even claim that resistance-type 
exercise training reverses ageing in skeletal muscle [14]. 
 To elucidate some of these complex processes that occur in skeletal muscle during 
ageing, we examined the effects of prolonged resistance-type exercise training in frail and 
healthy older subjects on the skeletal muscle transcriptome. By comparing genome-level 
gene expression in frail and pre-frail older subjects, healthy older subjects and young 
subjects we aim to better understand the molecular causes of frailty. Secondly, we aimed to 
determine the effect of resistance-type exercise training on the skeletal muscle transcriptome 
in both frail and healthy older people. 
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Methods
Experimental Design
We collected a total of 259 muscle biopsy samples from pre-frail and frail older subjects (61 
subjects, 92 samples), healthy older subjects (73 subjects, 114 samples) and young males (53 
subjects, 53 samples). Some of these samples were follow-up samples taken after 24 weeks 
of resistance-type exercise training (31 samples from the frail older subjects, 41 samples from 
the healthy older subjects). Training for both groups was similar and consisted of progressive 
full-body resistance-type exercise training. However, the frail older group had training 
sessions twice per week, whereas the healthy older group trained three times per week. In 
addition, subjects took a protein or control drink for the duration of the study. The healthy 
older group received a 15 gram portion of milk protein or control supplement at breakfast. 
The frail older group received a similar drink containing 15 gram supplement drink (milk 
protein or control) at breakfast and lunch. More details can be found in the respective papers 
[15, 16]. Table 2.1 shows the characteristics of our study population at baseline. Table 2.2 
shows the effect of the training intervention on the older subjects that were included in this 
study and where follow-up data is available.
Table 2.1 – Subject characteristics of the baseline only subjects. FE = frail older subjects, HE = healthy older 
subjects, YO = young male subjects.
 FE HE YO
N (male / female) 24 / 6 27 / 5 53 / 0
Age (years) 79.8 ± 8.9 74.1 ± 4.5 21.3 ± 2.4
Height (m) 1.71 ± 0.09 1.73 ± 0.08 1.84 ± 0.06
Weight (kg) 80 ± 12.4 75.9 ± 12.9 76.5 ± 10.3
BMI (kg / m2)
27.3 ± 4.2 25.2 ± 3.2 22.6 ± 3
Body Fat (%) 28.8 ± 7.2 23.4 ± 5.5 15.4 ± 4.6
Lean Mass (kg) 52.1 ± 6.3 55.5 ± 8.6 61.9 ± 6
Leg Extension 1RM (kg) 65 ± 20 68 ± 17 124 ± 20
Leg Press 1RM (kg) 127 ± 31 155 ± 41 203 ± 36
Subjects
Biopsies from frail and pre-frail  older subjects were collected from participants of two studies 
performed by Tieland et al. [15, 17]. For these studies frail and pre-frail older subjects were 
selected based on the Fried criteria for frailty [2]. These subjects will hereafter be referred to 
as frail older subjects. These characteristics are unintentional weight loss, weakness, self-
reported exhaustion, slow walking speed, and low physical activity. Subjects in the healthy 
older group were not considered frail by any of these criteria at the start of the intervention 
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study [16]. Several additional baseline samples from healthy older subjects were collected 
from several studies from our group [18, 19]. These samples were taken before any 
intervention was undertaken and serve as additional reference samples. Baseline samples 
from young subjects were from healthy male subjects [20]. These were also taken before 
any intervention took place and serve as reference samples. All studies were approved by 
the medical ethical committee of either Wageningen University or Maastricht University and 
comply with the Declaration of Helsinki.
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Figure 2.1 A and B – Change of leg extension 1RM after prolonged exercise training for each individual. Left are 
frail elderly subjects, right are healthy elderly subjects. 
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Figure 2.2 A and B – Change of lean body mass after prolonged exercise training for each individual. Left are frail 
older subjects, right are healthy older subjects.
Table 2.2 – Subject characteristics of the subjects with before and after samples. FE = frail older subjects, HE 
= healthy older subjects, YO = young male subjects. * indicates a significant effect of resistance-type exercise 
training (p < 0.05). 
 FE pre FE post HE pre 0HE post
N (male / female) 11 / 20 26 / 15
Age (years) 76.5 ± 7.0 69.9 ± 5.0
Height (m) 1.66 ± 0.09 1.71 ± 0.09
Weight (kg) 78.5 ± 13.6 79.6 ± 14.1* 76.7 ± 13.2 77.1 ± 13.2
BMI (kg / m2) 28.5 ± 4.1 29 ± 4.3 * 26.1 ± 2.8 26.2 ± 2.8
Body Fat (%) 36.7 ± 8.5 36.6 ± 8.8 25.9 ± 5.9 24.4 ± 5.9 *
Lean Mass (kg) 46.1 ± 10.0 46.9 ± 9.9 * 54.6 ± 11.1 56.0 ± 11.3 *
Leg Extension 1RM (kg) 59 ± 18 81 ± 24 * 81 ± 17 114 ± 23 *
Leg Press 1RM (kg) 130 ± 35 178 ± 49 * 179 ± 40 230 ± 50 *
27
EXPRESSION OF PROTOCADHERIN GAMMA IN SKELETAL 
MUSCLE TISSUE IS ASSOCIATED WITH AGE AND MUSCLE WEAKNESS
Ch
ap
te
r 2
Muscle biopsy
Muscle samples were obtained with a 5 mm Bergstrom muscle biopsy needle from the m. 
vastus lateralis, after local anaesthesia of the skin and fascia. Samples were freed from any 
visible blood and non-muscle tissue and immediately frozen in liquid nitrogen and then 
stored at -80° C. All samples were obtained in the morning, in an overnight fasted state, with 
at least 3 days of no heavy physical activity.
Sample preparation and microarray analysis
Total RNA was isolated from the skeletal muscle tissue by using Trizol reagent (Invitrogen, 
Breda, Netherlands). Thereafter RNA was purified using the Qiagen RNeasy Micro kit (Qiagen, 
Venlo, Netherlands) and RNA quality was checked using an Agilent 2100 bioanalyzer (Agilent 
Technologies, Amsterdam, Netherlands). Total RNA (100 ng) was labelled using an Ambion 
WT expression kit (Life Technologies, Bleiswijk, Netherlands) and hybridized to human whole 
genome Genechip Human Gene 1.1 ST arrays coding 19.732 genes, (Affymetrix, Santa Clara, 
CA). Sample labelling, hybridization to chips and image scanning was performed according 
manufacturer’s instructions.
Data analysis
Microarray signals were normalized using robust multichip average (RMA). Data was filtered 
using Universal exPression Codes filtering (UPC) with a 50% cut-off, corresponding to a 50% 
likelihood that a gene is expressed [21]. Significant differences of individual genes were 
tested using the limma R library [22]. Baseline differences were tested between the three 
groups (frail older, healthy older or young) . Our model included gender, supplementation 
and group. For the effect of exercise we included subject, gender, time and supplementation 
in the model. The training effect for frail older and healthy older subjects was analysed 
separately due to differences in training frequency. P-values were adjusted using false 
discovery rate (FDR) [23]. A q-value below 0.05 was considered significant. Pathway analyses 
were performed using Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, www.qiagen.
com/ingenuity) on the filtered dataset with the UPC filtered genes used as the background. 
A sparse partial least squares (sPLS) model for leg extension 1RM was made using the caret 
R library [24]. The dataset was split into a training set (75%) and a testing set (25%) before 
fitting the model using cross-validation. This model was validated using 10 times repeated 
10-fold cross-validation. Final number of components for the sPLS model selected by grid 
search was 3. Principal Component Analysis (PCA) was performed using the FactoMineR R 
library [25]. Plots were made using the R libraries ggplot2 and gplots [26, 27].
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Results
Baseline differences in transcriptome
Large differences in gene expression profiles between young and older adults (healthy and 
frail) were found, with the expression of 5228 genes significantly differentially expressed 
between young subjects and both groups of older subjects. However, fold changes of 
the majority of these genes were relatively subtle, which suggested small but consistent 
differences between these groups. Only 825 genes out of these 5228 genes showed fold 
changes higher than 1.2. Venn-diagrams can be found in supplementary figures S2.1A and 
S2. 1B. The top 20 genes that were significantly different at baseline between the three 
groups are presented in table 2.3. Top canonical pathways reported by IPA include oxidative 
phosphorylation, TCA cycle and glucose metabolism (supplementary figure S2.2).
Table 2.3 – Top 20 genes significantly different between young and old. FE = frail older subjects, HE = healthy 
older subjects, YO = young men.
Gene
FC FE vs. 
HE
FC FE vs. 
YO
FC HE vs. 
YO
q-value FE 
vs. HE
q-value FE 
vs. YO
q-0alue HE 
vs. YO
IGFN1 -1.12 -6.43 -5.71 0.64 0.00 0.00
UNC13C 1.07 6.20 5.78 0.60 0.00 0.00
MYLK4 -1.35 -5.13 -3.81 0.07 0.00 0.00
C12orf75 1.45 4.54 3.13 0.01 0.00 0.00
SLC38A1 -1.11 -3.50 -3.14 0.55 0.00 0.00
HCN1 1.16 3.36 2.90 0.30 0.00 0.00
MYH8 1.16 3.28 2.83 0.50 0.00 0.00
CFAP61 1.36 3.39 2.49 0.00 0.00 0.00
NR4A3 -1.86 -3.70 -2.00 0.02 0.00 0.00
FAM83B 1.11 2.91 2.63 0.39 0.00 0.00
DAAM2 -1.06 -2.51 -2.36 0.42 0.00 0.00
NNMT 1.33 2.71 2.04 0.03 0.00 0.00
ZNF382 1.21 -2.09 -2.54 0.05 0.00 0.00
TPPP3 1.33 2.62 1.97 0.01 0.00 0.00
COL28A1 1.07 2.36 2.20 0.42 0.00 0.00
METTL21EP 1.05 -2.19 -2.29 0.78 0.00 0.00
HIST1H3E 1.11 -2.08 -2.30 0.30 0.00 0.00
SNORD115-32 1.02 2.17 2.14 0.91 0.00 0.00
SERPINA5 1.04 -2.11 -2.19 0.89 0.00 0.00
METTL21C 1.98 2.84 1.44 0.00 0.00 0.03
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Table 2.4 shows the top 20 genes that were different between healthy and frail older subjects 
at baseline. Top genes included METTL21C, FRZB and non-coding RNA. Pathways that were 
significantly different between the frail and healthy older subjects were related to glucose 
metabolism and RNA processing (supplementary figure S2.2). In general, expression of genes 
related to glucose metabolism were lower in both frail older and healthy older subjects 
compared to young, with frail older subjects showing the lowest expression of the groups. 
Principal Component Analysis (PCA) summarizes this observation, where the healthy older 
subjects seemed to be between the frail older subjects and the young subjects on the first two 
components (supplementary figure S2.3 and S2.4). While pathways related to mitochondrial 
function were some of the most significantly affected pathways, the fold changes of the 
individual mitochondrial genes were relatively small. Fold changes for these mitochondrial 
genes were in the range of 1.1 and 1.2. 
Table 2.4 – Top 20 genes significantly different between the frail elderly and the healthy elderly at baseline. 
FE = frail older subjects, HE = healthy older subjects.
Gene FC FE vs. HE q-value FE vs. HE
METTL21C 1.98 0.00
NR4A3 -1.86 0.02
VTRNA1-1 -1.71 0.00
MIR206 1.58 0.00
SNORA38B -1.58 0.00
S100A8 1.51 0.04
FRZB -1.48 0.03
HES1 -1.47 0.00
P2RY13 1.46 0.00
MIR133B 1.45 0.01
C12orf75 1.45 0.01
SNORA60 -1.44 0.00
SNORD60 -1.43 0.00
LYZ 1.43 0.03
SNORD80 -1.42 0.00
SNORD82 -1.42 0.00
SNORD29 -1.41 0.00
EVI2B 1.40 0.01
UPK3A -1.40 0.00
ID1 -1.40 0.00
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Effect of prolonged resistance-type exercise training
Prolonged resistance-type exercise training showed a significant effect on the gene 
expression profiles in both frail and healthy older people (431 and 1395 significantly changed 
genes, respectively). 307 genes were changed in both groups after resistance-type exercise 
training. Changes in expression of all these overlapping genes were in the same direction. A 
table with the top 20 genes changed by training is presented in table 2.5. Training resulted 
in the differential expression levels of many genes that are related to the connective tissue 
and the extracellular matrix, including collagen genes and laminin genes, suggesting 
significant tissue remodelling due to the training. Upstream analysis using IPA showed that 
TGF-β signalling-related genes were significantly activated in both groups, primarily due to 
the increased expression of collagen and laminin genes (supplementary figure S2.5). Other 
significant genes include myofibrillar proteins such as myosin heavy chain isoforms and 
troponin isoforms. 
 Genes related to glucose metabolism shifted away from the expression levels of the 
older subjects at baseline towards the levels of the younger phenotype. This trend is reflected 
in many other genes, where the majority of genes significantly changed by exercise training 
shifted towards ‘younger’ expression levels (325 genes out of 431 in the frail older subjects, 
1106 out of 1395 in the healthy older subjects). Figure 2.3 shows a heat map of 184 genes 
that are significantly changed by training in both groups and are significant when comparing 
young with either frail or healthy older  subjects. Most of these genes shift towards younger 
levels.
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Table 2.5 – Top 20 genes significantly different in both frail elderly and healthy elderly subjects after training. 
FE = frail older subjects, HE = healthy older subjects.
Gene FC FE training FC HE training q-value FE training q-value HE training
FRZB 1.97 1.55 0.00 0.00
IGFN1 1.58 1.80 0.04 0.00
MYLK4 1.45 1.69 0.01 0.00
COL3A1 1.45 1.68 0.01 0.00
ANKRD2 -1.44 -1.61 0.01 0.00
THBS4 1.34 1.66 0.05 0.00
PFKFB3 1.61 1.38 0.01 0.01
COL4A1 1.35 1.46 0.00 0.00
CAPN6 1.37 1.45 0.03 0.00
COL1A2 1.35 1.45 0.03 0.00
EDNRB 1.24 1.56 0.01 0.00
GCNT2 -1.51 -1.28 0.00 0.00
CFAP61 -1.24 -1.54 0.03 0.00
C12orf75 -1.42 -1.33 0.01 0.00
CCDC80 1.34 1.40 0.03 0.00
OLFML2B 1.38 1.34 0.00 0.00
SPARC 1.28 1.44 0.00 0.00
COL4A2 1.32 1.37 0.00 0.00
LGI1 -1.31 -1.33 0.02 0.00
ACOT11 -1.30 -1.34 0.04 0.00
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Figure 2.3 – heatmap of 184 genes that are significantly diff erent between young and older subjects, and are 
significantly changed by prolonged resistance-type exercise training in both groups. 
To further analyse the relationship between the 307 genes that are robustly aft er training 
in both groups changed (q-value < 0.05) we performed sPLS regression to calculate leg 
extension 1RM based on gene expression in the baseline samples. The aim was to evaluate 
whether diff erences in expression of the genes that were changed by training represent the 
overall strength of the muscle at baseline. The samples obtained aft er training were excluded 
for this analysis. A plot of the predicted leg extension 1RM strength against the measured 
leg extension 1RM strength is presented in figure 2.4. Gene importance for the final model is 
presented in table 2.6. Cross-validation mean R2 of the model was 0.73, the mean RMSE was 
17.7. The RMSE for the withheld testing set was 19.1. The top genes contributing to the model 
include genes from the protocadherin gamma gene cluster, CTNNBIP1, C20orf26 (CFAP61), 
C12orf75 and USP54. We calculated the eigengene for all protocadherin gamma genes and 
correlated this eigengene with leg extension 1RM. The protocadherin gamma eigengene 
showed a strong direct negative correlation (Pearson r = -0.73) with 1RM leg extension 
strength. A plot of this negative correlation is presented in supplementary figure S2.7.
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Figure 2.4 – Scatter plot of predicted leg extension 1RM of the baseline samples using sPLS and the actual 
measured 1RM. Red dots indicate samples that were part of the testing data set (25% of the total data set). 
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Table 2.6 – Variable importance and coefficients of the top 20 variables for the sPLS model.
Gene Variable Importance Coefficient
CFAP61 100 -1.94
PCDHGA10 99.3 -0.83
PCDHGB5 97.5 -1.18
PCDHGB1 95.1 -1.02
CTNNBIP1 91.9 1.13
USP54 90.6 -0.86
PCDHGA8 83.5 -0.91
PCDHGB7 82.4 -0.80
MYOZ2 81.3 -0.61
PCDHGA11 78.5 -0.64
C12orf75 78.2 -0.82
PCDHGA7 77.8 -0.86
PCDHGA2 76.4 -0.92
HEXIM2 76.0 0.24
GRSF1 75.2 0.39
GCNT2 75.1 -1.07
FBP2 72.3 0.26
PLEKHO1 68.5 0.24
CRY2 68.1 -1.60
PABPC4 67.5 0.85
Discussion
In this study we compared the transcriptomes of skeletal muscle of healthy young, healthy 
older, and frail older subjects to better understand the skeletal muscle related part of the frail 
phenotype. A schematic overview of our findings is presented in figure 2.5. To our knowledge 
this is the first study investigating the effect of age on the muscle transcriptome to include 
frail and pre-frail older subjects. We observed clear and pronounced differences at baseline 
between young and older subjects. In our data frailty seems to present itself in the muscle 
transcriptome primarily as a more advanced stage of ageing (see also supplementary figures 
S2.3 and S2.4). This may, at least partly, be due to the higher average age of the frail group. 
There is, however, still significant overlap in age due to the high variation in age in both 
groups (79.8 ± 8.9, 74.1 ± 4.5 mean age and standard deviation for frail and healthy older 
subjects respectively, table 2.1 and 2.2). 
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Figure 2.5 – Schematic summary of our findings. 
Baseline differences between young and older subjects
There were significant diff erences in genes related to mitochondrial function and oxidative 
phosphorylation (supplementary figure S2.2). It is well known that mitochondrial function is 
impaired in older adults [5] which can be a responsive feature to muscle inactivity [28] and 
mitochondrial protein carbonylation [29]. In this case the average expression of mitochondrial 
genes is lowest in the frail older subjects at baseline. These expression diff erences may also 
represent a lower abundance of mitochondria [6]. 
 There are two genes among the top diff erentially expressed genes between the 
three baseline groups that are as yet unknown, C20orf26 (CFAP61) and C12orf75. Both these 
genes have a higher expression levels in the older subjects and training appears to attenuate 
expression of these genes. Not much is known about the function of CFAP61 except that it is 
highly expressed in skeletal muscle tissue and may be related to calcium signalling and/or 
energy conversion [30]. C12orf75 may be related to cell proliferation and stem cell signalling 
[31].
 In our data frail subjects showed significantly higher expression levels of METTL21C 
when compared to both the young and healthy older subjects, with a greater fold change 
diff erence between healthy and frail subjects than between the young and the older subjects 
(table 2.5). Training decreases the mean expression of METTL21C in both groups, but this 
does not reach significance using our significance cut-off . However, in the frail group it does 
reach a q-value of 0.08 aft er training, showing a fold change of -1.58. METTL21C encodes 
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for a protein-lysine methyltransferase belonging to a group of proteins that are involved 
in methylation of chaperone proteins, where METTL21C appears to methylate HSP70 and 
HSP90 [32] and has recently been found to be associated with skeletal muscle development 
[33]. In vitro inhibition of METTL21C expression in myoblasts showed impaired myotube 
differentiation and calcium signalling, suggesting that METTL21C plays an important role in 
the function of muscle cells and possibly also the overall quality of the muscle. 
Effect of prolonged resistance-type exercise training
The majority of genes that significantly changed following prolonged resistance-type exercise 
training showed a shift in the expression levels towards levels observed in the younger group 
(figure 2.3). A previous study has shown a similar effect[14]. Indeed, Melov et al. state that 
training reverses the effect of ageing. While there is a shift towards younger expression levels, 
this does not necessarily mean that there is reversal of ageing. A more likely explanation 
is that the skeletal muscle in these older subjects have been ‘detrained’ due to more 
sedentary lifestyle when compared with healthy younger controls. Physical inactivity is a 
major contributor to age-related muscle loss and weakness and is one of the criteria of frailty 
[2]. In this way participation in prolonged resistance-type exercise training is likely to shift 
gene expression to younger levels. Furthermore, in our data the young subjects had higher 
muscle strength (table 2.1). Training leads to subtle but consistent changes in the muscle 
transcriptome [34]. Thus, a shift towards younger expression levels would be consistent with 
the increased strength after more prolonged resistance-type exercise training. 
 The genes that shift towards younger expression levels include genes related 
to the extracellular matrix, vascularisation, glucose metabolism and muscle contraction 
(supplementary figures S2.2, S2.5 and S2.6). The muscle biopsies were taken at least three 
days after the last training session. Thus, we are not observing acute effects of a single bout 
of resistance-type exercise, but rather longer term consistent changes in gene expression. 
Notably absent among the changes induced by prolonged resistance-type exercise training, 
however, are the primary differences observed when we compare young and older subjects: 
mitochondrial function. Possible explanations are that these changes are too subtle to pick up 
after 24 weeks of resistance-type exercise training or that prolonged resistance-type exercise 
training does not significantly affect these genes. Timing of the muscle biopsies relative to the 
last training session may also be a factor. It may be that expression of these mitochondrial 
genes only change acutely after resistance-type exercise rather than chronically.
 Prolonged resistance-type exercise training showed fewer significantly affected 
genes in the frail group. Part of this can be explained by the differences in treatment. The 
healthy older subjects had training sessions three times per week whereas the frail older 
subjects received two sessions per week. The load of the training was also lower in for the frail 
subjects. However, it may also be that the frail are less capable of adapting to the additional 
stress of prolonged resistance-type exercise training. Fortunately, the frail subjects still 
showed a significant response to the training stimulus despite their less adaptive phenotype 
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[2]. Others have already reported that older adults in general have a decreased response to 
resistance-type exercise on a transcriptome level [35], and this may also play a role in the 
smaller response in the frail older subjects compared to the healthy older subjects. 
Gene expression and muscle strength
Prolonged resistance-type exercise training led to strength increases in all individuals 
to the point that training increased strength levels in the frail older subjects close to the 
levels observed in the healthy older subjects at baseline (Figure 2.1). However, it did not 
necessarily lead to increases in lean body mass in all individuals (figure 2.2). This suggests 
that we primarily observed an increase in muscle quality, cross-bridge cycling efficiency, 
calcium handling and/or neuromuscular adaptation rather than an increase in muscle cross-
sectional area. Our data provide evidence suggesting disturbances in axon guidance and 
muscle innervation in the older subjects. 
 We performed sPLS regression analysis to calculate leg strength based on expression 
levels of the genes that are robustly changed after prolonged exercise training in both groups 
in the baseline samples. Our rationale was that since these genes are changed in both groups 
after training, where the leg extension 1RM is significantly higher, that expression of these 
genes could also reflect muscle strength at baseline without training.  We were able to build a 
reasonably accurate regression model to calculate leg extension 1RM at baseline based on gene 
expression (mean cross-validation R2 of 0.73 and RMSE of 17.7, figure 2.4). Thus, expression of 
the genes robustly changed by exercise also seems to be indicative of muscle strength, not 
only after training but also prior to prolonged exercise training. This suggests that expression of 
these genes may be used as a biomarker to training status prior to study entry.
 Several of the most important variables in our sPLS model for muscle strength 
belonged to the protocadherin gene cluster. Genes of the protocadherin gamma gene cluster 
were significantly different between frail older subjects, healthy older subjects and young 
subjects at baseline. Expression of these genes also went down after training in both groups. 
Older subjects had higher expression of this gene than young subjects and expression was 
highest in the frail older subjects. There are good indications that this gene cluster is relevant 
for neuromuscular performance. Many of the genes from this cluster are also significantly 
changed after training in both groups. Protocadherin gamma genes ranked very highly in the 
variable importance for our correlative model for leg extension 1RM (table 2.6).
 Protocadherin gamma genes are primarily expressed in neural tissues such as the 
brain and the spinal cord and appears to be involved in axonal guidance [36]. Protocadherin 
proteins show homeophilic binding to other protocadherin proteins and in this way these 
proteins provide recognition sites for axonal binding. By expressing different protocadherin 
gamma genes from the gene cluster axons can be guided to different locations [37]. In 
knockout mice these genes appear to be indirectly related to muscle function: knock-out 
mice show severe muscle weakness and tremors, although this is attributed to loss of spinal 
motor neurons [38, 39]. It may also be that it is expressed at the muscle side of the synapse 
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to facilitate axon guidance towards muscle, and increased expression in this case is due to 
the denervation-reinnervation cycles seen in ageing muscle. Therefore, we hypothesise that 
as muscle loses innervation it increases expression of the protocadherin gamma cluster to 
facilitate axon binding from other nerves.
 Protocadherin gamma is not the only significant group of genes related to 
neuromuscular function that we found in our data. There are several other genes differentially 
expressed between frail and healthy older subjects that are related to the innervation of 
muscle, including acetylcholine esterase (AChE) and kyphoscoliosis peptidase (KY). Both play 
important roles in the function of the neuromuscular junction [40, 41]. The top differentially 
expressed gene at baseline, unc-13 homolog C (UNC13C), is involved in neurotransmitter 
release [42, 43]. Both MYLK4 and IGFN1 are also among the top significantly different genes 
between the three groups at baseline. Little is known about MYLK4 and IGFN1, but both 
have been indirectly associated with neuromuscular function. MYLK4 has been shown to be 
significantly downregulated in AChE knockout mice, together with KY, suggesting that it is 
somehow involved in the signal transduction [44]. Like KY, IGFN1 has been associated with 
both muscle structure and neurological function [45, 46]. This gene also binds EEF1A2, which 
is the gene associated with the wasted (Wst) mouse phenotype [46, 47]. This phenotype 
shows significant immunological and neuromuscular defects [48]. IGFN1 has many splicing 
variants, which suggests that it plays a pleiotropic role in the muscle. Another indication of 
denervation is the increased expression of the perinatal myosin heavy chain isoform MYH8 in 
older subjects. Previous studies have found that expression of this gene is increased in tissue 
where the muscle fibres have lost innervation [49, 50]. 
Conclusions
Our data suggests a significant remaining plasticity of ageing skeletal muscle to adapt to 
regular resistance type exercise. Many age-related changes in skeletal muscle gene expression 
are partially reversed by prolonged resistance-type exercise training. Expression of the genes 
robustly changed following prolonged resistance-type exercise training in frail and healthy 
older subjects did not only reflect the effect of training itself, but also reflected muscle 
strength at baseline. Expression of the protocadherin gamma gene cluster is negatively 
correlated with muscle strength in our data and may be related to muscle denervation and 
re-innervation. 
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Clinical relevance
We have identified a gene cluster that may be related to denervation and re-innervation 
cycles in the muscle. Loss of motor neurons has been suggested to play an important role in 
age-related muscle weakness and sarcopenia, but is unfortunately not yet fully understood. 
Prolonged resistance-type exercise training was able to modulate the expression of 
protocadherin gamma. Hence, studying the expression of this gene may provide novel 
insights on whether or not denervation and re-innervation is modulated by interventions or 
lifestyle factors such as nutrition and physical activity. Furthermore, in this paper we show 
that steady-state gene expression provides information on the strength of the muscle itself. 
This suggests that steady-state gene expression could potentially be used as a tool to provide 
insight into muscle strength of a subject, but theoretically also other muscle health-related 
factors.
Limitations
While we have a large sample size for such a study, we also have a very heterogeneous 
study population. The ratio of male to female among both groups of older adults is not 
entirely equal. We have adjusted for this in our statistical analyses where possible. Another 
limitation is that the muscle biopsies from the frail older adults were obtained from a study 
performed at Wageningen University, whereas the muscle biopsies from the healthy older 
adults and the young adults were obtained from studies performed at Maastricht University. 
Protocols for muscle biopsy collection and preparation in Wageningen are based on those 
from Maastricht and thus are very similar, but there may still be some bias that we cannot 
account for statistically. The microarray analyses were performed within the same lab at the 
same time by the same technician, which means that batch effects should be minimal. The 
protocols for the prolonged resistance-type exercise training were slightly different for the 
frail older adults and the healthy older adults. The primary difference being that the healthy 
older adults trained three times per week and the frail older adults trained twice per week. As 
a consequence, the training stimulus for the frail older adults was somewhat lower in these 
individuals and this could partially explain the decreased response among the frail older 
subjects. This difference in treatment also prevented us to compare the training responses 
in both groups directly. 
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Abstract
Populations around the world are aging rapidly and concomitant loss of physiological 
functions negatively affects quality of life at older age. A major contributor to the frailty 
syndrome of ageing is loss of skeletal muscle. In this study we assessed the skeletal muscle 
biopsy metabolome of healthy young, healthy older and frail older subjects to determine 
the effect of age and frailty on the metabolic signature of skeletal muscle tissue. Moreover, 
effects of prolonged whole-body resistance type exercise training on the muscle biopsy 
metabolome of older subjects were examined. The baseline metabolome was measured 
in muscle biopsies collected from 30 young, 66 healthy older subjects and 43 frail older 
subjects. Follow-up samples from frail older (24 samples) and healthy older subjects (38 
samples) were collected after 6 months of prolonged resistance-type exercise training. Young 
subjects were included in order to have a reference for expected shifts of the older towards 
a younger metabolic phenotype. Primary differences in skeletal muscle metabolite levels 
between young and healthy older subjects were related to mitochondrial function, fiber type, 
and tissue turnover. Similar differences were observed when comparing frail with healthy 
older subjects. Prolonged resistance-type exercise training revealed a correlative adaptive 
response of amino acids, especially branched chain amino acids, and genes related to tissue 
remodeling. The impact of exercise on branched chain amino acids derived acylcarnitines 
in older subjects points to a downward shift in branched chain amino acid catabolism upon 
training. We observed modest correlations between muscle metabolite and plasma levels. 
This prohibits the use of the latter as read-outs of muscle metabolism and stresses the need 
for direct assessment in muscle tissue biopsies. 
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Introduction
Populations around the world are aging rapidly and concomitant loss of physiological 
functions compromises independence at older age. It has been estimated that people older 
than 60 y will make up 22% of the world population and people older than 80 y will account 
for 4.4% of the world population in 2050 [1]. A major contributor to the frailty syndrome of 
ageing is skeletal muscle loss, which can lead to increased disability in the older population. 
In most people muscle mass and strength start to decline around the age of 35 y with more 
progressive muscle loss observed after the age of 65 y [2-6].
 From a recent study [7] we learned that prolonged resistance-type exercise training 
partially shifts the skeletal muscle transcriptome of older subjects toward an expression 
pattern observed in muscle tissue of young subjects, with changes in gene expression related 
to vascularisation, tissue remodelling and glucose metabolism. We hypothesize a similar 
shift towards the young phenotype in the muscle metabolome after resistance-type exercise 
training in older subjects. The transcriptome analysis also revealed substantial differences 
between healthy young men, healthy older subjects and frail older subjects before any 
intervention was undertaken. Particularly genes related to mitochondrial function were 
downregulated in older subjects compared to young. 
 Although the effects at gene expression level are expected to be reflected in 
metabolic regulation, our insights are limited to only few studies, mostly in animals. Recent 
work showed that ageing affects glucose and fatty acid metabolism in muscle of mice [8]. 
A study on aged rats suggests a muscle group-specific perturbation of lipid and glucose 
metabolism consistent with mitochondrial dysfunction [9]. A recent study in humans 
showed that lipid content and oxidative activity in skeletal muscle are related to muscle 
fiber type in ageing and metabolic syndrome [10]. Another human study showed that upon 
training mitochondrial function and intermediary metabolism were reprogrammed in 
insulin-insensitive obese subjects [11]. Within these human studies the deployed metabolic 
profiling platforms had limited coverage and focused on specific sub-metabolomes. 
 A major bottleneck in achieving extended coverage was the limited amount of 
muscle tissue material that can be obtained from human studies. The recent development 
of a comprehensive targeted metabolic profiling platform [12] optimized and validated for 
small muscle biopsies paved the way to understand the observed phenotypical differences 
at a more comprehensive level. Here we establish the effect of aging and frailty on the skeletal 
muscle metabolome. We further examine the impact of prolonged resistance-type exercise 
training on the metabolome of frail and healthy older subjects. We included a population 
of young subjects in our study in order to have a reference for expected shifts of the older 
towards a younger metabolic phenotype. 
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Materials and Methods
Experimental design
Muscle biopsies (Vastus lateralis) and circulating metabolites samples were collected from 
pre-frail, frail older [13, 14], healthy older [15, 16] and young subjects [17]. Medical history of 
all subjects was evaluated by medical questionnaires which were analyzed by a physician. 
Subjects who were unable to participate in the training due to pain, were excluded prior 
to starting the intervention. Included subjects who showed severe discomfort during the 
training sessions were excluded from further participation in the study. Baseline metabolite 
levels were measured in skeletal muscle tissue of 30 young, 66 healthy and 43 frail older 
subjects (Table 3.1). We also measured metabolites in plasma and serum for 50 young, 76 
healthy and 62 frail older subjects (Supplementary Table S3.1). The transcriptome of our 
muscle biopsy set was measured in an earlier study[7]. 
Table 3.1.Characteristics of subjects of which skeletal muscle tissue biopsies were studied
  Young Healthy older Frail older
N (male / female) 30/0 47/19 25/18
Age (years) 21.7 ± 2.5 71.7 ± 5.2 77.5 ± 8.0
Height (m) 1.83 ± 0.06 1.72 ± 0.08 1.67 ± 0.09
Weight (kg) 76.7 ± 11.8 75.9 ± 13.3 77.5 ± 11.1
BMIa (kg / m2) 22.6 ± 2.7 25.5 ± 3.0 27.5 ± 3.7
Body Fat (%) 14.9 ± 4.9 24.5 ± 5.6 32.1 ± 8.8
 Data was presented as mean ±SD. a: body mass index.
Samples from healthy young male subjects were derived from several studies performed 
within our group, in which exactly the same technique and processing was used for sample 
collection. We used young male subjects as a reference group and samples were only taken 
at baseline. Samples from the frail and healthy older subjects were obtained from two study 
centers. More details of the studies can be found in the respective papers [13, 16]. 
 In addition, muscle biopsies were obtained after 6 months of resistance-type 
exercise training for 38 healthy and 24 frail older subjects. All muscle biopsies and circulating 
metabolites samples were obtained in the morning, in an overnight fasted state, after 
standardized meal the evening before, and no strenuous physical activity for 3 days prior to 
muscle biopsy collection. 
 Fried criteria [18] were used to assess the frailty in older subjects, in which frailty is 
viewed in terms of the unintentional weight loss, weakness, self-reported exhaustion, slow 
walking speed, and low physical activity. Based on the above mentioned criteria, the healthy 
older subjects were not considered frail or pre-frail at the start of the intervention study [19].
In our study population, all older subjects regardless of their health status (frail or healthy) 
improved in muscle performance following 6 months resistance-type exercise training 
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(Supplementary Figure S3.1 Table S3.2 ) as illustrated by significantly increased leg extension 
and leg press strength after training (P-value < 0.01) [7, 13, 19]. Both healthy older and frail 
older subjects followed similar progressive full-body resistance type exercise training. In brief, 
the training consisted of a 5 minute warm-up on a cycle ergometer, followed by 4 sets on the 
leg-press and leg-extension machines. In addition, 3 sets on chest press, lat pulldown, ped-
dec and vertical row machines were performed (Technogym, Rotterdam, The Netherlands).
However, the healthy older subjects trained 3 times per week and frail subjects trained 2 
times per week. Moreover, subjects received a protein or control supplement during the 
study. Healthy older subjects took 15 gram milk protein or control drink at breakfast and 
frail older subjects took a similar 15 gram drink (milk protein or control) at breakfast and 
lunch every day throughout the entire 6 months intervention. Full details can be found in 
the earlier papers on the phenotypical impact of training on our study population [13, 19].All 
studies were approved by The Medical Ethics Committee of either Wageningen University or 
Maastricht University and comply with the Declaration of Helsinki.
Metabolomics analysis of circulating metabolites
Amino acids and biogenic amines were derivatized (Acc-Tag) in 5 µL aliquots of plasma. 
Samples were analyzed using an ACQUITY UPLC system with autosampler (Waters, Etten-
Leur, The Netherlands) coupled with a Xevo Tandem quadrupole mass spectrometer (Waters) 
operated using QuanLynx data acquisition software (version 4.1; Waters). An Accq-Tag Ultra 
column (Waters) was used. The Xevo TQ was used in the positive-ion electrospray mode 
and all analytes were monitored in Multiple Reaction Monitoring (MRM) using nominal mass 
resolution. Acquired data were evaluated using TargetLynx software (Waters), by integration 
of assigned MRM peaks and normalization using proper internal standards[20].
 Acylcarnitines, trimethylamine-N-oxide, choline, betaine, deoxycarnitine and 
carnitine were analyzed in 5 µL plasma, spiked with an internal standard, using a UPLC-MS/
MS. Also here an Accq-Tag Ultra column was used. The Xevo TQ was used in the positive-ion 
electrospray mode and all analytes were monitored in Multiple Reaction Monitoring (MRM) 
using nominal mass resolution. In-house developed algorithms [21] were applied using the 
pooled QC samples to compensate for shifts in the sensitivity of the mass spectrometer over 
the batch.
 Organic acids were measured by GC-MS using 50 µL of plasma sample prepared 
using a two-step derivatization procedure with subsequent oximation using methoxyamine 
hydrochloride (MeOX) and silylation using N-Methyl-N-(trimethylsilyl)trifluoroacetamide 
(MSTFA. Samples were measured on an Agilent GC (7890A) coupled to Agilent Quadrupole-
MS with EI source (Agilent MSD 5975C). Separation was performed using a HP-5MS column 
(30 m x 0.25 m x 0.25 μm; Agilent). The raw data were pre-processed using Agilent MassHunter 
Quantitative Analysis software for GC-MS (Agilent, Version B.04.00), and quantitation of 
metabolite response was calculated as the peak area ratios of the target analyte to the 
respective internal standard. In-house developed algorithms were applied using the pooled 
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QC samples to compensate for shifts in the sensitivity of the mass spectrometer over the 
batch. Serum metabolite concentrations determined by NMR were measured as described 
by Mihaleva et al. [22]. In short, serum samples were ultrafiltrated and automated quantum 
mechanical line shape fitting of 1H NMR spectra was performed using PERCH.
In tissue metabolome analysis
Metabolites were extracted from 10 mg of wet muscle tissue. This tissue was further lyophilized 
and weighted to determine the dry tissue mass. After pulverizing the tissue, metabolites were 
extracted using methanol/chloroform/water (MCW). The extraction method used in this 
study has extensively been described and characterized elsewhere [12]. 
 Amines, acylcarnitines and oxylipins were measured using the platforms also 
used for measurement of these metabolites in plasma. The validation of these methods 
for human tissue biopsies is described in detail elsewhere [21]. To compensate for shifts in 
the sensitivity of the mass spectrometer over multiple batches of measurements, in-house 
developed algorithms were applied [21]. The metabolite response was determined by the 
peak area ratio of the target analyte to the appropriate internal standard. These response 
ratios were used in the subsequent data analysis. ATP, ADP, creatine and phosphocreatine 
were determined spectrophotometrically using established enzymatic assays. For the first 3 
metabolites, commercially available fluorimetric assay kits were used (BioVision cat.# K354-
100, K355-100 and K635-100) following the manufacturer’s instructions. Phosphocreatine 
was measured according to a colorimetric assay kit protocol described by Szas et al.[23]. In 
total 96 metabolites including amine, acylcarnitines, organic acids, oxylipins and a number 
of nucleotides were measured. 
Statistical analysis
Statistical analysis was performed on log-transformed data. We used analysis of variance 
(ANOVA) for between group comparisons at baseline. P-value<0.05 was considered significant. 
We used linear mixed models for assessment of the training effect. Our model included exercise 
training, subject, sex, protein supplementation and within subject correlation. Analyses 
of the training effect was performed separately for frail and healthy older subjects due to 
differences in training frequency. To summarize acylcarnitines into one single metabolite 
(eigen metabolite), the Non-linear Iterative partial least squares (NIPALS) algorithm [24] of 
the mixOmics R library was used to calculate the Singular Value Decomposition (SVD) of 
acylcarnitines. The mixOmics R library was used to perform multilevel sparse partial least 
squares (sPLS) [25, 26]for integration of metabolomics and transcriptomics. A canonical 
correlation cut-off of 0.80 was used for building the network. FactoMineR was used to perform 
principal component analysis (PCA) [27]. All analyses were done using R (version 3.02). 
ASCA (ANOVA Simultaneous Component Analysis) was performed to determine global 
differences on metabolites. ASCA is a multivariate method that partitions variation in the data 
and enables to interpret these partitions by simultaneous component analysis [28]. Analysis 
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was performed separately for the frail and healthy older subjects, using delta values of each 
metabolite for each individual (value after training - value before training) with supplement, 
sex and their interaction in the model as factors. Analysis was done under Matlab  (version 
R2012a).
Results
Baseline comparisons between healthy older, frail older and young subjects
Comparison of the circulating metabolites profiles of young and healthy older subjects 
revealed a range of metabolites that differed significantly between both groups. Analysis of 
variance (ANOVA) showed that amino acids and acylcarnitines were responsible for the main 
differences in circulating metabolites between older and young subjects. These differences 
were in line with previous observations of age-related effects on the circulating metabolome 
[8, 29, 30].
 Figure 3.1 shows a principal component analysis (PCA) of the biogenic amine 
profiles of the muscle biopsies obtained from young, healthy older and frail older subjects, 
before and after exercise. We observed clear age-related differences in the biogenic amine 
profiles of skeletal muscle, as well as a difference between healthy and frail older subjects. 
The PCA plot also revealed an effect of prolonged resistance-type exercise training on amine 
concentrations in muscle tissue. PCA revealed a similar effect for organic acids in muscle 
(Supplementary Figure S3.2). 
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Figure 3.1.  Principal component analysis (PCA) plot of biogenic amines detected in muscle biopsies. To visualize 
whether groups are significantly different from each other, confidence ellipses (95% Confidence Interval) were 
drawn around them.
ANOVA yielded a series of skeletal muscle metabolites that significantly differ between 
healthy older subjects and young subjects. Many of these metabolites are amino acids and 
organic acids (Table 3.2). The outcome of ANOVA modeling of muscle metabolites in healthy 
vs. frail older subjects is presented in Table 3.3.
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Table 3.2. Muscle metabolites that are significantly different between healthy older and young men. 
a: Out of a comprehensive muscle biopsy metabolic profile those metabolites are presented that are significantly 
(P-value =<0.05) different between young and older subjects according to univariate ANOVA models. b: Fold Change
Metabolite P-value FCb (Older/Young)   
TCA Cycle
Succinic acid 0.02 0.76
2-ketoglutaric acid 0.03 0.76
Fumaric acid 0.04 0.82
Lactic acid 0.05 0.69
Energy
ATP <0.01 0.75
ADP 0.01 0.88
Branched chain amino acids
Valine <0.01 0.81
Leucine <0.01 0.81
Isoleucine 0.03 0.84
Acylcarnitines
Acetylcarnitine (C2) <0.01 0.49
Malonylcarnitine (C3-DC) <0.01 0.46
Intracellular buffering
Carnosine <0.01 0.7
Arginine, Proline Pathway
Ornithine <0.01 1.55
Arginine <0.01 1.34
4-hydroxy-proline 0.01 0.69
Proline 0.02 0.84
Glycylglycine 0.05 0.87
Methionine <0.01 0.8
Other amino acids
Lysine <0.01 1.44
Aspartic acid <0.01 1.45
Oxylipins
LA (LOX)
9-HODE <0.01 1.4
13-HODE 0.01 1.37
13-KODE 0.03 1.3
LA(CYP450)
9,10-EpOME 0.04 1.39
ALA (LOX)
9-HOTrE 0.01 1.71
DGLA (LOX)
15S-HETrE 0.02 0.83
8-HETrE 0.03 0.85
Aminobutyric acids
 β amino isobutyric acid <0.01 1.61
β-aminobutyric acid 0.01 0.82
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Table 3.3.Muscle metabolites that are significantly different between frail and healthy older subjects. a: Out 
of a comprehensive muscle biopsy metabolic profile those metabolites are presented that are significantly 
(P-value =<0.05) different between frail and healthy older subjects according to a univariate ANOVA models 
that accounted for Group effects (Frail vs. Healthy), Sex effect, and Group and Sex interaction; Significance of 
Group (Frail vs. Healthy older subjects) and Group & Sex interactions has been indicated; b:fold change; c: not 
significant (NS)
Metabolite Group Sex  Interaction FCb(Frail/Healthy)  
TCA Cycle
Citric acid <0.01 NS c NS 0.54
Acylcarnitines
Isovalerylcarnitine (C5) <0.01 NS NS 0.42
Octenoylcarnitine (C8) 0.03 0.03 NS 0.77
Malonylcarnitine(C3-DC) 0.02 NS NS 0.77
Carnitine (C0) 0.01 NS NS 0.75
Intracellular buffering
Carnosine 0.01 NS NS 0.8
Oxylipins
LA (CYP450)
12,13DiHOME 0.04 NS 0.03 1.18
DGLA (LOX)
8HETrE 0.03 NS NS 0.81
15SHETrE <0.01 NS NS 0.77
Polyamine metabolism     
Spermidine 0.01 0.02 NS 1.24
Spermine 0.04 NS NS 0.9
Other amino acids 
Histidine <0.01 NS NS 0.79
Asparagine 0.01 NS NS 0.81
Taurine 0.01 NS NS 0.79
Serine 0.01 NS NS 0.86
Glycine 0.02 NS NS 0.81
oacetylserine 0.02 NS NS 0.9
Homoserine 0.02 NS NS 0.85
Tyrosine 0.02 NS NS 0.83
Tryptophan 0.02 0.04 NS 0.83
Methionine 0.02 NS NS 0.83
Glutamine 0.03 NS NS 0.82
Pyroglutamic acid 0.03 NS NS 0.83
Glutamic acid 0.04 NS NS 0.82
Glycylglycine <0.01 NS NS 0.77
Aminobutyric acids
β amino isobutyric acid 0.05 NS NS 0.79
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Effect of prolonged resistance-type exercise training in frail and healthy older subjects
In the PCA plot in Figure 3.1 we can observe that prolonged resistance-type exercise training 
has an effect on the biogenic amine profile of skeletal muscle tissue of frail and healthy 
older subjects. The trends in the PCA plot suggest that upon training both healthy and frail 
older subjects shift towards a younger phenotype (see also the plot for the average value of 
isoleucine in Supplementary Figure S3.3a). The variation in this PCA plot may not only be 
due to phenotype (young, healthy and frail old) and exercise, but also to sex and protein 
supplementation. Hence we performed ANOVA Simultaneous Component Analysis (ASCA) 
to account for these different sources of biological variation. We observed that prolonged 
resistance-type exercise training had a weak effect on muscle tissue metabolite levels. No 
significant interaction of protein supplementation with training in both frail and healthy older 
subjects could be observed. Interaction of sex with training was not significant in healthy 
older subjects, but was significant in frail older subjects (P-value=0.03). 
 Next we used linear mixed models on univariate metabolite levels to account for 
phenotype, exercise, protein supplementation and sex as sources of biological variation. 
We observed that prolonged resistance-type exercise training affected muscle levels 
of acylcarnitines in both the healthy older and frail older subjects (Table 3.4 and 3.5, 
respectively). These effects pertain to propionyl (C3), methylmalonyl (C4-DC), and isovaleryl 
(C5) acylcarnitines as products of the oxidation of amino acids, branched chain amino 
acids (BCAA), and C6-C20 acylcarnitines as products of fatty acid oxidation [31]. For several 
acylcarnitines the exercise effects were nearly significant (P-value >0.05), hence we used 
the singular value decomposition to summarize the levels of fatty acid derived and amino 
acid derived acylcarnitines (denoted as FAAC and AAAC, respectively in Figure 3.4 and 3.5). 
Subsequently, we also performed linear mixed models to determine the effect of training 
on the fatty acid derived and amino acid derived acylcarnitines. The amino acid derived 
acylcarnitines levels were significantly decreased after training for both healthy and frail 
older subjects (see example of the effects for propionylcarnitine in Supplementary Figure 
S3.3, b). 
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Table 3.4. Training effect on muscle metabolites in healthy older subjects a a: Metabolites are presented that 
significantly (P-value =<0.05) differ pre- and Post-training in healthy older subjects according to univariate linear 
mixed models.We note that we constructed also linear mixed models that account for other factors and their 
interactions, but these were not found to be significant. b: fold change, c,d: Single Value Decomposition (SVD) 
were calculated for amino and fatty acid acylcarnitines, denoted as AAAC and FAAC, respectively.
Metabolite Training FC(post/pre training)b
Pipecolic acid 0.002 1.64
Isovalerylcarnitine (C5) 0.005 0.56
Linoleylcarnitine (C18:2) 0.01 0.61
Oleylcarnitine (C18:1) 0.01 0.7
Propionylcarnitine (C3) 0.01 0.73
Palmitoylcarnitine (C16) 0.02 0.75
11.12.EpETrE 0.03 1.26
Tetradecenoylcarnitine (C14:1 0.03 0.47
AAACc 0.02 0.77
FAACd NS 0.96
Table 3.5. Training effect on muscle metabolites in frail older subjects a: Metabolites are presented that 
significantly (P-value =<0.05) differ pre- and post-training in frail older subjects according to univariate linear 
mixed models that account for Supplement, Sex and (Training and Supplement) Interaction. We note that 
we constructed also linear mixed models that account for other interactions, but these were not found to be 
significant. b: fold change, c: Not Significant, d & e: Single Value Decomposition (SVD) were calculated for amino 
acid and fatty acid acylcarnitines (AAAC and FAAC, respectively). 
Metabolite Training Supplement Sex Interaction FC (post/pre training)b
Propionylcarnitine (C3) <0.01 NSc NS NS 0.75
Glucose <0.01 NS <0.01 NS 1.35
Lactic acid 0.01 NS <0.01 NS 1.55
Tetradecenoylcarnitine (C14:1) 0.03 NS NS NS 2.00
Methionine 0.04 <0.01 NS NS 1.22
Tryptophan 0.04 NS NS NS 1.21
β Alanine 0.05 NS NS 0.01 0.92
Isoleucine 0.05 <0.01 0.02 NS 1.21
Myristoylcarnitine (C14) 0.05 NS NS NS 1.73
AAACd 0.01 NS NS NS 0.76
FAACe NS NS NS NS 1.95
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We used multilevel sPLS to integrate muscle changes in the transcriptome and metabolome 
after training. Here the goal was to investigate the interaction of two matched data sets and the 
selection of subsets of either positively or negatively correlated variables across all subjects. 
This multivariate approach highlighted the training effects within subjects separately from the 
biological variation between subjects. We applied canonical mode, which highlights the strongest 
correlations between the two data sets. Subsequently, we selected significantly changed genes 
based on training (FDR<0.05) in both frail and healthy older subjects. We observed that amino 
acids, particularly branched chain amino acids, correlate with genes related to connective tissue/
extracellular matrix such as collagen, laminin and SPARC (Figure 3.2). 
Figure 3.2. Correlation network of muscle metabolites and genes. 
Only significantly changed genes were selected (FDR<0.05). Metabolite canonical correlation cutoff <= 0.80. 
Circle: gene, rectangle: metabolite. Green: positive correlation.
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Correlation between muscle and plasma metabolites levels
Within this study we simultaneously collected fasting plasma and muscle biopsies. We 
investigated to what extent baseline plasma metabolite levels reflect muscle metabolite 
levels. We first constructed separate correlation heatmaps for muscle and plasma 
metabolites within each compartment. In Figure 3.3a-b one can observe that metabolites 
that are in the same group of metabolites (e.g. amino acids, acylcarnitines) are correlated 
to each other within both plasma and muscle. However, the correlation heatmap of muscle 
and plasma metabolites (Figure 3.3c) showed only minor to moderate correlations between 
muscle and plasma metabolites (Pearson correlation between 0.3 and 0.5). The correlation 
networks (Figure 3.3d) show that strongest correlations pertain to 3-hydroxybutyric acid, 
4-hydroxyproline, proline, branched chain amino acids and several acylcarnitines. Correlation 
of serum and muscle metabolites are presented in Supplementary Figure S3.4. Results are 
generally in line with plasma-muscle metabolite correlations.
Glycolic acid (P)
L-Tryptophan (T) L-lysine (P)Lactic acid (T)
L-carnosine (T)
2-hydroxybutyric acid (P)
L-histidine (P)
Acetylcarnitine (T)
Butyrylcarnitine (T)
L-Tyrosine (T)
L-tyrosine (P)
L-valine (P)
DL-3-aminoisobutyric acid (T)
Acetylcarnitine (P)
L-alpha-aminobutyric-acid (P)
L-Methionine (T)
spermidine (T)
L-Alpha-aminobutyric acid (T)
L-leucine (P)
Butyrylcarnitine (P)
L-proline (P)
L-Proline (T)
Glycine (T) L-Isoleucine (T)Putrescine (T)
Glyceric acid (P)
3-Hydroxybutyric acid (P)
Octenoylcarnitine 1 (P)
Isovalerylcarnitine (P)
Tetradecenoylcarnitine (P)
Octenoylcarnitine (T)
3-Hydroxybutyric acid_1 (T)Decenoylcarnitine 1 (P)
FA (18:1) (P)
Malonylcarnitine (T)
L-4-hydroxyproline (P)
L-isoleucine (P)
L-homoserine (P)
L-glycine (P)
L-tryptophan (P)
L-Valine (T)
L-Leucine (T)
L-4-hydroxy-proline (T)
Figure 3.3 - Correlation heatmap of muscle to muscle metabolites (a), plasma to plasma metabolites (b), 
muscle to plasma metabolites (c). Pearson correlation were used. (d) Correlation network of the most strongly 
correlated muscle and plasma metabolites (Pearson correlation). Red and blue indicate positive and negative 
correlations, respectively. Thick lines: correlation ~0.5, thin lines: 0.3 <correlation <0.5. Pink nodes: muscle 
tissue (T) metabolites and yellow nodes: plasma (P) metabolites.
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Discussion
Comprehensive metabolic profiling of muscle biopsies: age and resistance-type exercise 
training effects in a heterogeneous study population
Comprehensive metabolic profiling of muscle biopsies revealed baseline differences 
between the muscle biopsy metabolomes of healthy young, healthy older and frail older 
subjects. Furthermore, distinct effects of prolonged resistance-type exercise training in the 
latter two groups could be observed. Critical was the deployment of five robust profiling 
platforms using a single and thoroughly validated muscle-biopsy extraction procedure [12]. 
The analytical variation in these profiles, was around 20-30% which was smaller than the 
biological variation in the muscle biopsies. In order to separate the sources of biological 
variation in our heterogeneous study population we relied on univariate linear mixed models. 
The metabolic effects of sex and supplementation however turned out to be relatively minor 
compared to phenotype and response to prolonged resistance-type exercise training. A 
multivariate approach (ASCA) did not show any significant effects of training, probably 
because not all sources of biological variation could adequately be accounted for [32]. In the 
following discussion we limit ourselves to univariate approach since it more strictly accounts 
for heterogeneity of our study population. 
Baseline comparisons
TCA cycle metabolites (succinic acid, fumaric acid, 2-ketoglutaric acid) were lower in the 
healthy older subjects compared to young subjects. These differences were accompanied by 
lower levels of ATP, ADP, branched chain amino acids and acylcarnitines in the healthy older 
subjects. This indicates impaired mitochondrial function or a lower number of mitochondria 
in the muscle of the older subjects. It may also be a reflection of the lower habitual physical 
activity of the older subjects. These observations are in line with data on the transcriptomics 
profile of these subjects, which show that genes related to mitochondrial function and 
oxidative phosphorylation have decreased expression in the older subjects compared to 
young subjects, with the lowest expression occurring in the frail older subjects [7]. This is also 
in agreement with other studies [8, 33-37], where the mitochondrial electron-transport chain 
is also among the significantly different pathways in muscle metabolism when comparing 
older and young subjects. 
 Worth mentioning are the lower levels of 4-hydroxyproline and proline in the 
healthy older subjects compared to the young subjects. Both of these amino acids have been 
associated with collagen turnover [38, 39]. Two precursors of proline, ornithine and arginine, 
have higher muscle levels in the older subjects. Higher levels of ornithine and arginine, 
together with lower levels of 4-hydroxyproline and proline, may be due to dysfunction of 
the mitochondrial ornithine aminotransferase [40], leading to accumulation of arginine and 
ornithine. This is in line with slightly lower expression of genes related to tissue remodeling, 
such as collagen in the older subjects compared to the young subjects [7]. 
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 In healthy older subjects we observed higher muscle levels of β-isoamino butyric 
acid (BAIBA) than in young subjects. Hypothetically, this metabolite is produced upon 
exercise by expression of PGC-1α and has been proposed as a myokine stimulating browning 
of white adipose tissue and hepatic β-oxidation [41]. In our study population we observe 
gene transcription downregulation of PGC-1α target genes in healthy older subjects with 
respect to young and in frail older subjects with respect to healthy older subjects [7]. At 
posttranslational level activity of PGC-1α is modulated by NAD+ dependent deacetylation by 
SIRT1 (Figure 3.4-b) [42]. Since NAD+ levels are decreasing with age [43], we expect also here 
a downregulation of PGC-1α [44]. The expected decrease of β-isoamino butyric acid (BAIBA) 
levels is however only observed when comparing frail to healthy older subjects, whereas 
we observe a significant increase in BAIBA in healthy older subjects compared to young 
subjects. Thus, the observed changes in baseline levels of BAIBA levels in muscle in our 
study population do not appear to be consistent with age-related down regulation of PGC-
1α. Hence we cannot confirm the recently stated hypothesis that BAIBA acts as a PGC-1α 
induced myokine. An explanation could be that in our study differences in PGC-1α expression 
are caused by age and frailty dependent processes, whereas previously described PGC-1α 
-mediated effects on BAIBA were caused by acute exercise. 
 Two polyamines, spermine and spermidine, were found to be significantly different 
in the frail compared to the healthy older subjects. Polyamines are involved in tissue 
regeneration and cell proliferation and differences are associated with both exercise and 
muscle pathology [45-47]. The genes directly involved in the polyamine pathway are however 
not differentially expressed between frail and healthy older subjects. Hence the observed 
differences in polyamine levels between the frail and healthy older subjects are more likely 
to be attributed to effects at the level of enzyme activity or metabolite transport. Previous 
studies have shown that perturbations in polyamine metabolism are associated with 
neuromuscular disorders [48, 49]. On the transcriptome level we indeed found indications of 
neuromuscular perturbations in the frail older subjects [7]. In addition, increased spermine 
levels were recently linked to skeletal muscle atrophy [50]. However, our data suggests that 
at baseline this process is in the opposite direction when comparing frail and healthy older 
subjects, even though frail older subjects generally have less skeletal muscle and are likely 
to exhibit more extensive muscle atrophy. Ost et al. recently reported that spermidine is 
increased in the skeletal muscle of mice overexpressing uncoupling protein 1. The authors 
proposed that this might be an adaptive response to cope with the additional oxidative 
stress [51]. 
 The level of carnosine is decreased in healthy older subjects relative to young 
subjects, and in frail relative to healthy older subjects. Carnosine is an abundant metabolite 
in muscle where it plays an important role in intracellular pH buffering [52]. Carnosine has 
also been associated with chelation of metal ions and antioxidant activity [53]. Carnosine 
levels are higher in type II muscle fibers compared to type I. A likely explanation for the 
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significantly lower levels of carnosine in healthy and frail older subjects is therefore the 
decrease of muscle fiber II/I ratio with respectively age and lack of exercise[54].
 Several oxylipins derived from linoleic acid (LA) and α-linoleic acid (ALA) occur at 
higher levels in the muscle of the healthy older subjects compared to young subjects. On 
the other hand, metabolites derived from the D-6 desaturase product dihomo-γ-linoleic 
acid (DGLA) are reduced in healthy older subjects. We postulate that due to reduced D-6 
desaturase activity linoleic acid and α-linoleic acid accumulate in the muscle of the healthy 
older subjects, whereas downstream D-6 desaturase product dihomo-γ-linoleic acid 
products are depleted [55]. 
Effect of prolonged resistance-type exercise training
We compared the effect of prolonged resistance-type exercise training in both healthy 
and frail older subjects with all metabolites using multilevel sPLS. There was a profound 
correlation between the adaptive response to training between the transcriptome and 
amino acids in the muscle metabolome (canonical correlations between 0.7 and 0.8). There 
were particularly high correlations between expression changes of extracellular matrix genes 
and amino acids. Although it is unlikely that there is a direct link between expression of these 
genes and levels of these metabolites, it does imply that these changes in amino acid levels 
are part of the adaptive response to resistance-type exercise training. 
 At the metabolite level, the most striking effects of resistance-type exercise training 
in frail and healthy older subjects were observed for the C3 (propionyl) and C5 (isovaleryl) 
muscle acylcarnitines derived from branched chain amino acids. After training, the amino 
acid derived acylcarnitines showed a significant decrease both in the healthy and frail older 
subjects, accompanied by an increase of branched chain amino acids. A likely explanation is 
that the flux-determining mitochondrial branched chain α-keto acid hydrogenase (BCKDH) 
complex [56] has a compromised response to prolonged resistance-type exercise training. 
As is schematically depicted in Figure 3.4-a, the BCKDH complex can respond to exercise 
via different mechanisms. PGC-1 is a known activator of BCKDH, but training did not have 
an effect on its gene expression in our study. Exercise is known to increase NAD+ levels [44] 
and could thus activate PGC-1α in a post-translational manner via SIRT1. Apparently also 
this mechanism is not activated by training in the older subjects. These effects are specific 
for branched chain amino acids oxidation and no significant effects on fatty acid derived 
acylcarnitines were found. A decrease in branched chain amino acids oxidation may stimulate 
mTOR related pathways activation and protein synthesis [57, 58], which is beneficial for 
older subjects. As this mechanism occurs at enzymatic level, the available metabolomics 
and transcriptomics data can however not confirm this hypothesis and in future studies 
proteomics would be called for.
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Figure 3.4 - (a) Schematic representation of mitochondrial oxidation of free fatty acids (FFA) and branched 
chain amino acids (BCAA). Arrows indicate effect of prolonged resistance-type exercise training on older 
subjects (healthy and frail) on BCAA (increase) and acylcarnitines (decrease) as well as the proposed (dashed-
arrows) downregulation of the branched chain α-keto acid hydrogenase (BCKDH) complex. (b) Schematic 
representation of age-related NAD+ dependent acetylation of PGC1α. Dashed arrows indicate NAD+ and SIRT1 
dependent downregulation of PGC-1α and β-isoamino butyric acid (BAIBA).
Correlation of plasma and muscle metabolome
The weak correlations between plasma and muscle metabolite levels indicate that plasma 
levels only partially reflect muscle metabolism, even though muscle is one of the largest 
metabolically active tissues in the human body. This seems to suggest that these metabolites 
are also produced by other metabolic compartments. In a recent study, lack of correlation 
between acylcarnitine levels in plasma and tissues in mice was attributed to differences in 
turnover in plasma and muscle compartments, and contribution of other compartments 
than muscle to plasma acylcarnitine levels [59]. The same rationale very likely also applies 
to amino acids involved in collagen metabolism (proline, 4-hydroxyproline), which can also 
be formed in bone. Adipose tissue is also a metabolically active compartment for branched 
chain amino acids besides muscle [60], and this will likely weaken plasma-muscle level 
correlations. As a consequence, correlations between plasma metabolites and muscle 
metabolites are too modest to support their use as direct read-outs of muscle metabolism 
[61, 62].
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Conclusion
The major differences in muscle metabolome of healthy older and young subjects relate 
to mitochondrial function, fiber-type composition, and tissue turnover. Similar differences 
were observed when comparing frail older subjects with healthy older subjects. Prolonged 
resistance-type exercise training showed a correlative adaptive response of amino acids 
and genes responsible for tissue remodeling. The effect of exercise on amino acid derived 
acylcarnitines in healthy and frail older subjects points towards decreased branched 
chain amino acids catabolism likely due to attenuated activation of the flux-determining 
mitochondrial branched chain α-keto acid hydrogenase complex in older subjects. Only 
modest correlations between muscle metabolite and plasma levels were found, which 
prohibits the use of the latter as read-outs of muscle metabolism.
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Abstract
Knee immobilization can induce rapid loss of muscle mass and strength in humans. We 
assessed the effect of knee immobilization with creatine supplementation or placebo on the 
skeletal muscle transcriptome and metabolome.
 Sixteen healthy young men underwent knee immobilization for 7 days using a full-
leg cast. Subjects received 20g creatine or a placebo supplement per day for 5 days prior to 
immobilization, followed by 5g creatine or placebo per day during immobilization. Muscle 
biopsies were obtained from the vastus lateralis prior to immobilization and immediately 
after cast removal and subjected to transcriptomics. Metabolomics were performed on a 
subset of the muscle biopsies (12 subjects in total, 6 subjects per group). 
 Knee immobilization caused muscle mass loss (-574 ± 115 mm2 whole leg cross-
sectional area, P < 0.01) and strength loss (-7.4 ± 1.8 kg leg extension 1RM, P < 0.01) in all 
participants, with no differences between creatine and placebo groups. Knee immobilization 
significantly induced expression of ubiquitin-mediated proteolysis genes, whereas glucose 
metabolism and mitochondrial genes were downregulated. Gene expression changes 
due to immobilization tended to be smaller in the creatine group. Genes belonging to the 
HDAC4-Myogenin axis were significantly upregulated, which was attenuated by creatine 
supplementation. Knee immobilization induced a significant decrease in several metabolites 
including fatty acid derived acyl carnitines, putrescine, ornithine, proline and lactic acid. 
 Knee immobilization appears to induce the HDAC4-myogenin axis, which is 
primarily associated with denervation and motor neuron diseases. Transcriptional changes 
in skeletal muscle due to knee immobilization were attenuated by creatine supplementation. 
The metabolome showed changes consistent with the decreased expression of energy 
metabolism genes. 
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Introduction
Brief periods of physical inactivity can have a dramatic negative effect on skeletal muscle mass 
and function in humans. In addition to the rapid loss of muscle strength and size, secondary 
negative effects on the muscle may ensue, including a decrease in insulin sensitivity,  loss in 
the capacity to synthesize protein, decline in basal metabolic rate, and gain of fat mass [1-5]. 
As a consequence, limb immobilization (e.g., due to a fracture) can have negative effects in 
for example athletes, but also older adults who are more vulnerable to muscle loss. Thus, 
novel strategies to combat the negative effects of brief periods of physical inactivity are in 
great demand. 
 Creatine supplementation has been used as a strategy to augment gains in 
muscle mass and strength, particularly by athletes in strength and power sports. Creatine 
supplementation can increase the concentration of creatine phosphate in skeletal muscle, 
thereby raising the rapidly available energy supply in the muscle [6-10]. This larger supply of 
energy allows for a higher training load,  potentially leading to improved strength and muscle 
gains during prolonged resistance-type exercise training. Creatine supplementation may 
also have secondary benefits that may influence muscle hypertrophy and muscle strength 
gains. For example, it draws water into the muscle cells, which is thought to modulate 
muscle signalling [11]. It is common to see rapid weight gain after initiation of creatine 
supplementation, due to muscle cell swelling [12, 13].
 Given the anabolic potential of creatine supplementation, several studies have 
evaluated the use of creatine supplementation as a tool to limit the loss of muscle mass 
and strength during limb immobilization. However, the results of these studies are thus far 
inconsistent. Two studies observed an attenuation of muscle losses during immobilization 
in the creatine group, one in rats and one in humans [14, 15]. We were, however, unable to 
replicate these results [16]. Another study also investigated whether creatine supplementation 
combined with resistance-type exercise training after a period of immobilization could 
improve recovery time. It was observed that creatine supplementation indeed had a positive 
effect on recovery time and modulated regulatory factors in the muscle. However, no 
beneficial effect of creatine with regard to muscle mass and strength losses was observed 
during immobilization [17]. 
 Because of the wide and pronounced effects immobilization can have on both muscle 
size and metabolism we were interested in investigating both the muscle transcriptome and 
metabolome in relation to both knee immobilization and creatine supplementation during 
this period of muscle disuse. Transcriptomics and metabolomics allow us to characterize 
in more detail the transcriptional and metabolic changes that occur during immobilization. 
These techniques may also reveal the more subtle effect creatine supplementation has on 
the skeletal muscle transcriptome, especially given that creatine supplementation appears 
to have an effect on regulatory factors and cell metabolism. In short, our aim is to investigate 
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genes, metabolites and pathways involved in immobilization-induced muscle atrophy and to 
determine whether this response can be modulated by creatine supplementation. 
Methods
Experimental design and procedures
This study used a subset of participants from a larger randomized, double-blind placebo 
controlled study. More detailed methods and materials can be found elsewhere [16]. Subjects 
were randomly allocated into either the placebo (n=8) or the creatine (n=8) supplemented 
group. Standardized meals were consumed the evening prior to the muscle biopsies. All 
measurements, with exception of the strength measurements, were taken in a fasted state. 
 A muscle biopsy was taken and muscle size (cross-sectional CT scan of the upper 
legs) and strength (1RM leg extension) was measured two days prior to immobilization. One 
leg was immobilized using a full leg cast for seven subsequent days. On the day of the cast 
removal, another muscle biopsy was taken and muscle size and strength measurements were 
repeated. Microarrays and metabolomics analyses were performed on the muscle biopsies. 
The subset of subjects was based on muscle tissue availability for all time points. A sufficient 
amount of muscle tissue for the metabolomics analysis was available for 12 subjects (n=6 for 
both groups) and 16 subjects for the transcriptomics analysis (n=8 for both groups). 
 Muscle mass was assessed with a single slice CT-scan (Philips Brilliance 64, Philips 
Medical Systems, Best, the Netherlands). Scan position was marked for to ensure accurate 
repeated measurements. Maximal leg extension strength was estimated using unilateral 
single repetition maximum (1RM) tests for both legs. After warming up, subjects were asked to 
take place on a leg extension machine (Technogym, Rotterdam, The Netherlands). Subjects 
were then asked to perform leg extensions using strict form. Weight was increased until the 
subject could no longer lift the weight. During the screening visit, sub-maximal strength was 
approximated using multiple repetition maximum to ensure a starting weight close to the 
true 1RM for the strength measurements. The highest weight that was successfully lifted was 
used as 1RM. 
Limb immobilization 
One randomly selected leg was immobilized at the Maastricht University Medical Centre. 
The leg was cast at a 30o angle to prevent weight bearing activities of the immobilized leg. 
Subjects were given crutches for the duration of the leg immobilization period. Subjects 
were instructed to perform daily ankle exercises to minimize risk of thrombosis via activation 
of the calf pump. After seven days of immobilization the cast was removed at the hospital. 
Following cast removal subjects were transported by wheelchair to prevent any muscle 
loading prior to muscle biopsies. 
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Subjects
This study included sixteen healthy, young men. Exclusion criteria included history or family 
history of thrombosis, any joint complaints and any co-morbidities interacting with mobility or 
muscle metabolism of the lower limbs. None of the subjects had performed strength training 
over the past half year, used anti-coagulants, corticosteroids, growth hormone, testosterone, 
immunosuppressant drugs or exogenous insulin. During the screening, subjects gave written 
informed consent after they were fully informed about the nature and possible risks of the 
experimental procedures. The study was approved by the Medical Ethical Committee of the 
Maastricht University Medical Centre+ and performed in accordance with the Declaration of 
Helsinki. 
Muscle Biopsy
Body weight was measured with a digital balance with an accuracy of 0.1 kg (SECA GmbH, 
Hamburg, Germany). Muscle biopsies were taken from the middle region of the vastus lateralis 
muscle under local anaesthesia, ~15 cm above the patella and ~3 cm below entry through 
the fascia, using the percutaneous needle biopsy technique [18]. All biopsies were taken from 
the leg that was subsequently immobilized. Muscle samples were dissected carefully and 
freed from any visible non-muscle material and were immediately frozen in liquid nitrogen. 
Subsequently, muscle samples were stored at -80 °C until further analysis. 
Supplements and supplementation protocol
The placebo group received a placebo supplement consisting of 7.5 g maltodextrin and 7.5 g 
of dextrose monohydrate (AVEBE, Veendam, The Netherlands). The creatine group received 
the same supplement with the addition of 5 g creatine monohydrate (Creapure AlzChem, 
Trostberg, Germany). Creatine supplements could not be distinguished from the placebo 
supplement with respect to colour, taste, smell or appearance. All subjects were instructed 
to dissolve the supplement in lukewarm water prior to ingestion. During the first five days 
of creatine loading, subjects consumed four supplements per day (providing a total of 20 
g creatine per day for the creatine group) at breakfast, lunch, dinner and before going to 
bed. After the five day loading period subjects consumed one supplement per day for the 
remainder of the study. This protocol was designed according to the guidelines on creatine 
supplementation set by the American College of Sports Medicine [13]. 
Microarray analysis
RNA was isolated (RNeasy Micro kit, Qiagen, Venlo, the Netherlands), quantified (Nanodrop 
ND 1000, Nanodrop technologies, Wilmington, DE, USA) and integrity was checked by an 
Agilent 2100 Bioanalyser with RNA 6000 microchips (Agilent Technologies, South Queensferry, 
UK). Total RNA was labelled using the GeneChip® WT plus Reagent Kit and hybridized to 
GeneChip® Human Gene 1.1 ST Array (Affymetrix, Inc. Santa Clara, CA, USA). Sample labelling, 
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hybridization to chips, and image scanning were performed according to the manufacturers’ 
instructions.
Metabolome analysis
Metabolites were extracted from 10 mg of wet muscle tissue. This tissue was further lyophilized 
and weighted to determine the dry tissue mass. After pulverizing the tissue, metabolites 
were extracted using methanol/chloroform/water (MCW). The extraction method used in 
this study has extensively been described and characterized elsewhere [19].   Amino acids 
and biogenic amines in plasma were derivatized (AccQ-TAG) 5 µL aliquots of muscle extract 
and measured by a UPLC system which was interfaced to quadrupole mass spectrometer. 
Acylcarnitines, trimethylamine-N-oxide, choline, betaine, deoxycarnitine and carnitine were 
analyzed in 5 µL muscle extract, spiked with an internal standard and also measured by 
UPLC-MS, but without derivatisation. Organic acids in plasma were measured by GC-MS, after 
oximation and silation derivatization. Full details of these platforms have been described in 
earlier studies  [19, 20].
Data analysis
Physical characteristics (i.e. muscle size and strength) were evaluated using linear mixed 
models. Microarray data were assessed for quality using the MADMAX pipeline and additionally 
by visually inspecting the probe level residuals and NUSE plots [21]. Data was normalized 
using Robust Multichip Average (RMA) [22]. Gene level summarization was performed using 
the most recent Custom CDF from the Brainarray project [23]. Genes were filtered using UPC 
filtering with a 50% expression likelihood cut-off in at least 8 samples [24].
 Statistical analysis was performed using the limma R library [25]. Contrasts were 
set for immobilization effect in both groups and an interaction term for the creatine group 
versus the placebo group. P-values were calculated using Intensity Based Moderated t-tests 
(IBMT) [26]. Significant genes were first selected using the False Discovery Rate adjusted 
F-statistic p-value < 0.05. Unadjusted p-values below 0.01 for the contrasts were considered 
statistically significant within the genes that passed the F-test. Gene set enrichment analysis 
(GSEA) was done using the piano R library on pre-ranked lists, ranked by the t-values from the 
limma contrasts [27]. We used the most recent library of canonical pathways from MsigDb 
[28]. A q-value of 0.10 was considered significant for the GSEA results. Missing data in the 
metabolome were imputed by taking half the lowest value for that metabolite (5 values in 
total, 1 for cytidine triphosphate, 3 for uridine triphosphate and 1 for valerylcarnitine). Data 
was log2 transformed prior to analysis. Statistical analysis of metabolome was done using 
paired t-tests (post vs. pre-immobilization) for each metabolite. Data visualization was done 
using ggplot2 and gplots [29, 30].
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Results
Immobilization effect
Seven days of knee immobilization induced rapid loss of muscle mass. Leg CSA was reduced 
by 574 ± 115 mm2 and quadriceps CSA was reduced by 484 ± 65 mm2. These changes were 
accompanied by decreased maximal strength, as revealed by a reduction in leg extension 
1RM of 7.4 ± 1.8 kg. Creatine supplementation did not have a significant effect on the loss 
of both muscle mass and muscle strength (table 4.1, page 78). A full discussion of the 
physiological effects of knee immobilization with or without creatine supplementation has 
been previously published [16].
 Knee immobilization induced significant changes in the muscle transcriptome in 
both the placebo group and the creatine group, with 520 genes significantly affected in total 
(F-test q-value < 0.05). Fewer genes were altered by knee immobilization in the creatine group 
than in the placebo group (229 vs. 439, respectively). Table 4.2 shows the top 20 significant 
genes based on fold change in the placebo group. Supplementary table 1 contains all 
significant genes according to the main effect F-test. 
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Table 4.2 – Top 20 significant genes in the placebo group sorted on absolute signal log ratio. P-values for 
the immobilization effect in the creatine and placebo group as well as the interaction effect of creatine with 
immobilization are unadjusted IMBT p-values. FC is the signed fold change. Cre is the change in the creatine 
group, Pla is the change in the placebo group and Inter is the interaction effect between creatine supplementation 
and immobilization.
Gene FC Pla FC Cre P-val. Pla P-val. Cre P-val. Inter Q-val. F-test
NMRK2 -5.23 -2.00 0.000 0.011 0.013 0.003
SMCO1 -4.66 -2.75 0.001 0.015 0.331 0.016
GDNF 4.64 2.56 0.000 0.003 0.136 0.004
ACTN3 -4.38 -1.58 0.001 0.210 0.057 0.029
NR4A1 -3.73 -1.43 0.000 0.174 0.015 0.010
HDAC4 3.24 1.67 0.000 0.006 0.010 0.002
DHRS7C -3.14 -2.26 0.003 0.026 0.498 0.036
AMPD3 2.84 2.28 0.004 0.017 0.625 0.033
GADD45A 2.68 2.52 0.008 0.012 0.894 0.040
SLC16A3 -2.65 -1.74 0.000 0.003 0.077 0.004
LRRC14B -2.65 -1.53 0.002 0.125 0.163 0.045
TP63 2.62 1.37 0.000 0.068 0.012 0.006
COQ10A -2.48 -2.08 0.001 0.007 0.607 0.016
TFRC -2.45 -2.19 0.000 0.001 0.709 0.007
AKR1C2 2.43 1.50 0.000 0.050 0.096 0.014
PFKFB3 2.41 2.70 0.007 0.003 0.783 0.022
IP6K3 2.32 1.73 0.000 0.000 0.102 0.002
FAM46C -2.32 -1.24 0.000 0.154 0.007 0.006
ASB14 -2.32 -1.08 0.001 0.697 0.015 0.035
CCNG2 2.30 1.78 0.000 0.008 0.366 0.012
Among the top 20 significant genes for the placebo group are genes related to energy 
metabolism, including Nicotinamide Riboside Kinase 2 (NMRK2), Solute Carrier Family 
16, Member 3 (Monocarboxylic Acid Transporter 4; SLC16A3), 6-Phosphofructo-2-Kinase/
Fructose-2,6-Biphosphatase 3 (PFKFB3), Inositol Hexakisphosphate Kinase 3 (IP6K3) and 
Nuclear Receptor Subfamily 4 Group A Member 1  (NR4A1 / Nur77) (table 4.2). Neurological 
function genes were also among the top genes changed by knee immobilization, including 
Histone Deacetylase 4 (HDAC4),  Glial Cell Derived Neurotrophic Factor (GDNF), Maturin, 
Neural Progenitor Differentiation Regulator Homolog (MTURN) and Ataxin 1 (ATXN1). 
 Consistent with these top genes are the results from GSEA. GSEA revealed 
downregulation of glycolysis, gluconeogenesis and mitochondrial function pathways (table 
4.3, supplementary table S4.2).  GSEA also revealed increased expression of proteasomal 
genes and ubiquitin mediated proteolysis pathways. However, two markers of muscle 
breakdown, TRIM63 and FBXO32 (Better known as MURF1 and MAF-bx/Atrogin-1, respectively) 
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were not strongly affected by the immobilization despite the upregulation of ubiquitin 
mediated proteolysis genes and proteasomal genes (table 4.2, supplementary table S4.1). 
Nevertheless, a regulator of muscle atrophy, Growth Arrest And DNA Damage Inducible Alpha 
(GADD45A), is among the top genes (table 4.2). Upstream regulator analysis using Ingenuity 
showed that knee immobilization led to decreased expression of insulin target genes and 
increased expression of  Forkhead box O3 (FOXO3), DNA-binding protein inhibitor ID2 and 
ID3 target genes, indicative of the decreased expression of glucose metabolism genes and 
increased expression of atrophy genes, respectively (table 4.4).  
Table 4.3 – Top 20 significant enriched genesets (GSEA) in significant in both the placebo arm and the effect of 
creatine supplementation during immobilization (interaction effect). Pla is the immobilization effect, Inter is the 
interaction effect. ES is the enrichment score; negative ES denotes downregulation.
Pathway Pla ES Inter ES Pla Q-val Inter Q-val
Reactome Unwinding Of DNA -0.80 0.72 0.000 0.015
Biocarta SRCRPTP Pathway -0.75 0.63 0.004 0.053
Biocarta Glycolysis Pathway -0.74 0.70 0.041 0.055
Biocarta Monocyte Pathway -0.72 0.61 0.014 0.065
Reactome Gluconeogenesis -0.71 0.46 0.000 0.094
Biocarta B-lymphocyte Pathway -0.70 0.63 0.017 0.057
Reactome Pyrimidine Catabolism -0.70 0.60 0.018 0.079
PID IL8 CXCR2 Pathway -0.68 0.68 0.000 0.000
Reactome Pol Switching -0.67 0.77 0.024 0.006
Biocarta TCRA Pathway -0.67 0.58 0.036 0.091
PID IL8 CXCR1 Pathway -0.67 0.65 0.000 0.000
Reactome PD1 Signaling -0.66 0.55 0.004 0.060
Biocarta IL5 Pathway -0.65 0.64 0.064 0.073
Reactome Regulated Proteolysis Of P75NTR -0.64 0.84 0.071 0.006
PID Alpha-Synuclein Pathway -0.64 0.59 0.000 0.003
Biocarta Lym Pathway -0.63 0.66 0.074 0.059
Biocarta Barrestin Src Pathway -0.63 0.53 0.025 0.094
Reactome Signaling By Notch2 -0.63 0.76 0.054 0.011
Reactome Regulation Of Complement Cascade -0.63 0.59 0.055 0.089
Reactome P38MAPK Events -0.63 0.60 0.051 0.059
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Effect of Creatine Supplementation
Figure 4.1 shows the change in gene expression for each during leg immobilization in both 
the placebo group and creatine group. The creatine group did not show a strong distinct 
eff ect on the transcriptome and in general the response was correlated with the placebo 
group. However, the magnitude of the change in gene expression was generally lower in the 
creatine group, as shown in table 4.2 and figure 4.1. The shaded area in figure 4.1 covers 
the genes whose expression change was attenuated in the creatine group compared to 
the placebo group. GSEA showed a similar result, as gene sets that were significant for 
knee immobilization were predominantly counter-regulated by creatine supplementation 
(table 4.3, supplementary table 4.2 and 4.3). Upstream analysis also showed that creatine 
supplementation modulated Myocyte Enhancement Factor 2C (MEF2C) target genes during 
immobilization (table 4.4).  
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Figure 4.1 – Signal log ratios of significant genes during immobilization (placebo group vs. creatine group). 
All genes are significant based on the overall ANOVA F-test (q-value < 0.05).  Red points are considered genes 
significantly aff ected by creatine supplementation (raw p-value for interaction < 0.01). Shaded area shows genes 
where the change in gene expression is smaller in the creatine group compared to the change in the placebo 
group. 
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Table 4.4 – Top 10 upstream regulators from Ingenuity Pathway Analysis.
Upstream Regulator p-value of overlap Activation z-score
Immobilization - Placebo group  
ID2 0.000 0.302
ID3 0.001 -0.560
ALKBH5 0.002  
FOXO3 0.002 2.084
IFI16 0.003 0.810
Insulin 0.003 -1.868
SPIB 0.005 0.378
MAP2K5 0.005  
HDAC4 0.006 0.842
Immobilization - Creatine group  
ITSN1 0.003  
FOXD1 0.003  
NFE2L2 0.005 3.075
RORC 0.006  
ONECUT1 0.007  
GPD1 0.009  
SLC25A13 0.009  
RARRES3 0.010  
Foxo 0.019  
HCK 0.019  
Creatine Interaction   
FNIP1 0.000 -2.200
PDGF BB 0.000 -1.997
FGF10 0.001 1.276
ZFPM1 0.001  
STAT5B 0.001 -1.497
ETV7 0.002  
MEF2C 0.002 2.614
TAF4B 0.003  
DIO2 0.003  
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Changes in Metabolome during Immobilization
Most metabolite levels showed decreased levels after immobilization, regardless of 
significance (figure 4.2). Predominant among the significant metabolites (p-value < 0.05) 
were fatty-acid derived acyl carnitines, including malonylcarnitine, dodecenoylcarnitine, 
acetylcarnitine and decenoylcarnitine. These carnitines all showed decreased levels after 
immobilization. A single carnitine, 2-methylbutyroylcarnitine, a product of branched chain 
amino acid oxidation, showed increased levels after immobilization. Two metabolites 
from polyamine metabolism, ornithine and putrescine, also showed decreased levels 
after immobilization. Two other metabolites in the polyamine pathway, spermine and 
spermidine, did not pass quality control. Lactic acid and GABA levels were also decreased 
after immobilization. No significant effects of creatine supplementation on the metabolome 
were observed.
4−Aminobutyric acid (GABA)
Lactic acid
Proline
Acetylcarnitine
Malonylcarnitine
2−Methylbutyroylcarnitine
Dodecenoylcarnitine
Decenoylcarnitine
Butyrylcarnitine
Ornithine
Putrescine
0.0
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Significance (P < 0.05): Amines Carnitines Not Significant Organic Acids Polyamine Metabolism
Figure 4.2 – Volcano plot of metabolites changed during immobilization. Metabolites are coloured by type. 
Black points are metabolites that were not significant (p-value < 0.05). Dotted line represents a p-value cut-off 
of 0.05. 
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Discussion
Knee immobilization rapidly reduced muscle mass and strength. Contrary to our hypothesis, 
creatine supplementation did not attenuate loss of muscle mass and strength by knee 
immobilization.  However, we observed that changes in the skeletal muscle transcriptome 
were attenuated in the creatine group as compared to the placebo group, despite a lack 
of significant differences in muscle size and strength loss. Analysis of the response in the 
skeletal muscle metabolome during immobilization revealed a decrease in fatty-acid derived 
acyl-carnitines and two metabolites involved in polyamine metabolism. We did not observe 
any differences due to creatine supplementation in the metabolome, likely due to the low 
sample size, and high inter-individual variation in the metabolomics data. 
 Previous studies have observed that short-term physical inactivity can lead to 
decreased insulin sensitivity and anabolic resistance [3, 4, 31]. Our findings are consistent 
with these previous observations, which are likely due to the decreased energy demands of 
inactive skeletal muscle. Several downregulated genes among the top 20 genes are involved 
in energy metabolism, including NMRK2, SLC16A3, PFKFB3 and NR4A1 (table 4.2). The latter, 
NR4A1 (frequently referred to as Nur77), is a major regulator of glucose metabolism in muscle 
tissue [32-34]. The results of gene set enrichment analysis are consistent with the decreased 
expression levels of these energy metabolism genes, showing decreased expression of 
mitochondrial function genes and glucose metabolism genes (table 4.3). 
 The decreased levels of several fatty acid derived acyl-carnitines also imply a 
decreased turnover of fatty acids. These shifts in expression of genes related to energy 
metabolism and the decrease in fatty acid derived acyl-carnitines are likely also due to the 
significant reduction in energy demand during immobilization. The only metabolite that 
was increased after immobilization was 2-methylbutyroylcarnitine, which is a downstream 
product of branched chain amino acid oxidation. The most likely explanation is increased 
amino acid oxidation due to muscle protein breakdown.
 We observed a reduction in the levels of putrescine and ornithine. Putrescine 
is a metabolite that is part of polyamine metabolism, while the conversion of ornithine 
to spermine is the rate limiting step in polyamine synthesis. Unfortunately, spermine and 
spermidine, the two other main polyamines in polyamine metabolism, did not pass quality 
control. The polyamine pathway regulates a wide range of metabolic processes, including cell 
cycle and growth pathways [35-37]. Importantly, it is also involved in muscle health, where it is 
associated with both muscle growth and muscle atrophy [38, 39]. Previous evidence suggests 
that putrescine is increased in denervated muscle in rats [40]. Furthermore, unloading via a 
hind-limb suspension model impacts muscle polyamine levels in mice, although the effects 
appear to be different between fast-twitch and slow-twitch muscle and mainly concern 
spermine and spermidine [39, 41, 42]. Unfortunately, there are very few data on the role of 
polyamine metabolism in human skeletal muscle. 
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 Both Histone Deacetylase 4 (HDAC4) and Myogenin were significantly upregulated 
after immobilization, whereas HDAC9 was downregulated. The HDAC4/Myogenin axis involves 
HDAC4, HDAC9, Myogenin and Myocyte Enhancement Factor 2 (MEF2) and has been primarily 
studied in the context of neurogenic muscle atrophy [43, 44]. HDAC4 interacts with Myogenin 
and together these factors regulate muscle atrophy genes [45]. MEF2 is a major regulator of 
skeletal muscle gene expression and has been shown to be inhibited by HDAC4 [46]. Even 
though there is no denervation or neuromuscular pathology in these healthy volunteers, 
it may be that the chronic lack of muscle contraction leads to a similar lack in calcium 
fluxes in the sarcoplasm, thus inducing a similar muscle programme that regulates both 
muscle atrophy and neurogenesis. Previous studies have shown that HDAC4 and Myogenin 
are also involved in diseases with a neuromuscular component such as Huntington’s and 
Amyotrophic Lateral Sclerosis [47-51]. 
 Immobilization led to differential expression of several other genes that play a role 
in neuromuscular signalling, which seems to be consistent with the increased expression 
of HDAC4 and Myogenin. Glial cell derived neurotrophic factor (GDNF), involved in motor 
neuron survival and regeneration, was significantly upregulated and features among the 
top 20 differentially expressed genes (table 2). Muscle cholinergic receptor subunits were 
all upregulated, although only the B1 subunit (CHRNB1) reached statistical significance 
(supplementary table 1). Lastly, acetylcholine esterase was significantly downregulated 
(supplementary table 1). Ataxin-1 (ATXN1) was also significantly upregulated, which is 
known to interact with HDAC4 and MEF2 and plays a central role in spinocerebellar ataxia 
1 [52]. In aggregate these gene expression changes suggest a compensatory response to 
restore neuronal signalling via increased expression of muscle acetylcholine receptors, 
enhanced motor neuron survival via GDNF, and decreased breakdown of acetylcholine at the 
neuromuscular junction.
 Gene expression changes due to immobilization were smaller in the creatine group 
than in the placebo group (table 4.2, figure 4.1, supplementary table S4.1). It is unknown 
how creatine can modulate the transcriptomic response to knee immobilization. A possible 
indirect factor could be activation of p38 MAPK by creatine supplementation. Previous studies 
have shown that creatine supplementation increases expression of p38 MAPK and induces 
activation of p38 MAPK, likely via osmotic stress [53, 54]. Furthermore, the p38 MAPK pathway 
has previously been shown to modulate MEF2 activity [55, 56]. Another mechanism could be 
the upregulation of basic helix-loop-helix e40 (BHLHE40). This gene was upregulated in the 
creatine group (FC 1.48, p-val. 0.003) but unaffected in the placebo group (supplementary 
table S4.1). Previous studies have shown that BHLHE40 can repress the activity of myogenic 
factors, including MyoD and Myogenin [57, 58]. It is possible that the induction of BHLHE40 
mediates the attenuating effect of creatine supplementation on the transcriptomic response 
since Myogenin plays an important role in HDAC4-induced muscle atrophy. Additionally, 
the study by Hespel et al. also showed that creatine supplementation modulated Myogenin 
protein levels after knee immobilization [17].
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 In contrast to the observed effect of creatine on the skeletal muscle transcriptome, 
we were unable to find an effect of creatine supplementation on muscle size and strength. 
It is possible that the effects of creatine supplementation will start to manifest during longer 
term knee immobilization, as is the case with a fracture. Of course, gene expression does 
not necessarily translate directly to protein expression and as such these results should be 
interpreted with caution.  However, these results do suggest that it might be worthwhile to 
investigate whether the lack of effect of creatine supplementation is due to the brief period 
of immobilization or whether there is a true lack of effect of creatine supplementation on 
muscle atrophy.  
Conclusion
Short term knee immobilization led to decreased expression of genes involved in energy 
metabolism and seemed to induce muscle atrophy via the HDAC4/Myogenin axis. This 
mechanism has previously been studied primarily in the context of denervation. In humans 
HDAC4 activity in skeletal muscle is primarily observed in disease states such as ALS and 
Huntington’s, whereas here it is induced in healthy human volunteers. This suggests that 
knee immobilization can be used as a model to study the HDAC4/Myogenin axis in healthy 
humans. Metabolomics showed alterations in the polyamine metabolism, suggesting 
involvement of polyamine metabolism in muscle disuse atrophy. Creatine supplementation 
seemed to attenuate gene expression changes due to knee immobilization but this result did 
not translate into a measurable effect on changes in muscle size and strength. 
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Abstract
Vitamin D deficiency is common among older adults and has been linked to muscle 
weakness. Vitamin D supplementation has been proposed as a strategy to improve muscle 
function among older populations. We investigated the effect of calcifediol on the skeletal 
muscle transcriptome in vitamin D deficient (25(OH)D between 20 and 50 nmol/L) frail older 
adults (65+) in a double-blind placebo controlled trial. 
 Twelve subjects were included in the placebo group and ten subjects were included 
in the calcifediol group. Muscle biopsies were obtained before and after six months of 
calcifediol (10 µg per day) or placebo supplementation. Whole genome gene expression 
profiling was done using Affymetrix HuGene 2.1ST arrays.
 Calcifediol supplementation led to a significant increase in blood 25(OH)D levels 
compared to the placebo group. No difference between treatment groups was observed on 
strength outcomes. P-values were uniformly distributed across all genes, suggesting that low 
p-values are likely to be false positives. PLS-DA was unable to separate treatment groups. 
Significant genes did not reveal pathways associated with muscle function or vitamin D 
signalling. 
 We did not observe a robust effect of calcifediol supplementation on the skeletal 
muscle transcriptome among frail older adults. Our findings indicate the effects of vitamin 
D supplementation on skeletal muscle may be either absent, weak, or limited to a subset of 
muscle cells. 
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Introduction
Muscle weakness and muscle loss increase with age, potentially leading to an increased 
risk of falls, frailty and loss of independence among older adults [1]. Many older adults  are 
also deficient in vitamin D. Various observational studies have found associations between 
vitamin D deficiency and impaired muscle function and/or physical performance among 
older populations [2-6]. As a consequence, vitamin D supplementation has been proposed 
as a strategy to improve muscle function among older populations. 
 Vitamin D is suspected to affect muscle health via both indirect and direct 
mechanisms. Indirectly vitamin D can influence muscle function via its role in calcium and 
phosphate homeostasis [7, 8]. Vitamin D has also been proposed as a direct modulator 
of skeletal muscle signalling via activation of the vitamin D receptor. Several cell culture 
studies have suggested a role of vitamin D receptor signalling in skeletal muscle health and 
function [9-12]. In addition, inactivation of the vitamin D receptor in mice leads to impaired 
muscle development and differential expression of key myogenic regulators [13]. Conversely, 
calcitriol was found to inhibit myoblast proliferation and differentiation in primary myocytes 
isolated from human skeletal muscle [14]. 
 While there is evidence from in vitro studies and animal knock-out models suggesting 
a transcriptional role of the vitamin D receptor in skeletal muscle, more recently this role has 
come into question [15]. Wang et al. (2011) showed that most of the antibodies for the vitamin 
D receptor lacked specificity, potentially leading to false positives. Intriguingly, despite the 
fact that the vitamin D receptor was present and functional in myocytes isolated from human 
skeletal muscle and C2C12 myotubes, Olsson and colleagues (2016) were unable to detect 
appreciable levels of the vitamin D receptor in mature human skeletal muscle. We performed 
RNA microarray measurements on muscle biopsies obtained from frail older participants 
of a randomized, placebo controlled double blind trial investigating the effect of calcifediol 
(25-hydroxycholecalciferol or 25(OH)D) supplementation on muscle function [16]. Our goal 
was to determine the overall impact of vitamin D on skeletal muscle gene regulation in vivo in 
humans and identify potential target genes in skeletal muscle. 
Materials & Methods
Study Design & Population
This study is part of a larger clinical trial. Procedures for this study will be described briefly, 
more details can be found elsewhere [16]. This study used a randomized, parallel-arm 
double blind design. Subjects in the calcifediol arm received 10ug 25(OH)D per day (DSM 
Nutritional Products Ltd.). Subjects were instructed to take their capsules in the morning 
during breakfast. A subset of samples was taken from the main study based on how much 
muscle was available for microarray analysis (12 subjects in the placebo arm and 10 subjects 
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in the calcifediol arm).  Participants were frail and pre-frail older adults (65+) with serum 
levels of 25(OH)D between 20-50nmol/L. Frailty was assessed using the Fried criteria [17]. 
Strength Measurements
Isometric leg muscle strength (leg extension and leg flexion) was assessed using a Biodex 
System 4 dynamometer (Biodex Medical Systems, Shirley, NY, USA). Subjects were seated 
upright with their chest and waist secured by belts. Experiments were performed with 
knee angle of 60⁰ and hip angle of 90⁰. Subjects performed 3 maximal voluntary isometric 
contractions for five seconds, with 30 seconds of rest between trials and five minutes of rest 
between knee-extension and knee-flexion trials. Researchers provided standardized verbal 
encouragement during the strength tests.
Muscle Biopsies
Muscle biopsies were taken from the middle region of the vastus lateralis muscle under local 
anaesthesia, ~15 cm above the patella and ~3 cm below entry through the fascia, using the 
percutaneous needle biopsy technique [18]. Muscle samples were dissected carefully and 
freed from any visible non-muscle material and were immediately frozen in liquid nitrogen. 
Subsequently, muscle samples were stored at -80 °C until further analysis. 
Microarray analysis and qPCR
RNA was isolated (RNeasy Micro kit, Qiagen, Venlo, the Netherlands), quantified (Nanodrop 
ND 1000, Nanodrop technologies, Wilmington, DE, USA) and integrity was checked by an 
Agilent 2100 Bioanalyser with RNA 6000 microchips (Agilent Technologies, South Queensferry, 
UK). Total RNA was labelled using the GeneChip® WT plus Reagent Kit and hybridized to 
GeneChip® Human Gene 2.1 ST Array (Affymetrix, Inc. Santa Clara, CA, USA). Sample labelling, 
hybridization to chips, and image scanning were performed according to the manufacturers’ 
instructions. 
 We performed qPCR on the vitamin D receptor gene (forward: 
GTGGACATCGGCATGATGAAG, reverse: GGTCGTAGGTCTTATGGTGGG). 500ng RNA was reverse 
transcribed to cDNA using a iScript cDNA synthesis kit (Bio-Rad Laboratories, Veenendaal, 
Netherlands). Real-time PCR was performed using SensiMix (Bioline, GC biotech, Alphen aan 
den Rijn, Netherlands) on a CFX384 Real-Time PCR detection system (Bio-Rad Laboratories, 
Veenendaal, Netherlands). 
Data analysis
All data analysis was done in R [19]. Changes in muscle strength and vitamin D levels were 
evaluated using linear mixed models using the lme4 library[20]. Microarray data were 
assessed for quality using the MADMAX pipeline and additionally by visually inspecting 
the probe level residuals and NUSE plots[21]. Data was normalized using Robust Multichip 
Average (RMA) (Bolstad et al., 2003). Gene level summarization was performed using the most 
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recent Custom CDF from the Brainarray project [22]. Genes were filtered using UPC filtering 
with a 50% expression likelihood cut-off in at least 10 samples, the smallest subset within 
this dataset [23].
 Univariate statistical analysis of gene expression was performed using the limma R 
library (Ritchie et al., 2015). Contrasts were set for time effect in both placebo and calcifediol 
groups and an interaction term for the calcifediol group versus the placebo group. P-values 
were calculated using Intensity Based Moderated t-tests[24]. Genes with a p-value below 
0.05 and an absolute fold change above 1.2 were considered statistically significant. Gene 
ontology was performed using EnrichR[25]. Pathway and upstream regulator analysis was 
performed using Ingenuity Pathway Analysis (Qiagen, The Netherlands). Partial least squares 
discriminant analysis (PLS-DA) was performed using the caret and pls libraries[26]. PLS-DA 
model was validated using 5×5-fold repeated cross-validation. Model performance was 
evaluated using area under ROC curve (AUROC). Receiver Operator Characteristic (ROC) curve 
and heatmaps were made using ROCR and ComplexHeatmap libraries, respectively [27, 28]. 
Results
Vitamin D Status and Muscle Strength
Calcifediol supplementation led to significant increases in total 25(OH)D and 24,25(OH2)D3 
levels compared to placebo (table 5.1). At the end of the study, subjects in the placebo group 
were on average still below the deficiency cut-off used for this study (50 nmol/L), whereas 
the calcifediol group was not. No differences were observed in muscle strength outcomes 
(BioDex leg extension and flexion peak torque, table 5.1). A full discussion of physiological 
outcomes of vitamin D3 supplementation and calcifediol supplementation can be found 
elsewhere [16]. 
Table 5.1 – Subject characteristics and main effect of calcifediol supplementation
Placebo - Pre Placebo - Post 25(OH)D - Pre 25(OH)D - Post
N 12 10
Gender (M / F) 6 / 6 6 / 4
Age (years) 74.1 ± 5.8 71.8 ± 5.7
BMI (kg/m2) 27.2 ± 4.0 28.0 ± 4.0
Weight (kg) 76.2 ± 14.0 80.7 ± 14.9
Body Fat (%) 32.1 ± 6.9 31.3 ± 6.6 32.5 ± 7.8 32.4 ± 7.8
Total 25(OH)D (nmol / L) 37.5 ± 11.9 43.8 ± 14.1 34.1 ± 9.3 87.3 ± 20.6 ***
24,25(OH
2
)D
3
 (nmol / L) 1.9 ± 0.8 2.7 ± 1.5 1.8 ± 0.7 8.0 ± 3.7 ***
BioDex Leg Extension Peak Torque (Nm) 129.7 ± 48.9 133.6 ± 64.1 145.9 ± 50.3 157.2 ± 56.1
BioDex Leg Flexion Peak Torque (Nm) 57.0 ± 29.9 55.2 ± 35.0 64.8 ± 22.5 70.0 ± 23.6
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Effect of Calcifediol on Muscle Transcriptome
Overall, we were unable to find strong effects of calcifediol supplementation on the skeletal 
muscle transcriptome. Both the microarrays and qPCR revealed very low expression of the 
vitamin D receptor in our muscle biopsies (median raw intensity on microarrays of 12.1, 
amplification curves for the vitamin D receptor gene are shown in figure 5.1). Unadjusted 
P-values were uniformly distributed in both treatment groups and for the interaction between 
group and time (figure 5.2A,B,C). As a consequence, genes with a low p-value are likely to be 
false positives. Correcting for multiple testing using false discovery rate led to no differentially 
expressed genes using any sensible cut-offs (all q-values ~ 1). Using PLS-DA we attempted to 
separate the transcriptomic response to calcifediol supplementation from the response in 
the placebo group. This approach did not reveal any consistent patterns in the data (AUROC 
< 0.5 during 5×5-fold repeated cross-validation, figure 5.2D; accuracy of 0.46, Kappa of -0.12). 
Figure 5.1 – qPCR Amplification curves of the vitamin D receptor in muscle biopsies
0
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Using an optimistic p-value cut-off of 0.05 and signed fold change cut-off of |1.2| revealed 
123 genes differentially regulated in the calcifediol group. The top 20 for genes changed in 
the calcifediol arm can be found in table 5.2. Significant genes did not include pathways or 
processes related to vitamin D receptor signalling (supplementary table 5.1 and 5.2). Genes 
previously described as putative target genes for the vitamin D receptor [29-31] did not show 
differential expression, with the exception of the insulin-like growth factor 1 receptor (IGF1R, p 
< 0.05, fold change of -1.27 for the interaction effect between time and treatment;  figure 5.3).
NO EFFECT OF CALCIFEDIOL SUPPLEMENTATION ON 
SKELETAL MUSCLE TRANSCRIPTOME IN VITAMIN D DEFICIENT FRAIL OLDER ADULTS
99
Ch
ap
te
r 5
Table 5.2 – Top 20 genes based on absolute fold change in the calcifediol arm
Gene FC – 25(OH)D FC - Pla. P-val. - 25(OH)D P-val. - Pla. P-val. Interaction
SCD 2.01 1.19 0.002 0.374 0.069
S100A8 1.88 1.02 0.044 0.947 0.142
ANKRD1 1.80 1.52 0.020 0.065 0.600
HBB 1.64 1.01 0.039 0.976 0.125
LOC102724637 -1.62 -1.16 0.005 0.312 0.134
HBA2 1.57 -1.07 0.050 0.754 0.095
MIR4521 1.56 1.23 0.041 0.274 0.411
ALOX12-AS1 -1.55 -1.01 0.001 0.958 0.010
GTF2IP20 -1.52 -1.01 0.001 0.950 0.013
OXCT1 -1.45 -1.13 0.021 0.378 0.237
BORCS7 1.40 1.13 0.046 0.432 0.323
LOC101928316 -1.39 1.03 0.039 0.822 0.091
VSIG10 -1.39 -1.04 0.004 0.679 0.049
THRSP 1.39 -1.12 0.037 0.416 0.039
FMC1 -1.37 -1.01 0.012 0.959 0.060
MYLK3 -1.35 -1.09 0.014 0.431 0.172
CCDC80 1.35 1.20 0.028 0.139 0.495
LOC105378929 -1.34 -1.20 0.037 0.142 0.551
E2F6 -1.33 -1.16 0.014 0.147 0.359
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Figure 5.2 - A,B,C and D -Top left (A): P-values for the change in gene expression for all genes after filtering; 
before and after calcifediol supplementation. Uniform distribution (i.e. no increased frequency of genes for 
lower p-values) indicates an absence of an effect. Top right (B):  values for the change in gene expression; before 
and after in the placebo group. Bottom left (C): P-values for the interaction effect (change in the calcifediol group 
vs. change in placebo group). Bottom right (D): receiver operator characteristic curve for the PLS-DA model. 
NO EFFECT OF CALCIFEDIOL SUPPLEMENTATION ON 
SKELETAL MUSCLE TRANSCRIPTOME IN VITAMIN D DEFICIENT FRAIL OLDER ADULTS
101
Ch
ap
te
r 5
Calcifediol Placebo
BGLAP
MYOD1
CAMP
CYP27B1
NRIP1
THBD
MYH2
CRYAB
SMAD4
SOD1
PPARD
MEF2A
MEF2C
SMAD3
PPARGC1A
LRRC8A
VDR
HSP90AA1
CALB1
SLC37A2
CYP24A1
S100G
G0S2
ASAP2
MYOG
CALM1
DUSP10
IGF1R
DDIT4
CD14
SMAD7
MYF5
ACVR2A
NINJ1
SLR
1
0.5
0
−0.5
−1
 
Figure 5.3 – Heatmap of gene expression changes (signal log ratio, SLR) of putative genomic targets of the 
vitamin D receptor
Discussion
Supplementation with calcifediol led to a significant increase in vitamin D status as 
determined by total 25(OH)D levels (34.1 ± 9.3 to 87.3 ± 20.6, p < 0.001). However, we were 
unable to confidently identify skeletal muscle genes that were affected by calcifediol 
supplementation in deficient pre-frail older adults. Neither a univariate technique (limma) 
nor a multivariate technique (PLS-DA) led to the identification of a robust signature of vitamin 
D supplementation in skeletal muscle. This is also in accordance with the lack of effect on 
muscle function [16].
 Using somewhat permissive cut-offs we found 123 genes differentially regulated 
in the calcifediol supplemented arm. However, the same cut-offs led to 59 differentially 
regulated genes in the placebo group. Interaction contrast for time x treatment led to 
identification of 143 genes. Given the flat p-value distributions (figure 5.2), it is difficult to 
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attribute these differentially expressed genes to vitamin D supplementation without risking 
an unacceptable number of false positives. 
 Gene ontology analysis, pathway analysis and upstream regulator analysis of these 
genes also did not reveal any effects on pathways related to muscle function, vitamin D 
receptor signalling, calcium metabolism or phosphate metabolism (supplementary table S5.1 
and S5.2). Known target genes of the vitamin D receptor were also not significantly affected 
(figure 5.3). Many of these genes were identified in immune cells, particularly microarray 
studies using immune cells [30]. ChIP-seq data suggests that the target genes for the vitamin 
D receptor can vary greatly depending on the cell type [32]. To our knowledge, no ChIP-seq 
analysis has been carried out on skeletal muscle cells. Other genes were selected based on a 
recent paper of by Hassan-Smith and colleagues (2017), where muscle gene expression was 
correlated with circulating levels of 1,25(OH2)D3 and 25(OH)D. Correlations were generally 
weak (~0.3 – 0.5), but considered statistically significant. 
 There are several possible explanations for a lack of effect in this study. Importantly, 
there is still some discussion as to whether the vitamin D receptor is expressed in skeletal 
muscle tissue. Our data showed that the vitamin D receptor is very weakly expressed in our 
samples (figure 5.1). Reports of vitamin D receptor expression in skeletal muscle go back 
several decades [33, 34]. However, more recently it was revealed that antibodies for the 
vitamin D receptor may not be sufficiently specific, leading to overestimation of vitamin D 
receptor protein levels in skeletal muscle [35]. Olsson and colleagues observed that while 
precursor cells and myotubes express the vitamin D receptor, mature skeletal muscle does 
not [14]. This could also partly explain why we observed no significant effects, as we used 
whole muscle tissue rather than specific sub-populations of cells. The signal from these 
specific cells would be diluted by the signal from the muscle tissue as a whole. Since satellite 
cells are generally quiescent, it may be possible that the effect of vitamin D can only be 
observed once proliferation and differentiation processes are triggered. 
 Another possibility is that the participants in this study were not sufficiently 
deficient to observe an effect. We did not include individuals with a vitamin D status below 
20 nmol/L due to ethical concerns. It is conceivable that very severe deficiency has a much 
stronger impact on muscle function, thus leading to a bigger observable effect. However, 
severe deficiency might also lead to alterations in calcium and phosphate metabolism, each 
of which can have an effect on muscle function [36, 37]. 
 We suspected that deficient frail older adults were the most likely to benefit from 
vitamin D supplementation in relation to muscle function. Despite this, it seems that the 
effect of vitamin D on the muscle transcriptome is weak, if there even is an effect. Since it 
is possible that the vitamin D receptor is only present in proliferating satellite cells, it might 
be particularly difficult to observe a transcriptomic effect in whole skeletal muscle in vivo. 
Studies in subjects with more severe deficiency could potentially reveal more robust effects, 
but would likely also lead to the involvement of phosphate and calcium metabolism. In 
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short, our data suggest that vitamin D does not plays a significant role in gene regulation in 
human skeletal muscle.
Conclusion
We did not observe a robust effect of calcifediol supplementation on the skeletal muscle 
transcriptome among frail older adults in this randomized, double blind placebo-controlled 
clinical trial. Our findings indicate the effects of vitamin D supplementation on skeletal 
muscle transcriptome may be either absent, weak, or limited to a subset of muscle cells. 
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Abstract
Physical inactivity can lead to rapid loss of skeletal muscle mass and strength and negatively 
impacts overall health. Here we compare the transcriptomic changes between a week of 
bed rest and a week of knee immobilization, in addition to other available muscle atrophy 
datasets. Our goal was to determine the similarities and differences among various causes of 
muscle atrophy in humans. In addition, we aimed to assess which model for human disuse 
atrophy most closely resembles the transcriptomic signature of older age and age related 
frailty.
 Muscle biopsies were obtained before and after 7 days of either bed rest or plaster 
cast knee immobilization. Gene expression microarrays were used to measure transcriptomic 
changes induced by muscle disuse. Additional data were obtained from the Gene Expression 
Omnibus (GEO) database and prior studies on the effect of knee immobilization, unilateral 
lower limb suspension, protein deficiency, bed rest, age and frailty on muscle gene expression. 
 Both knee immobilization and bed rest led to significant changes in the muscle 
transcriptome (861 and 708 differentially expressed genes, respectively). However, the 
overlap in significantly changed genes was relatively small (61 genes). Knee immobilization 
was characterized by ubiquitin-mediated proteolysis and induction of the HDAC4/Myogenin 
axis, whereas bed rest revealed increased involvement of the immune system and increased 
expression of lysosomal genes. Both atrophy models showed decreased expression of 
energy metabolism genes (glucose metabolism and oxidative phosphorylation). Systematic 
analysis of other studies revealed similar negative regulation of energy metabolism genes. 
We built regression models to estimate recent losses in muscle cross-sectional area (r2 of 
0.35). Comparison of expression profiles revealed that knee immobilization was the closest 
to age and frailty signatures. Finally, canonical markers of muscle atrophy (FBXO32 and 
TRIM63) lacked robustness for the assessment of human muscle atrophy.
 We showed a proof-of-concept technique of determining muscle atrophy using 
microarray data. Knee immobilization showed the highest similarity with age-related 
transcriptomic changes. This finding suggests that knee immobilization may be the most 
similar form of disuse atrophy to assess the effectiveness of strategies to prevent age-related 
muscle loss in humans. Our study suggests that the mechanisms of muscle atrophy vary 
across disuse models.
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Introduction
Brief periods of muscle disuse can have lasting negative effects on muscle health and overall 
health. Not only does muscle disuse lead to rapid loss of muscle mass and strength, physical 
inactivity can also lead to a reduction in insulin sensitivity, increased adiposity and  an overall 
decrease in metabolic rate [1-3]. Furthermore, it has been suggested that brief periods of 
muscle disuse accumulate over a lifetime, which might contribute to sarcopenia [4].
 Muscle atrophy results from an imbalance between overall muscle protein synthesis 
and muscle protein breakdown rates. Which part of the equation is dominant during muscle 
loss (i.e. decreased synthesis or increased breakdown) is subject to discussion [5]. In addition, 
the underlying mechanisms of muscle atrophy can vary depending on the cause of the 
atrophy, making the study of muscle atrophy particularly difficult. Potential mechanisms for 
muscle protein breakdown include autophagy, apoptosis, calpains and ubiquitin-mediated 
proteolysis [6, 7]. 
 Up until now the most frequently used method of presence of muscle atrophy at 
the molecular level, particularly over longer periods such as in relation to sarcopenia and 
cachexia, has been to measure expression of genes that are thought to mediate proteolysis 
in skeletal muscle. The most characterized genes in this context are FBXO32 and TRIM63, two 
ubiquitin E3 ligases thought to specifically mediate muscle protein breakdown, which were 
identified using transcriptomics studies in animal models [8-10].  These genes are believed to 
be common to many forms of muscle loss [11]. However, these genes have been inconsistent 
markers for muscle atrophy, particularly in human studies, and have been subject to some 
criticism [12, 13].  
 As a consequence, there is a need for a more comprehensive strategy to assess 
muscle atrophy at the molecular level, particularly in humans. Muscle disuse can be used 
to induce transient muscle atrophy in order to study underlying mechanisms in healthy 
humans in vivo. However, to complicate matters, there are various models for disuse atrophy, 
including bed rest, leg cast immobilization, and limb suspension. These models differ in 
various ways. For example, bed rest can affect muscles across the whole body, potentially 
leading to atrophy and metabolic effects in all muscles, whereas cast immobilization and 
limb suspension are limited to muscles in specific limbs. Bed rest can also potentially lead 
to other systemic changes, including increased inflammation and changes in levels of 
(stress) hormones [14]. Knee immobilization using a plaster cast, particularly when placed 
at an angle, prevents complete use of a limb. Milder models, such as unilateral lower limb 
suspension or knee immobilization using a brace, potentially do not completely remove 
muscle loading [15].
 Many processes are involved in muscle atrophy.  It can be hypothesized that that 
some of these processes are distinct for different causes of atrophy. Transcriptomics can 
be used to evaluate a wide range of underlying mechanisms simultaneously and could 
potentially shed light on how to more reliably study muscle atrophy in humans. Here we 
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compare the transcriptomic response to seven days of bed rest and seven days of knee 
immobilization in young healthy men. We also compare these responses to other publicly 
available datasets on muscle atrophy. Lastly, we aim to determine which source of muscle 
atrophy approximates the patterns in gene expression associated with decreased muscle 
mass and strength observed in frail older adults. 
Materials and Methods
Study designs
Samples were derived from two studies performed previously. Both studies involved seven 
days of physical inactivity: either strict bed rest or full leg immobilization using a plaster cast. 
Participants were young, healthy men with no fractures or illnesses (subject characteristics can 
be found in table 1). Subjects who underwent leg immobilization were part of a randomized 
parallel-arm placebo controlled study on the effect of creatine supplementation during knee 
immobilization [16, 17]. Subjects who underwent bed rest were part of a study to assess the 
impact of bed rest on insulin sensitivity  [18]. All samples were taken in an overnight fasted 
state. Muscle cross-sectional area (CSA) was determined using single slice CT scans. Strength 
loss was assessed using 1-repetition maximum (1RM) leg extension tests. These 1RM tests 
were unilateral for the knee immobilization study and bilateral for the bed rest study.  On the 
test day before seven days of physical inactivity, the precise scanning position was marked 
with semi-permanent ink for replication on test day after the seven-day period of inactivity. 
More details on the experimental procedures and outcomes of these studies can be found in 
their respective papers [16, 18].
Microarray analysis
RNA was isolated (RNeasy Micro kit, Qiagen, Venlo, the Netherlands), quantified (Nanodrop 
ND 1000, Nanodrop technologies, Wilmington, DE, USA) and integrity was checked by an 
Agilent 2100 Bioanalyser with RNA 6000 microchips (Agilent Technologies, South Queensferry, 
UK). Total RNA was labelled using the GeneChip® WT plus Reagent Kit and hybridized to 
GeneChip® Human Gene 1.1 ST Arrays (Affymetrix, Inc. Santa Clara, CA, USA). Sample labelling, 
hybridization to chips, and image scanning were performed according to the manufacturers’ 
instructions. All samples for the 7-day bed rest study and 7-day knee immobilization were 
analysed in a single batch. 
Data analysis
Physical characteristics (i.e. muscle size and strength) were evaluated using linear mixed 
models. Microarray data were assessed for quality using the MADMAX pipeline [19] and by 
visually inspecting the probe level residuals and NUSE plots. Data was normalized using 
Robust Multichip Average (RMA) [20]. Gene level summarization was performed using the 
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most recent Custom CDF from the Brainarray project [21]. Genes were filtered using UPC 
filtering with a 50% expression likelihood cut-off in at least 8 samples, the smallest subset 
of samples within our dataset [22]. Statistical analysis was performed using the limma 
R library [23]. All models were evaluated using a paired analysis (after intervention versus 
before intervention). P-values were calculated using Intensity Based Moderated t-tests (IBMT) 
[24].Gene set enrichment analysis (GSEA) was performed on pre-ranked lists, ranked by the 
t-values from limma. We used the most recent library of canonical pathways from MsigDb 
[25]. Data visualization was done using Cytoscape, ggplot2 and gplots [26-28]. Upstream 
regulator analysis was done using Ingenuity Pathway Analysis. An unadjusted p-value of 
0.01 was considered significant for gene level (univariate) analysis. A q-value of 0.10 was 
considered significant for the GSEA results.
Regression analysis
We used a sparse partial least squares (sPLS) regression model to determine the recent 
change in muscle CSA. Relative change in muscle cross-sectional area (i.e.  percentage of 
total CSA lost) of the quadriceps was used as dependent variable. Leg extension was chosen 
because the biopsies were obtained from the m. vastus lateralis. Two models were made: 
one where all genes after UPC filtering were used as independent variables (naïve model) 
and one model where the independent variables were genes that were significantly changed 
during both bed rest and knee immobilization in the placebo arm (common genes model). 
Data from the samples taken after physical inactivity were used for the model. The goal 
was to determine a signature of recent muscle atrophy in these samples. Hyperparameter 
selection and validation was done using leave-one-out cross-validation. Fitting procedure 
was performed using the caret library [29].  
Atrophy model comparison and similarity network
We conducted a search on the GEO database for available datasets to assess similarities 
in transcriptomic changes between different forms of muscle atrophy. We searched for 
studies with human muscle biopsies derived from healthy volunteers. Only studies using 
commercially available microarrays were considered. We included data from two ULLS 
studies (GSE21496 and GSE33886) [30, 31], a two-day knee immobilization study (GSE5110)
[32], a bed rest study (GSE24215)[33] and a protein deficiency study (GSE8441)[34]. All but 
one study used Affymetrix chips and all studies were performed in healthy human volunteers. 
A single study used Agilent arrays. An overview of the studies we obtained from GEO can be 
found in table 6.1.
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All Affymetrix datasets were summarized at the gene level using Brainarray custom CDFs and 
data was normalized using RMA. The Agilent dataset was downloaded pre-normalized from 
GEO and gene level expression was summarized using median expression per gene. Statistical 
testing was done by assessing changes in the transcriptome compared to baseline after 
physical inactivity or protein deficiency, as with the 7-day bed rest and knee immobilization 
studies.  To approximate age-related muscle loss we used samples from a study we published 
previously on transcriptomic differences between young subjects, frail older subjects and 
healthy older subjects [35]. The effect of frailty and age on the transcriptome were analysed 
cross-sectionally, adjusted for sex. 
 To assess similarities between models we used the Bioconductor R library 
OrderedList [36]. This library assesses the similarities based on the order of ranked lists. In 
our case all comparisons were ordered based on the gene level t-test statistic, where each 
intervention was compared to all other comparisons in a pairwise fashion. We specified that 
50% of the genes were invariant and we used unfiltered datasets for the comparisons. Some 
genes were dropped for some of these comparisons due to differences in chip architectures. 
The similarity scores and p-values were collated and were integrated and visualized using 
Cytoscape [28]. We made a force-directed graph based on the similarity score to visually 
represent similarities between interventions using distance. Some nodes were manually 
moved slightly to enhance legibility of the figure. 
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Results
Knee immobilization
The effect of knee immobilization on muscle size and strength was published previously [16]. 
Likewise, the effect of creatine supplementation on the muscle transcriptome during knee 
immobilization was also discussed elsewhere. Briefly, seven days of knee immobilization 
induced rapid loss of muscle mass. Leg CSA was reduced by 574 ± 115 mm2 and quadriceps 
CSA was reduced by 484 ± 65 mm2. These changes were accompanied by a reduction 
in unilateral leg extension 1RM of 7.4 ± 1.8 kg. Creatine supplementation did not have a 
significant effect on the loss of both muscle mass and muscle strength (table 4.1). However, 
we did observe that generally gene expression changes were less pronounced in the creatine 
group. A full discussion of the effects of creatine supplementation during leg immobilization 
on the muscle transcriptome and metabolome can be found in chapter 4 [17].  
Table 6.2 – descriptive statistics of study population. Asterisks indicate significant difference compared to 
baseline. * = p < 0.05, ** = p < 0.01, *** p < 0.001
KI Bed Rest
Pre Post Pre Post
N 8 9
Age (years) 22.9 ± 3.2 23.0 ± 2.1
height (m) 1.75 ± 0.09 1.81 ± 0.08
Weight (kg) 71.4 ± 14.5 76.4 ± 6
BMI (kg/m2) 23.1 ± 3.3 23.5 ± 2.4
Bilateral Leg Extension 1RM (kg) 131.1 ± 19.8 120.6 ± 19.8*
Lean Body Mass (kg) 56.9 ± 3.8 55.9 ± 4.0**
Body Fat (%) 21.2 ± 6.8 21.9 ± 7.2
Unilateral Leg Extension 1RM (kg) 53.3 ± 15.3 52.4 ± 16.5
Whole Leg CSA (mm2) 14510 ± 2004 14004 ± 1981** 14430 ± 1610 14151 ± 1728
Quadriceps CSA (mm2) 7844 ± 1363 7428 ± 1313*** 8060 ± 911 7843 ± 1024*
Among the top 20 significant genes for knee immobilization were genes related to energy 
metabolism, as well as genes related to neuromuscular function (table 6.3, discussed in 
chapter 4). GSEA revealed increased expression of proteasomal genes and ubiquitin mediated 
proteolysis pathways, whereas glycolysis, gluconeogenesis and mitochondrial function 
pathways were downregulated (supplementary table S6.1). Upstream regulators analysis 
showed decreased expression of insulin target genes and increased expression of Forkhead 
box O3 (FOXO3), which was consistent with the downregulation of glucose metabolism genes 
and upregulation of proteolytic genes in the GSEA results (supplementary table S6.2).
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Table 6.3 – Top 20 genes for knee immobilization, bed rest and genes significant in both disuse atrophy models. 
Genes were ranked by absolute fold changes after selecting for significance (p < 0.01). Rank product was used 
on the absolute fold changes to rank the genes for the common genes. FC is signed fold change, KI is knee 
immobilization and BR is bed rest.
Gene Description FC BR FC KI P-val. BR P-val. KI
Knee Immobilization
NMRK2 nicotinamide riboside kinase 2 -1.76 -5.30 0.027 0.000
GDNF glial cell derived neurotrophic factor -1.17 4.80 0.521 0.000
SMCO1 single-pass membrane protein with coiled-coil domains 1 -2.92 -4.74 0.008 0.001
ACTN3 actinin alpha 3 1.11 -4.43 0.735 0.000
NR4A3 nuclear receptor subfamily 4 group A member 3 -1.90 -4.05 0.100 0.002
NR4A1 nuclear receptor subfamily 4 group A member 1 -1.73 -3.72 0.037 0.000
IL18 interleukin 18 2.06 3.51 0.064 0.004
HDAC4 histone deacetylase 4 -1.02 3.20 0.888 0.000
DHRS7C dehydrogenase/reductase 7C -1.70 -3.15 0.097 0.002
PDE11A phosphodiesterase 11A 1.52 2.91 0.045 0.000
GADL1 glutamate decarboxylase like 1 -2.30 -2.88 0.027 0.009
AMPD3 adenosine monophosphate deaminase 3 1.42 2.82 0.224 0.002
CA14 carbonic anhydrase 14 -2.60 -2.82 0.011 0.010
GADD45A growth arrest and DNA damage inducible alpha 2.34 2.69 0.005 0.002
SLC25A30 solute carrier family 25 member 30 -1.89 -2.66 0.029 0.003
LRRC14B leucine rich repeat containing 14B -1.65 -2.59 0.048 0.001
TP63 tumor protein p63 1.32 2.58 0.061 0.000
AKR1C2 aldo-keto reductase family 1 member C2 1.00 2.56 0.994 0.000
SLC16A3 solute carrier family 16 member 3 -1.36 -2.54 0.051 0.000
COQ10A coenzyme Q10A -1.91 -2.48 0.006 0.001
Bed Rest
MYH8 myosin heavy chain 8 14.81 2.00 0.001 0.361
MYH3 myosin heavy chain 3 13.71 1.36 0.001 0.668
TNNT2 troponin T2, cardiac type 12.75 1.05 0.000 0.945
SPP1 secreted phosphoprotein 1 10.40 -3.30 0.006 0.165
CHRNA1 cholinergic receptor nicotinic alpha 1 subunit 8.83 3.09 0.000 0.026
MYBPH myosin binding protein H 8.46 2.66 0.001 0.126
TMEM8C transmembrane protein 8C 7.03 1.36 0.001 0.571
MYL4 myosin light chain 4 6.11 1.41 0.000 0.462
DCLK1 doublecortin like kinase 1 5.84 1.04 0.001 0.935
LRRC17 leucine rich repeat containing 17 5.47 -1.03 0.002 0.959
LAPTM5 lysosomal protein transmembrane 5 5.32 -2.36 0.006 0.153
CHI3L1 chitinase 3 like 1 5.19 1.19 0.007 0.778
PRG4 proteoglycan 4 5.14 -2.48 0.005 0.117
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PRUNE2 prune homolog 2 5.10 2.24 0.005 0.160
IFITM10 interferon induced transmembrane protein 10 4.65 1.07 0.002 0.886
CD68 CD68 molecule 4.62 -2.11 0.004 0.157
FPR3 formyl peptide receptor 3 4.51 -2.35 0.003 0.093
LYZ lysozyme 4.31 -2.07 0.009 0.194
MSR1 macrophage scavenger receptor 1 4.28 -1.64 0.003 0.301
C1QB complement C1q B chain 3.96 -1.91 0.003 0.158
Common Genes
SMCO1 single-pass membrane protein with coiled-coil domains 1 -2.92 -4.74 0.008 0.001
GADD45A growth arrest and DNA damage inducible alpha 2.34 2.69 0.005 0.002
CCDC39 coiled-coil domain containing 39 3.57 2.17 0.000 0.009
COQ10A coenzyme Q10A -1.91 -2.48 0.006 0.001
MYOG myogenin 2.13 2.01 0.001 0.003
GLRX glutaredoxin 1.95 2.02 0.001 0.001
ARPP21 cAMP regulated phosphoprotein 21 1.62 2.28 0.002 0.000
CDC42EP3 CDC42 effector protein 3 1.53 2.26 0.009 0.000
MPP6 membrane palmitoylated protein 6 1.49 2.25 0.002 0.000
MEGF10 multiple EGF like domains 10 1.86 1.79 0.001 0.002
YPEL1 yippee like 1 1.36 1.97 0.004 0.000
GOT1 glutamic-oxaloacetic transaminase 1 -1.68 -1.63 0.003 0.006
MYOZ3 myozenin 3 -1.73 -1.58 0.001 0.008
AMOT angiomotin -1.56 -1.65 0.009 0.006
CALM1 calmodulin 1 1.40 1.75 0.001 0.000
SLC1A4 solute carrier family 1 member 4 -1.40 -1.73 0.002 0.000
SLC29A1 solute carrier family 29 member 1 -1.42 -1.70 0.007 0.000
RIMKLB ribosomal modification protein rimK like family member B 1.48 1.61 0.001 0.000
RASGRP3 RAS guanyl releasing protein 3 -1.45 -1.63 0.009 0.002
TP53INP1 tumor protein p53 inducible nuclear protein 1 1.58 1.46 0.000 0.003
Bed rest
Like knee immobilization, bed rest led to rapid loss in muscle mass and strength. Lean 
body mass, as measured using DXA, was decreased by 1.4 ± 0.3 kg (p < 0.01) and leg CSA 
and quadriceps CSA were reduced by 279 ± 140 mm2 (not significant) and  216 ± 67 mm2 (p 
< 0.05), respectively. Leg extension 1RM was reduced by 5.0 ± 1.7 kg (p < 0.05) following bed 
rest. A full discussion of the effect on muscle morphology and insulin sensitivity can be found 
elsewhere [18]. 
 Among the top 20 genes (table 6.3) that were upregulated by bed rest are genes 
related to muscle development, including developmental myosin heavy chain isoforms 
(MYH3, embryonic and MYH8, perinatal), troponin T2 (TNNT2), myosin binding protein H 
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(MYBPH), Transmembrane Protein 8C (TMEM8C) and myosin light chain 4 and 5 (MYL4 and 
MYL5).  A marker of macrophages, CD68, was also among the top 20 genes. Further down 
the list are other genes expressed by macrophages and other immune cells, including 
CD163, CD14, CD4 and CD37 and various complement system genes, all showed increased 
expression compared to baseline. 
 Pathway analysis using GSEA showed decreased expression of genes involved in 
oxidative phosphorylation, glucose metabolism and fat metabolism. Upregulated pathways 
included lysosomal, apoptosis and various immune pathways, as well as tissue remodelling 
and angiogenesis pathways (supplementary table S6.3). Gene sets associated with ubiquitin 
mediated proteolysis were not significantly affected by bed rest using our cut-off (p < 
0.01) Upstream analysis using ingenuity revealed inhibition of several energy metabolism 
regulators including PPARα, PPARδ and PGC1α. Other regulators that were affected included 
KDM5A (activated), KLF15 (inhibited), mTOR (affected), IGF1R (inhibited) and insulin (affected). 
The full results of the upstream analysis for the effect of bed rest on the transcriptome can be 
found in the supplementary materials (supplementary table S6.4).
Model comparisons
Seven days bed rest or knee immobilization
Bed rest and knee immobilization showed distinct effects on the transcriptome. Bed rest 
caused 707 genes differentially expressed genes, whereas knee immobilization led to 861 
differentially expressed genes. Only 61 genes were differentially expressed in both disuse 
atrophy models. Of those 61 genes, 8 genes showed opposite regulation. A scatterplot 
comparing the change in expression (signal log ratios) of both interventions can be found 
in figure 6.1, highlighting the differences in transcriptomic responses. Genes significantly 
changed in both interventions included genes related to muscle development and muscle 
atrophy such as Myogenin, Multiple EGF Like Domains 10 (MEGF10) and growth arrest and 
DNA damage inducible alpha (GADD45A). Significant overlapping genes also included protein 
ubiquitination genes: UBE2E1, ZNF168 and UBE2H.  
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Figure 6.1 - Signal log ratios of gene expression changes during 7 days of knee immobilization versus 7 days of 
strict bed rest
GSEA and upstream analysis revealed that both forms of disuse atrophy led to decreased 
expression of mitochondrial function genes and energy metabolism genes. Comparison of the 
results suggests that bed rest seemed to have a larger impact on lipid metabolism, whereas knee 
immobilization seemed to have a bigger impact on glucose metabolism genes (supplementary 
tables S6.1 and S6.3). There were also dissimilarities between potential mechanisms underlying 
muscle atrophy: knee immobilization showed significant increases in ubiquitin mediated 
proteolysis genes and proteasomal genes, while bed rest suggests involvement of the immune 
system, as shown by increased expression of immune, apoptosis and lysosomal genes. Both 
models showed differential expression of genes related to neurological function, including 
axon guidance genes and acetylcholine receptor signalling (table S6.3). 
Other muscle atrophy models
We compared six other microarray datasets investigating muscle atrophy. These varied in 
platform, duration and atrophy model. An overview of included datasets can be found in table 
6.1. Only a single gene was significant in 7 of the 8 comparisons: Cholinergic Receptor Nicotinic 
Alpha 1 Subunit (CHRNA1). This gene was not significant in the seven-days knee immobilization 
using our cut-offs (p-value < 0.01), but it approached statistical significance (p-value 0.026). 
Collagen 4A1 was significant in 6 of the 8 comparisons, and 6 genes were significant in 5 of the 8 
comparisons, including MEGF10 and calmodulin (CALM1) which were also among the common 
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genes between 7 days of bed rest and knee immobilization. Other genes that were significant in 
several models include collagens, and genes involved in oxidative phosphorylation and energy 
metabolism. A heatmap of the top 50 genes across these six datasets can be found in figure 6.2. 
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Figure 6.2 – Top 50 genes across muscle atrophy datasets based on rank product. Color intensity denotes –log10 
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As with 7 days of bed rest and knee immobilization, significant pathways included oxidative 
phosphorylation, TCA cycle and energy metabolism pathways. Upstream regulator analysis 
also showed downregulation of regulators involved in energy metabolism (peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha, PGC1α; peroxisome proliferator 
activated receptors alpha, gamma and delta, PPARα, PPARγ and PPARδ) and anabolic 
signalling (insulin receptor, INSR; insulin like growth factor 1 receptor; IGF1R). An overview of 
upstream regulators that appear common to all models can be found table 6.4.
Table 6.4 – Upstream analysis of genes common to all atrophy models. P-values were derived using Fisher’s 
method across all datasets. Signal log ratios were calculated by taking the mean signal log ratio across 
interventions. 
Upstream Regulator Predicted Activation State Activation z-score p-value of overlap
INSR Inhibited -5.699 0.000
KDM5A Activated 5.312 0.000
MAP4K4 Activated 5.555 0.000
PPARGC1A Inhibited -5.793 0.000
ESRRA Inhibited -4.347 0.000
Esrra Inhibited -3.85 0.000
RICTOR Activated 6.297 0.000
RB1 Inhibited -3.782 0.000
LONP1 Activated 2.784 0.000
OGT  0.64 0.000
MED30   0.000
INS  1.101 0.000
PPARA Inhibited -4.28 0.000
IGF1R Inhibited -3.848 0.000
Insulin  0.364 0.000
APP  0.648 0.000
VEGFA  -1.942 0.000
FOXO1  -0.725 0.000
PPARG Inhibited -3.83 0.000
SURF1 Activated 2.345 0.000
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Similarity network
We made a network of all the included studies to get an overview of similarities between 
the various atrophy models (figure 6.3). We also included data on the effect of frailty and 
age on the skeletal muscle transcriptome to determine which atrophy model is most similar 
to the effect of frailty and age. This analysis revealed that the different modes of inducing 
disuse atrophy were similar, despite differences in duration. The two bed rest studies showed 
a transcriptional pattern that tended to be dissimilar from the full knee immobilization 
interventions but not ULLS. Protein deficiency showed the least overlap with other studies, 
but did show strong similarities with the bed rest and 3 weeks of ULLS.
 
Knee Immobilization (48 hours)
Protein Deficiency (7 Days)
Frailty
Knee Immobilization (7 days)
ULLS (24 hours)
ULLS (3 weeks)
Age
Bed Rest (7 days)
Age & Frailty
ULLS (48 hours)
Bed Rest (9 days)
Figure 6.3 - similarity network for muscle atrophy models in humans. Black lines indicate significant similarity 
(p < 0.01). Line width is proportional to similarity score (wider lines indicate higher similarity).
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Muscle Atrophy Prediction
We made two sPLS regression models (figure 6.4) to predict the amount of muscle loss 
that has occurred in the past 7 days in the participants: a naïve model with all genes after 
filtering as input and a model that used the genes significantly changed after both bed rest 
and knee immobilization. The final naïve model after grid search included 258 genes after 
sPLS feature selection, based upon two components with a sparsity parameter (eta) of 0.7. 
Cross-validation of the naïve model showed an r2 of 0.25 and RMSE of 1.95 on the held-out 
samples during cross-validation. Predictive genes were primarily genes involved in ubiquitin 
mediated proteolysis after EnrichR analysis of selected predictor genes (table 6.3).  The final 
model using only significant genes as predictors selected 27 genes, had 5 components and 
sparsity parameter of 0.7. Cross-validation showed an r2 of 0.35 and RMSE of 1.78. Variable 
importance of predictor genes for the common genes model is shown in supplementary 
figure S6.1.
Table 6.5 – Top 10 enriched Gene Ontologies among predictive genes from the naïve sPLS regression model (GO 
biological processes).
Term GO Accession P-value Adjusted P-value
modification-dependent macromolecule catabolic process GO:0043632 0.000 0.003
modification-dependent protein catabolic process GO:0019941 0.000 0.005
proteolysis involved in cellular protein catabolic process GO:0051603 0.000 0.009
ubiquitin-dependent protein catabolic process GO:0006511 0.000 0.023
protein catabolic process GO:0030163 0.000 0.023
proteasome-mediated ubiquitin-dependent protein catabolic 
process GO:0043161 0.000 0.104
proteasomal protein catabolic process GO:0010498 0.000 0.117
mRNA processing GO:0006397 0.001 0.146
RNA splicing GO:0008380 0.001 0.146
regulation of proteasomal ubiquitin-dependent protein 
catabolic process GO:0032434 0.001 0.146
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Figure 6.4 - Predicted versus observed muscle atrophy from sPLS regression models. Data points are from the 
held-out samples during leave-one-out cross-validation. 3A is for the sPLS model using only the genes significant 
in both 7 days of bed rest and 7 days of knee immobilization (61 genes; common genes model). 3B is for the naïve 
model using all genes after UPC filtering as input.
Discussion
Disuse atrophy can lead to rapid losses of muscle mass and muscle strength, as previously 
shown in a wide array of studies [37]. Here we compare two models for disuse atrophy: 
strict bed rest and knee immobilization using a leg cast. Bed rest and knee immobilization 
led to comparable losses in muscle mass and strength in the leg (table 6.1, [14]). However, 
we observed distinct transcriptomic responses to either 7 days of bed rest or 7 days of 
knee immobilization. Both studies were carried out at Maastricht University, had a similar 
population (young healthy men, table 6.1) and had the same duration of disuse (7 days). 
There are of course obvious differences between bed rest and knee immobilization as 
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models for disuse atrophy: bed rest-induced disuse atrophy leads to muscle losses over the 
whole body, whereas knee immobilization has localized effects. Our data suggest that there 
are major differences on a transcriptomic level in the vastus lateralis. 
 Predominant changes during knee immobilization are downregulation of energy 
metabolism genes and upregulation of ubiquitin mediated proteolysis genes. The latter 
consisted of both ubiquitination genes and proteasomal genes. Top genes for knee 
immobilization included HDAC4, a gene that is primarily associated with denervation 
induced muscle atrophy as part of the HDAC4/Myogenin axis [38]. Also among the top genes 
are various neuronal genes, suggesting a compensatory response to enhance neuronal 
survival and signalling via induction of glial derived neurotrophic factor (GDNF), increased 
expression of acetylcholine receptor subunits and decreased expression of acetylcholine 
esterase (ACHE) (table 6.3). A more detailed discussion of the effect of knee immobilization 
on the transcriptome and metabolome can be found in chapter 4 [17]. 
 Bed rest had distinct effects on the muscle transcriptome compared to knee 
immobilization. Among the top 20 are several genes that are associated with muscle 
regeneration, such as embryonal and perinatal myosin heavy chain isoforms MYH3 and MYH8 
and TMEM8C.  There were also various genes involved in muscle contraction, cytoskeleton 
organisation and extracellular matrix genes (primarily collagen genes). In aggregate these 
gene expression changes suggest significant tissue remodelling and regeneration. There 
were signs of involvement of the immune system, as markers of immune cells were strongly 
upregulated (table 6.3), particularly macrophage markers and phagosomal genes. Among 
the top upregulated genesets were lysosomal genes, whereas ubiquitin mediated proteolysis 
genes were not significantly upregulated. These differences suggest that muscle atrophy 
during bed rest is mediated via a different mechanism than knee immobilization, most likely 
involving autophagy. This pattern, i.e. the transcriptional response to bed rest being distinct 
from knee immobilization, is also evident on a global scale of gene expression, as shown 
in figure 6.1 and 6.3. Previously, bed rest has been associated with modulation of stress 
hormones and immune markers, which may also have had an effect on insulin sensitivity 
and anabolic resistance [18, 39, 40]. 
 We analysed one other study where bed rest was used as a model for muscle 
atrophy with a similar duration (9 days versus 7 days). However, some methodological 
differences exist between the studies: our study did not allow any visits to the bathroom, 
different microarray platforms were used (Agilent 4x44K G4112F vs. Affymetrix HuGene 2.1 
ST), and subjects were in an insulin stimulated state when muscle biopsies were collected 
in the study by Alibegovic et.al. Despite these methodological differences we observed 
very similar effects on the muscle transcriptome: decreased energy metabolism genes and 
increased expression of tissue remodelling genes and inflammation genes. Similar effects on 
upstream regulators were also observed, with inhibition of PGC1A and several PPARs (table 
6.4). The two studies showed a statistically significant similarity in our similarity network. 
However, our study showed less similarity with the unilateral lower limb suspension studies, 
THE TRANSCRIPTOMIC SIGNATURE OF MUSCLE ATROPHY AFTER KNEE 
IMMOBILISATION MOST CLOSELY RESEMBLES THE TRANSCRIPTOMIC SIGNATURES OF FRAILTY AND AGE
125
Ch
ap
te
r 6
possibly because the bed rest was stricter in our study as compared to Alibegovic et al.. We 
also did not observe ER stress-related effects in our bed rest study, though genes related to 
protein synthesis and processing were upregulated in our study. 
While plenty of genes were changed during both knee immobilization (861 genes) and bed 
rest (708 genes), the overlap in significantly affected genes was relatively small (61 genes). The 
overlapping genes include several genes that are associated with muscle function or atrophy 
such as MEGF10 and GADD45A. GADD45A is suspected to be a key regulator of muscle atrophy, 
and was upregulated in both bed rest and knee immobilization (table 6.3) [41, 42]. MEGF10 is 
associated with myogenesis and mutations in this genes are linked to myopathy [43]. A gene 
that is less obviously related to muscle function is the top gene SMCO1. Both bed rest and knee 
immobilization led to significant downregulation of SMCO1. The function of SMCO1 is currently 
unknown, but it is highly expressed in muscle tissue. Deletion of the 3q29 region containing 
this gene may be associated with neurological and developmental problems. Curiously, Ring 
Finger Protein 168, a gene that is also significantly upregulated during bed rest and knee 
immobilization, is hypothesized to bind this genomic region [44]. The only other literature 
reference on SMCO1 that we could find is an abstract, which describes SMCO1 as a muscle-
specific gene and possibly regulated via Myocyte Enhancement Factor 2 (MEF2) [45]. 
Similarities with other models
When evaluating all studies on skeletal muscle atrophy in humans that used transcriptomics 
we did not find any genes that are significantly regulated among all studies. This could partly be 
explained by the heterogeneity in methodology, atrophy models and study duration. However, 
the comparison of all these studies did reveal some interesting candidates that seem relatively 
robust among all interventions. For example, MEGF10 and SMCO1 and are among the top 
significant genes across all studies (figure 6.2, table 6.3, supplementary table S6.5). 
 Common patterns across all studies include tissue remodelling (e.g. collagen and 
cytoskeleton reorganization genes), decreased energy metabolism (glucose metabolism, fat 
metabolism and oxidative phosphorylation) and neuromuscular changes (e.g.  acetylcholine 
receptor subunit genes). Upstream regulator analysis also revealed that all models have a 
strong impact on energy metabolism, with inhibition of regulators of lipid metabolism, glucose 
metabolism, mitochondrial function genes and exercise response. A likely explanation of 
these changes is due to the lower energy demand of inactive skeletal muscle. 
 The canonical muscle atrophy genes FBXO32 and TRIM63 were not strongly 
regulated, with the largest significant fold change occurring for FBXO32 after 2 days of 
ULLS (FC = 1.51, p = 0.004). FBXO32 showed upregulation in the three studies with a shorter 
duration of disuse when using a p-value cut-off of 0.05 (1 and 2 days of ULLS and 2 days of 
knee immobilization). TRIM63 only showed significant differential expression after 1 day of 
ULLS. These data suggest that gene expression of these two genes are poor markers for more 
prolonged periods of muscle atrophy. 
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Similarity network
One of our goals for this study was to evaluate whether disuse atrophy models can be used 
as a surrogate for the study of age-related muscle mass loss and muscle weakness (i.e. 
sarcopenia and dynapenia). Sarcopenia occurs over a prolonged period of time, which makes 
it difficult to study. Furthermore, clinical sarcopenia is quite severe and it may be unethical to 
study strategies that might negatively affect muscle mass in this population. Ideally, if we are 
to evaluate strategies that can preserve muscle mass and function in atrophic situations, we 
would be able to use healthy young individuals that can bounce back relatively quickly from 
physical insults such as disuse-induced muscle atrophy. To address this question we made 
a similarity network. 
 The similarity analysis revealed that of all the models in this study, knee 
immobilization for 7 days showed the highest similarity with frailty (figure 6.3). Bed rest for 
7 days and protein deficiency were the furthest removed from the effects of both age, frailty 
and a combination of age and frailty. This supports the notion that bed rest is primarily 
associated with a clinical outcome, whereas knee immobilization appears to be the most 
relevant for muscle atrophy itself. The unilateral lower limb suspension models appeared to 
be intermediates between bed rest and knee immobilization. 
 The high similarity between protein deficiency and bed rest is remarkable. 
Thalacker-Mercer et al. had previously observed very similar effects to our bed rest dataset 
and with the protein deficiency dataset, also observing involvement of the immune system 
and upregulation of lysosomal genes [34]. With regard to muscle atrophy, these results 
seem to suggest that autophagy and the immune system are primarily involved in muscle 
losses during bed rest and protein deficiency, whereas proteasomal systems (i.e. ubiquitin-
mediated proteolysis and possibly apoptosis) are primarily involved in the age, frailty and 
knee immobilization side of the spectrum. 
Muscle atrophy model
The models we built to detect recent muscle atrophy showed reasonable predictive 
capabilities, despite the relatively small sample size for such an approach. For the naïve 
model, selected genes were primarily genes involved in ubiquitin-mediated proteolysis, a 
process that is often the main mechanism for muscle atrophy (table 6.5). However, it is also 
very likely that both the type of disuse atrophy and the duration of disuse atrophy have an 
effect on which genes are involved in the loss of muscle mass. As a result, this model should 
be viewed as a proof-of-concept rather than a functional method of determining muscle loss. 
Larger sample sizes, different types of disuse atrophy, and multiple time points are needed 
to more accurately use gene expression microarrays as read-out for muscle atrophy. The 
second model using only genes significantly differentially expressed after both bed rest and 
knee immobilization highlighted YPEL1 as the most predictive of recent muscle loss. 
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Conclusions
Knee immobilization and bed rest have distinct effects on the human skeletal muscle 
transcriptome. Comparison of both forms of disuse atrophy revealed that bed rest was 
characterized by changes in expression of genes involved inlysosomal protein degradation 
and the immune system, whereas knee immobilization was characterized by proteasomal 
proteolysis. The effect of knee immobilization showed the highest similarity with the 
transcriptomic signature of age and frailty. Based on the transcriptome, strategies that 
prevent muscle atrophy during knee immobilization may have the highest predicted value to 
be beneficial in the prevention of age-related muscle loss.  
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Signatures of muscle status in the transcriptome
Chapter 2 describes changes in the transcriptome associated with age, frailty and resistance-
type exercise training. We observed that age affects a wide range of genes and that frailty 
presents itself as a more pronounced effect of age. In the context of figure 1.1 in chapter 1, 
the frail and pre-frail individuals described in chapter 2 are further along the downward curve 
towards disability, as their phenotype classification based on the Fried criteria suggests [1]. 
Importantly, we also observe a shift towards a younger phenotype upon training, in both the 
frail older subjects and healthy older subjects, suggesting that frail and pre-frail individuals 
have sufficient adaptive reserves to respond to training, despite the frail phenotype. This 
change towards healthier muscle is also reflected in the transcriptome. Not only do their 
muscles become stronger and larger, but this change is also evident at a molecular level. 
 The predictive model built in chapter 2 highlights genes that are linked to muscle 
function in frail older adults, healthy older adults and young men. This analysis revealed 
that the protocadherin gamma gene cluster showed a correlation with muscle strength. 
We suspected that this gene cluster was related to neuromuscular function, since this set 
of genes is involved in axon guidance. Muscle innervation is of vital importance for muscle 
function. While the protocadherin gamma gene cluster was a quite robust predictor of 
muscle strength, several other genes, functionally largely unknown, may also be important 
for muscle health and are worth highlighting here. 
 First, ubiquitin specific peptidase 54 (USP54) is a gene that consistently popped 
up in the various comparisons discussed in this thesis (figure 7.1). Not only is it associated 
with muscle strength (table 2.6), training, age and frailty, but it is also upregulated by knee 
immobilization and downregulated by creatine supplementation during knee immobilization 
(figure 7.1). USP54 is a deubiquinating enzyme. The role of this enzyme is unknown within 
skeletal muscle, but it is associated with cancer progression, suggesting it may be involved in 
cellular growth an proliferation [2]. Second is cilia and flagella associated protein 61 (CFAP61). 
This gene is also linked to muscle strength, age, frailty, training and knee immobilization. As 
briefly discussed in chapter 2, the function of this gene is still unknown, but may be associated 
with calcium metabolism. Lastly there is dishevelled associated activator of morphogenesis 
2 (DAAM2). This gene is part of the Wnt signalling pathway and, like USP54 and CFAP61, is 
associated with strength, age, training and knee immobilization. This gene is also mentioned 
the literature: in the context of muscle age [3], demyelination [4] and neuromuscular 
degeneration associated with Huntington’s disease [5]. Since Wnt signalling has previously 
been associated with muscle aging and muscle fibrosis [6], this gene in particular may be 
interesting for future study.
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Figure 7.1 – Heatmap of the top 50 genes differentially expressed across the studies described in this thesis. SLR: 
signal log ratio. Cre: Creatine. FOA: Frail older adults. HOA: Healthy older adults. YA: Young adults.
In chapter 4 the role of vitamin D on the skeletal muscle transcriptome in frail older adults is 
investigated. Although there was no observable effect of vitamin D on the transcriptome, the 
population in this study overlaps with that of those in chapter 2 and 3. We also have muscle strength 
data from the participants of the vitamin D study, allowing us to also validate the predictive model 
from chapter 2. However, muscle strength data were obtained using different methods: BioDex and 
microFET. Both methods measure isometric maximal strength, whereas a dynamic strength test (1 
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repetition maximum) was used to train the predictive model in chapter 2. Moreover, newer array 
designs were used in chapter 4 (Aff ymetrix HuGene 2.1 vs. 1.1 ST arrays in chapter 2). Despite these 
methodological diff erences, the model we built to determine leg strength also showed predictive 
capabilities in the individuals in the vitamin D study, highlighting the robustness of the link between 
steady-state gene expression patterns and muscle strength and function (figure 7.2 and 7.3).
Figure 7.2 – Observed Biodex Leg Extension torque vs. predicted leg extension 1RM using the model described 
in chapter 2 in samples from the study described in chapter 5.
Figure 7.3 – Observed MicroFET leg extension force production vs. predicted leg extension 1RM using the model 
described in chapter 2 in samples from the study described in chapter 5.
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Markers of muscle atrophy 
While muscle strength appears to a have a robust signature in the muscle transcriptome, 
this does not seem to be the case for muscle size (i.e. muscle atrophy). In chapter 6 we found 
that the transcriptomic response to 7 days of bed rest and 7 days of knee immobilization 
are very dissimilar. Both models lead to similar (localized) rates of muscle atrophy [7], but 
this muscle atrophy is likely mediated via different mechanisms and regulators, as shown in 
chapter 6. Knee immobilization led to induction of histone deacetylase 4 / myogenin axis and 
proteasomal genes, whereas bed rest showed induction of autophagy and immune genes. 
The dissimilarity between these transcriptomic responses alone suggests that finding marker 
genes for muscle atrophy can prove challenging. Previous studies used mice to identify genes 
that are common to many types of muscle atrophy, leading to the widespread use of atrophy 
genes MAF-bx  and Murf-1 (FBXO32 and TRIM63, respectively) [8-10]. However, these genes 
have shown to be inconsistently associated with muscle atrophy, particular in relation to 
age-related muscle loss [11, 12]. 
 The goal of the two predictive sPLS models in chapter 6 was to identify genes that 
could be used as suitable markers for muscle atrophy in human tissues. One model, the naïve 
model, used all genes after filtering. This model identified ubiquitin-mediated proteolysis 
genes as the most reliable read-outs for the amount of muscle loss, but not FBXO32 and 
TRIM63. The second model used genes that were significantly changed in both models. 
This model showed higher predictive accuracy than the naïve model, but this may be due 
to ‘double-dipping’ (i.e. positively biasing the accuracy of the model by using pre-selected 
genes). The variable importance list for this model did reveal that Yippee Like 1 (YPEL1) was 
the most predictive of muscle loss in these two datasets (scatter plot of the change in YPEL1 
expression and change in muscle size can be found in figure 7.4). The role of this gene is 
largely unknown, especially in the context of skeletal muscle. However, it may be involved 
in cell morphology and apoptosis [13, 14]. Cross-referencing this gene with the list of genes 
across all atrophy models from chapter 6 reveals that this gene is only significant in our bed 
rest and knee immobilization datasets.  This  illustrates the difficulty in finding suitable read-
outs for muscle atrophy. However, YPEL1 may be an interesting candidate gene for further 
study in the context of muscle function and atrophy. 
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Figure 7.4 – Change in YPEL1 gene expression during muscle disuse (either knee immobilization or bed rest) 
compared with loss of muscle cross-sectional area (CSA) over the same period.
A possible explanation for this difficulty may be timing. Timing plays a crucial role in the 
assessment of molecular effects of various stimuli in skeletal muscle (or in this case, a lack 
of stimuli). Each gene has a different response profile to a certain stimulus, depending on its 
regulation and role. Some genes may peak immediately after a stimulus, while others can peak 
hours or even days after a stimulus (illustrated in figure 7.5).  Others still may simply increase 
or decrease expression as an adaptation to repeated stimuli (f. ex. exercise training effect) or 
due to a lack of repeated stimuli (f. ex. detraining due to physical inactivity) [15].  While this is 
in the context of discrete stimuli such as an exercise session, duration of disuse may also play 
a role. Short disuse (such as one day or two days) may be characterized by different profiles 
of genes than longer duration (such as weeks or even months). The individual responses of 
genes can also be dependent on the status of the muscle. For example, detrained muscle is 
suspected to respond more severely to a single bout of exercise, whereas this stimulus would 
result in a negligible response in trained muscle (repeated bout effect) [16] . 
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Figure 7.5 - Potential curves for gene expression in response to a stimulus, highlighting the importance of 
timing for sampling.
In this context, it is likely that different study populations, different models and different 
durations of disuse are characterized by different profiles of genes. This lack of consistency 
among atrophy-related genes is highlighted in figure 6.4. The most robust gene is a subunit 
of the acetyl-choline receptor (CHRNA1), which is unlikely to be a gene that mediates muscle 
protein breakdown. In this analysis, YPEL1 is ranked 294th as the most consistent, whereas 
the canonical muscle atrophy genes FBXO32 and TRIM63 are ranked 1696th and 4327th, 
respectively. As mentioned in chapter 6, some of the most interesting potential markers for 
muscle atrophy are multiple EGF-like domain 10 (MEGF10) and growth arrest and DNA damage 
inducible alpha (GADD45A; ranked 13th and 93rd, respectively). 
Countermeasures against sarcopenia 
Age-related muscle loss develops over the course of a lifetime. As a consequence, it is a 
difficult process to study in intervention trials, particularly nutritional and exercise training 
trials where the effects are relatively small and accrue over longer periods. Chapter 6 
(figure 6.3) shows that there is a significant overlap in the transcriptomic response to knee 
immobilization and the signature of age and frailty, whereas bed rest did not. This can also 
be seen to some extent in figure 7.1, where knee immobilization clusters with the age and 
frailty effects. 
 While using a disuse model to assess strategies as countermeasures for sarcopenia 
may not translate directly due to for example the differences in timeframe, there are some 
GENERAL DISCUSSION
141
Ch
ap
te
r 7
compelling benefits to doing so. First, the relatively short timeframe and large effects for 
muscle disuse allows for faster screening of muscle atrophy countermeasures. Second, 
young volunteers are more readily recruited than frail or sarcopenic older adults. Lastly, 
countermeasures for muscle disuse can also indirectly prevent age-related muscle loss by 
attenuating muscle loss during disuse events (as outlined in figure 1.2). However, there is 
no guarantee that successful strategies that protect muscle size and strength during knee 
immobilization are also beneficial in the treatment of sarcopenia. This finding merely shows 
that knee immobilization or more prolonged unilateral lower limb suspension, based purely 
on the transcriptome, is the most suitable analogue for age-related muscle loss, whereas bed 
rest is the least suitable. 
 Since creatine seems to attenuate the changes that occur in the transcriptome due 
to knee immobilization, this may be a (very) tentative indication that creatine is beneficial 
for older individuals with regard to muscle loss. Others have cautiously have suggested that 
creatine supplementation may be beneficial in the context of sarcopenia [17]. Creatine is 
known to enhance muscle growth during resistance-type exercise training  [18] and this effect 
is also seen among older individuals [19]. However, there is a lack of studies on the long term 
effect of creatine use on muscle size and function, especially in the context of sarcopenia [17].
Metabolomics in muscle research
Metabolomics allows for more detailed insight into energy metabolism. In particular, 
the relationship between amine levels and carnitine levels can shed light on amino acid 
oxidation, which might be especially relevant for muscle atrophy. Training led to a decrease 
in amino acid derived acyl carnitines, whereas amino acid levels were increased, implying a 
amino acid sparing effect. Conversely, we observed an increase in amino acid an amino acid 
derived acyl carnitine, even though the rest of the (fat derived) carnitines were decreased 
(chapter 4). These observations regarding amino acid oxidation were much less obvious in 
the transcriptome data.
 The studies in both chapter 3 and chapter 4 also hinted that polyamine metabolism 
may also be linked to age and muscle disuse.  Polyamines are especially interesting with 
regard to senescence due to their role in cell growth, survival and proliferation [20] and may 
even be useful as anti-aging compounds [21]. Various studies have also linked polyamine 
metabolism with muscle function [22]. The unique mechanism by which polyamines are 
regulated also highlights the importance of using multiple layers of ~omics simultaneously. 
Ornithine decarboxylase (ODC) activity is the main enzyme that regulates polyamine levels. 
Protein levels of ODC are regulated at the protein level via a negative feedback loop that 
is somewhat unique to polyamine metabolism [23]. As a consequence of this unique 
mechanism, changes in polyamine metabolism are particularly difficult to detect using 
transcriptomic techniques alone. 
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In chapter 3 we performed an integrative analysis of both the muscle metabolome and 
the transcriptome. While we found strong correlations within the tissue between the 
transcriptome and metabolome, the link with the metabolites and gene expression was 
likely indirect. The missing link between the transcriptome and metabolome is of course the 
proteome. Simultaneous measurement of the proteome and metabolome may also enhance 
the understanding of the link between the transcriptome and metabolome. 
 The weak correlations between plasma levels of metabolites with muscle levels of 
metabolites also highlights the importance of measuring the metabolome in the tissue itself. 
Myobolites, i.e. metabolites secreted by muscle that have a paracrine or systemic signalling 
role, have also been proposed as potentially interesting metabolites for further study [24]. 
However, even the putative myobolite β-aminoisobutyric acid, a metabolite suggested to 
promote fat oxidation in the liver [25], did not show strong correlations between muscle 
tissue and blood levels (chapter 3). These weak correlations could be due to the fact that 
the muscle was in a steady-state and it is possible that these myobolites can primarily be 
detected in an acute setting, such as during or immediately aft er exercise. Exploring the 
muscle metabolome immediately aft er or even during exercise might provide additional 
insights in the role of the muscle as a secretory organ. 
Future Perspectives
The muscle transcriptome and metabolome can provide unique insights into muscle 
health. Frailty showed a clear signature in the muscle transcriptome and metabolome, 
largely independent of chronological age. We also observed a robust link between the 
muscle strength and transcriptome. There are also other links between the transcriptome 
and muscle health, such as physical activity (figure 7.6) and muscle fibre type distribution 
(figure 7.7). Together these outcomes can provide insight into an individual’s lifestyle and 
overall health and perhaps pave the way towards personalized nutrition and exercise. Based 
on the transcriptome alone using a single sample we can estimate sex, age, frailty, muscle 
strength, muscle fiber type distribution and habitual physical activity. Other features, such 
as mitochondrial function, energy metabolism and various other indices can be contrasted 
using a reference dataset, such as in chapter 2 and 3. By providing a comprehensive overview 
of the health status of an individual’s muscle with a single measurment we can perhaps guide 
dietary and physical activity recommendations to optimize muscle health. 
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Figure 7.6 – Predictive model for general physical activity based on the transcriptome. Model was trained on 
ActiGraph data from the frail individuals (chapter 2 and 3). A (top): Observed vs. predicted actigraph counts 
(more means more physical activity). B (right): Top 20 predictor genes.
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Figure 7.7A and B – Predictive model for muscle fibre type distribution based on the transcriptome. Model was 
trained on histological data from the frail and healthy older individuals (chapter 2 and 3). A (top): Observed vs. 
predicted type 1 fiber distribution. B (bottom): Top 20 predictor genes.
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Before personalization based on ~omics profiling becomes feasible we would first need more 
detailed reference data. Comprehensive assessment of muscle function using a wide array of 
techniques (muscle performance, endurance, electromyography, histology, etc.) in addition 
to muscle biopsies would provide a large reference dataset to compare new samples to. 
Interventions, such as exercise, nutrition or pharmacological treatment, would have to be 
assessed both acutely and chronically to provide possible ways to shift  the molecular profile 
of skeletal muscle in targeted directions. For example, protein supplementation could be 
proscribed based on the transcriptome. In chapter 6 one data set provides the transcriptomic 
signature of protein deficiency (figures 6.2 and 6.3) which would be recognized based on the 
gene expression profile within a sample, without needing nutritional diaries. Exercise could 
be proscribed based on for example predicted muscle strength or physical activity levels, 
mitochondrial function indices and/or fibre type distribution. Such an approach may be very 
valuable in populations such as frail older adults where the capacity to perform suff iciently 
intense exercise is limited.
 Since muscle biopsies can lead to discomfort, it may be worthwhile to use muscle 
micro-biopsies rather than full Bergrström needle biopsies, as a relatively small amount of tissue 
is required for transcriptomics or metabolomics, and microbiopsies are more comfortable 
for subjects [26]. Another hurdle that needs to be passed in the use of these techniques for 
personalized exercise or nutrition is that of batch eff ects. Batch eff ects can significantly aff ect 
the results of ~omics techniques. While there are techniques to reduce batch eff ects, such as 
ComBat (which was employed to produce figures 7.2 and 7.3) or surrogate variable analysis [27], 
ideally control samples would be included in all batches to more accurately deal with batch 
eff ects. Other possible techniques to deal with batch eff ects are single sample normalization 
techniques such as fRMA, UPC or YuGene normalization [28-30].
 Muscle function can be dramatically improved, even in frail older individuals, with 
resistance-type exercise training. However, consistent intense exercise takes a lot of eff ort and 
may not even be an option for some individuals. Nutrition can play a key role in maintaining 
muscle mass and function for these individuals. Protein and amino acids for example have 
been widely studied in this context. There are possibly many other nutritional compounds 
that may be of interest, such as ursolic acid, β-hydroxy-β-methyl butyrate and creatine [31]. 
Ideally, these nutritional compounds would also be evaluated with regard to their eff ects on 
the transcriptome or metabolome. 
 While these nutrients show potential as countermeasures for sarcopenia, not just 
individual nutrients are of interest. More recently there has been a shift  towards defining 
dietary patterns rather than focusing on single foods and nutrients. The goal is to capture the 
complex interactions and synergies between foods, rather than investigating certain nutrients 
and foods in isolation [32]. An example of such a dietary pattern would be the Mediterranean 
diet, which has many potential health benefits, and is characterized, among other features, 
by a relatively low intake of animal protein and high intake of plant foods and unsaturated fat 
[33]. Ideally, nutritional interventions would also investigate the eff ects on skeletal muscle, 
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potentially also providing possible insights in their effects on the molecular processes in the 
skeletal muscle. Since frailty can roughly be regarded as the opposite of healthy aging, placing 
the effect of such a diet on the muscle transcriptome and metabolome in the context of the 
profiles discussed in this thesis might provide further insights of nutritional interventions 
with regard to healthy aging. 
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Chapter 2
Figure S2.1A – Venn diagram of significant genes (q-value < 0.05) changed after prolonged exercise training in 
frail (FE – training, green) and healthy older subjects (HE – training, red). FE vs HE are genes significantly different 
at baseline between frail and healthy older subjects (blue). 
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Figure S2.1B - Venn diagram of significant  genes (q-value < 0.05) at baseline between the young (YO) group and 
both frail (FE) and healthy older subjects (HE). Due to the high number of significant genes with relatively small 
differences an additional fold-change cut-off was used for these data (fold change > 1.2).
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Figure S2.2 – Top 40 (by p-value) significantly changed canonical pathways from Ingenuity Pathway Analysis. 
First two columns represent the prolonged exercise training eff ect in frail (FE) and healthy (HE) older subjects. 
Last three columns represent baseline diff erences between frail older subjects (FE), healthy older subjects (HE), 
and young subjects (YO). Colours indicate significance.
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Figure S2.3 - PCA of all UPC filtered genes for all groups, before and aft er prolonged exercise training. Ellipses 
indicate 95% confidence interval.
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Figure S2.4 - PCA of 307 exercise responsive genes for all groups, before and aft er prolonged exercise training. 
Ellipses indicate 95% confidence interval.
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Figure S2.5 – Top 40 (by score) significant upstream regulators from Ingenuity Pathway Analysis. First two 
columns represent the prolonged exercise training eff ect in frail (FE) and healthy (HE) older subjects. Last three 
columns represent baseline diff erences between frail older subjects (FE), healthy older subjects (HE), and young 
subjects (YO). Colours indicate predicted activation.
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Figure S2.6 – Top 40 (by score) significantly changed diseases and functions from Ingenuity Pathway Analysis. 
First two columns represent the prolonged exercise training eff ect in frail (FE) and healthy (HE) older subjects. 
Last three columns represent baseline diff erences between frail older subjects (FE), healthy older subjects (HE), 
and young subjects (YO). Colours indicate predicted activation.
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Figure S2.7 - Negative Correlation between the PCDHG gene cluster (eigengene as calculated using the NIPALS 
algorithm) and leg extension 1RM. 
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Chapter 3
Figure S3.1 - Change of leg extension 1RM after resistance type exercise training. Left are frail older subjects, 
right are healthy older subjects.
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Figure S3.2. PCA plot of metabolites detected by the organic acid platform in muscle tissue. To visualize 
whether groups are significantly different from each other, confidence ellipses (95% confidence interval) were 
drawn around them. Post: after training, pre: before training. 
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Figure S3.3 - Group means with 95 percent confidence intervals for (a) isoleucine and (b) propionylcarnitine. 
Standard deviations were relatively constant across groups. Frail_pre: frail older subjects before training, 
Frail_post: frail older subjects after training, Healthy_pre: healthy older subjects before training, Healthy_post: 
healthy older subjects after training. 
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Figure S3.4 - Correlation heatmap muscle and serum metabolite. Pearson correlation were used. Red indicates 
positive correlation and blue indicates negative correlation.
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Table S3.1 - Characteristics of subjects of which plasma samples were studied
 Young Healthy older Frail older
N (male / female) 50/0 51/25   35/27
Age (years) 21.7 ± 2.3 71.5 ± 5.1 78.1 ± 8.1
Height (m) 1.83 ± 0.05 1.71 ± 0.08 1.69 ± 0.09
Weight (kg) 76.4 ± 10.3 76.3 ± 12.9 79.2 ± 12.9
BMIa (kg / m2) 23.0 ± 2.9 25.5 ± 3.0 27.8 ± 4.1
Body Fat (%) 15.4 ± 4.5 24.7 ± 5.7 32.66 ± 8.7
a:body mass index.
Table S3.2 - Characteristics of the older subjects with before and after training samples.
 
Frail 
older prea
Frail
 older post b
Healthy 
older pre
Healthy 
older post
N (male / female) 10/14 22/16
Age (years) 76.0 ± 7.0 69.3 ± 4.0
Height (m) 1.66 ± 0.09 1.70 ± 0.09
Weight (kg) 77.7 ± 13.6 78.5 ± 14.0 75.9 ± 13.4 76.2 ± 13.6
BMIc (kg / m2) 27.9 ± 3.8 28.2 ± 3.9 26.0 ± 2.8 26.0 ± 2.8
Body Fat (%) 35.4 ± 8.3 35.2 ± 8.8 26.4 ± 5.4 24.7 ± 5.0*
Lean Mass (kg) 46.9 ± 9.9 47.4 ± 10.1* 53.6 ± 11.2 55.1 ± 11.5
Leg Extension 1RM (kg) 60.1 ± 18.9 82.7 ± 23.3* 79.8 ± 18.2 112.6 ± 22.5*
Leg Press 1RM (kg) 130.1± 33 176 ± 43.0* 175.9 ± 40.4 227.0 ± 49.9*
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Chapter 4
Table S4.1 – Top 100 genes significantly changed according to main effect F-test (q-value < 0.05). FC is the signed 
fold change. Q-value is the p-value adjusted using Benjamini-Hochberg False Discovery Rate. Pla.: placebo 
group. Cre.: creatine group. Inter.: interaction effect. ES: Enrichment Score. 
Symbol FC Pla. FC Cre. FC Inter. P-val Pla. P-val Cre. P-val Inter. Q-val. F-test
ATXN1 1.61 1.24 -1.3 0 0.001 0.003 0.001
HDAC4 3.24 1.67 -1.94 0 0.006 0.01 0.002
IP6K3 2.32 1.73 -1.34 0 0 0.102 0.002
KDM7A 2.12 1.79 -1.19 0 0 0.331 0.002
YPEL1 1.96 1.81 -1.08 0 0 0.615 0.002
CALM1 1.71 1.69 -1.01 0 0 0.917 0.002
TULP4 1.63 1.36 -1.2 0 0.001 0.108 0.003
NMRK2 -5.23 -2 2.61 0 0.011 0.013 0.003
MTURN 1.51 1.33 -1.14 0 0.001 0.205 0.003
JMY 1.54 1.29 -1.2 0 0.002 0.08 0.004
PER2 1.47 1.17 -1.25 0 0.018 0.016 0.004
SLK 1.42 1.19 -1.2 0 0.008 0.038 0.004
SLC16A3 -2.65 -1.74 1.52 0 0.003 0.077 0.004
ABCA5 2.29 1.61 -1.42 0 0.003 0.091 0.004
MPP6 2.21 1.66 -1.34 0 0.002 0.146 0.004
VPS36 1.34 1.23 -1.09 0 0.001 0.255 0.004
HOOK3 1.33 1.26 -1.06 0 0 0.434 0.004
MAPRE3 1.7 1.53 -1.11 0 0 0.454 0.004
PIAS2 1.48 1.39 -1.06 0 0 0.565 0.004
SMAD4 1.31 1.26 -1.04 0 0 0.577 0.004
TBC1D15 1.42 1.5 1.06 0 0 0.594 0.004
FILIP1 1.52 1.12 -1.35 0 0.096 0.005 0.004
GDNF 4.64 2.56 -1.81 0 0.003 0.136 0.004
XRN1 1.52 1.34 -1.13 0 0.001 0.273 0.004
PPM1L 1.68 1.61 -1.04 0 0 0.772 0.004
POMK 1.47 1.42 -1.03 0 0 0.798 0.004
FAM160B1 1.4 1.43 1.03 0 0 0.812 0.004
CHMP1B 1.99 1.92 -1.04 0 0 0.863 0.004
IMPAD1 1.75 1.74 -1.01 0 0 0.961 0.004
DCP2 1.75 1.47 -1.19 0 0.002 0.254 0.004
ZC3H12C 1.47 1.27 -1.16 0 0.003 0.153 0.004
ERGIC1 -1.34 -1.25 1.07 0 0.001 0.4 0.004
SLC36A2 -1.67 -1.36 1.22 0 0.004 0.139 0.004
TRIM33 1.38 1.32 -1.05 0 0.001 0.631 0.004
RDX 1.28 1.17 -1.1 0 0.004 0.173 0.004
NRP1 -1.4 -1.28 1.09 0 0.001 0.342 0.004
ARPP21 2.25 1.23 -1.83 0 0.129 0.005 0.005
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BCAR1 1.51 1.22 -1.24 0 0.013 0.05 0.005
GPI -1.65 -1.31 1.26 0 0.008 0.082 0.005
DHRS7B -1.45 -1.31 1.11 0 0.002 0.323 0.006
PNISR 1.38 1.09 -1.26 0 0.123 0.01 0.006
TP63 2.62 1.37 -1.91 0 0.068 0.012 0.006
OSBPL6 2.25 1.35 -1.67 0 0.05 0.02 0.006
CDK5RAP2 1.43 1.16 -1.23 0 0.028 0.037 0.006
ZC3H11A 1.48 1.22 -1.21 0 0.013 0.074 0.006
CHRNB1 1.66 1.3 -1.28 0 0.014 0.08 0.006
GSE1 1.38 1.18 -1.17 0 0.011 0.085 0.006
CLIP1 1.74 1.37 -1.27 0 0.008 0.129 0.006
PPIL4 1.65 1.36 -1.21 0 0.004 0.167 0.006
NFAT5 1.32 1.19 -1.11 0 0.005 0.172 0.006
TSR3 -1.4 -1.28 1.09 0 0.002 0.38 0.006
KMT2C 1.26 1.2 -1.05 0 0.002 0.469 0.006
UACA 1.42 1.34 -1.06 0 0.001 0.599 0.006
ANKRD12 1.35 1.31 -1.03 0 0.001 0.755 0.006
RICTOR 1.6 1.54 -1.04 0 0.001 0.781 0.006
RAD23B 1.31 1.28 -1.02 0 0.001 0.795 0.006
ATP9B 1.31 1.28 -1.02 0 0.001 0.813 0.006
TSPYL2 1.65 1.59 -1.03 0 0.001 0.842 0.006
AGO4 1.43 1.4 -1.02 0 0.001 0.852 0.006
EEF1D -1.27 -1.27 -1 0.001 0.001 0.999 0.006
RBBP6 1.27 1.08 -1.18 0 0.075 0.013 0.006
UBE2H 1.36 1.21 -1.12 0 0.005 0.199 0.006
FAM46C -2.32 -1.24 1.86 0 0.154 0.007 0.006
PARD3 1.44 1.16 -1.25 0 0.039 0.028 0.006
PFN2 1.98 1.32 -1.5 0 0.039 0.035 0.006
FGGY 1.78 1.29 -1.38 0 0.028 0.045 0.006
ACHE -2.11 -1.59 1.32 0 0.006 0.199 0.006
RORA 2.01 1.55 -1.29 0 0.005 0.206 0.006
NEK7 1.6 1.35 -1.19 0 0.005 0.218 0.006
SLFN5 1.58 1.42 -1.11 0 0.002 0.451 0.006
CLOCK 1.43 1.35 -1.06 0 0.001 0.628 0.006
LMBRD2 1.29 1.33 1.03 0.001 0 0.754 0.006
SLC16A10 1.61 1.56 -1.03 0 0.001 0.834 0.006
TNKS 1.42 1.4 -1.01 0 0.001 0.936 0.006
UBE2W 1.63 1.67 1.02 0.001 0 0.887 0.006
EEA1 1.41 1.16 -1.22 0 0.036 0.041 0.006
AFF4 1.53 1.32 -1.17 0 0.005 0.227 0.006
DNAJC16 1.27 1.24 -1.03 0 0.001 0.75 0.006
EXOC2 1.46 1.21 -1.2 0 0.017 0.087 0.006
WDR59 1.36 1.18 -1.15 0 0.012 0.115 0.006
ABCA10 2.13 1.62 -1.31 0 0.006 0.227 0.006
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SPG20 1.5 1.23 -1.22 0 0.016 0.095 0.007
FAM175A 1.9 1.31 -1.44 0 0.036 0.045 0.007
TXNL1 1.41 1.32 -1.07 0 0.002 0.569 0.007
EAPP 1.3 1.15 -1.14 0 0.017 0.107 0.007
IRF2BP2 -1.36 -1.22 1.11 0 0.006 0.245 0.007
FOXP2 1.64 1.42 -1.15 0 0.004 0.376 0.007
PHF20L1 1.27 1.2 -1.06 0 0.003 0.457 0.007
RFX5 1.38 1.29 -1.07 0 0.002 0.525 0.007
COL4A3 1.69 1.67 -1.01 0.001 0.001 0.936 0.007
SVIL 1.52 1.18 -1.29 0 0.051 0.034 0.007
NHLRC2 1.47 1.21 -1.22 0 0.021 0.087 0.007
HCFC2 1.3 1.19 -1.1 0 0.006 0.241 0.007
PLEKHA1 1.45 1.28 -1.13 0 0.005 0.288 0.007
SUPT6H 1.31 1.22 -1.07 0 0.004 0.425 0.007
TFRC -2.45 -2.19 1.12 0 0.001 0.709 0.007
CSPP1 1.4 1.16 -1.21 0 0.041 0.051 0.007
GTF2A1 1.3 1.31 1.01 0.001 0.001 0.926 0.007
KDM5C 1.37 1.28 -1.07 0 0.003 0.499 0.007
MAP3K5 -1.37 -1.18 1.17 0 0.02 0.106 0.007
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Supplementary table S4.2 – Top 50 enriched genesets results for the placebo group. Ranking based on Q-value. 
Q-value is the p-value adjusted using Benjamini-Hochberg False Discovery Rate. ES: Enrichment Score.
Name Direction ES Q-value
REACTOME UNWINDING OF DNA down -0.8 0
REACTOME PYRUVATE METABOLISM down -0.7 0
REACTOME GLUCONEOGENESIS down -0.7 0
KEGG STEROID BIOSYNTHESIS down -0.7 0
PID IL8 CXCR2 PATHWAY down -0.7 0
PID IL8 CXCR1 PATHWAY down -0.7 0
REACTOME TRANSPORT OF RIBONUCLEOPROTEINS INTO THE HOST 
NUCLEUS
up 0.66 0
PID ALPHA SYNUCLEIN PATHWAY down -0.6 0
REACTOME DNA STRAND ELONGATION down -0.6 0
REACTOME PYRUVATE METABOLISM AND CITRIC ACID TCA CYCLE down -0.6 0
REACTOME THROMBIN SIGNALLING THROUGH PROTEINASE 
ACTIVATED RECEPTORS PARS
down -0.6 0
REACTOME SIGNAL AMPLIFICATION down -0.6 0
REACTOME PEPTIDE CHAIN ELONGATION down -0.6 0
REACTOME GLUCOSE METABOLISM down -0.6 0
PID TXA2PATHWAY down -0.6 0
KEGG GLYCOLYSIS GLUCONEOGENESIS down -0.6 0
KEGG RIBOSOME down -0.5 0
REACTOME RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS 
BY CHEMIOSMOTIC COUPLING AND HEAT PRODUCTION BY 
UNCOUPLING PROTEINS 
down -0.5 0
REACTOME TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT down -0.5 0
KEGG HEMATOPOIETIC CELL LINEAGE down -0.5 0
REACTOME IMMUNOREGULATORY INTERACTIONS BETWEEN A 
LYMPHOID AND A NON LYMPHOID CELL
down -0.5 0
REACTOME SRP DEPENDENT COTRANSLATIONAL PROTEIN 
TARGETING TO MEMBRANE
down -0.5 0
REACTOME INFLUENZA VIRAL RNA TRANSCRIPTION AND REPLICATION down -0.5 0
PID TCR PATHWAY down -0.5 0
KEGG OXIDATIVE PHOSPHORYLATION down -0.5 0
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS down -0.5 0
KEGG PARKINSONS DISEASE down -0.5 0
KEGG ALZHEIMERS DISEASE down -0.4 0
REACTOME ADP SIGNALLING THROUGH P2RY1 down -0.6 0.002
KEGG LYSOSOME down -0.4 0.002
REACTOME RESPIRATORY ELECTRON TRANSPORT down -0.5 0.002
REACTOME PD1 SIGNALING down -0.7 0.004
REACTOME PYRIMIDINE METABOLISM down -0.6 0.004
KEGG CELL ADHESION MOLECULES CAMS down -0.4 0.004
KEGG PENTOSE PHOSPHATE PATHWAY down -0.6 0.004
BIOCARTA THELPER PATHWAY down -0.8 0.004
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REACTOME CHOLESTEROL BIOSYNTHESIS down -0.6 0.004
BIOCARTA SRCRPTP PATHWAY down -0.8 0.004
REACTOME GENERIC TRANSCRIPTION PATHWAY up 0.43 0.005
REACTOME PROSTACYCLIN SIGNALLING THROUGH PROSTACYCLIN 
RECEPTOR
down -0.6 0.007
REACTOME TRANSPORT OF MATURE TRANSCRIPT TO CYTOPLASM up 0.58 0.007
PID AMB2 NEUTROPHILS PATHWAY down -0.5 0.007
REACTOME THROMBOXANE SIGNALLING THROUGH TP RECEPTOR down -0.6 0.007
REACTOME HYALURONAN METABOLISM down -0.7 0.007
REACTOME FORMATION OF ATP BY CHEMIOSMOTIC COUPLING down -0.7 0.007
REACTOME METABOLISM OF CARBOHYDRATES down -0.4 0.008
REACTOME GLYCOLYSIS down -0.6 0.008
KEGG COMPLEMENT AND COAGULATION CASCADES down -0.5 0.008
BIOCARTA PROTEASOME PATHWAY up 0.65 0.013
BIOCARTA MCM PATHWAY down -0.6 0.013
KEGG AUTOIMMUNE THYROID DISEASE down -0.5 0.014
APPENDIX: SUPPLEMENTARY MATERIALS
171
Supplementary table S4.3 – Top 50 enriched genesets results for the interaction effect (immobilization  × 
creatine supplementation). Ranking based on Q-value. Q-value is the p-value adjusted using Benjamini-
Hochberg False Discovery Rate. 
Name Direction ES Q-value
PID IL8 CXCR2 PATHWAY up 0.68 0
PID IL8 CXCR1 PATHWAY up 0.65 0
KEGG LYSOSOME up 0.62 0
BIOCARTA VITCB PATHWAY up 0.76 0.003
REACTOME SIGNALING BY NOTCH4 up 0.77 0.003
REACTOME ACTIVATED NOTCH1 TRANSMITS SIGNAL TO THE NUCLEUS up 0.62 0.003
PID ALPHA SYNUCLEIN PATHWAY up 0.59 0.003
REACTOME THE ROLE OF NEF IN HIV1 REPLICATION AND DISEASE 
PATHOGENESIS
up 0.63 0.004
PID P75 NTR PATHWAY up 0.49 0.004
REACTOME SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING 
TO MEMBRANE
up 0.47 0.004
PID BCR 5PATHWAY up 0.51 0.005
REACTOME ASPARAGINE N LINKED GLYCOSYLATION up 0.49 0.005
REACTOME POL SWITCHING up 0.77 0.006
REACTOME REGULATED PROTEOLYSIS OF P75NTR up 0.84 0.006
REACTOME NRIF SIGNALS CELL DEATH FROM THE NUCLEUS up 0.75 0.007
KEGG GLYCOSAMINOGLYCAN DEGRADATION up 0.68 0.009
REACTOME RESPIRATORY ELECTRON TRANSPORT down -0.5 0.01
REACTOME RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS 
BY CHEMIOSMOTIC COUPLING AND HEAT PRODUCTION BY 
UNCOUPLING PROTEINS 
down -0.5 0.01
PID TXA2PATHWAY up 0.53 0.01
REACTOME MHC CLASS II ANTIGEN PRESENTATION up 0.45 0.01
REACTOME LAGGING STRAND SYNTHESIS up 0.62 0.01
PID GMCSF PATHWAY up 0.51 0.011
BIOCARTA RAS PATHWAY up 0.58 0.011
REACTOME SIGNALING BY NOTCH2 up 0.76 0.011
REACTOME SIGNALING BY ILS up 0.42 0.011
REACTOME CD28 DEPENDENT VAV1 PATHWAY up 0.73 0.011
PID ERBB1 DOWNSTREAM PATHWAY up 0.42 0.011
REACTOME FORMATION OF THE TERNARY COMPLEX AND 
SUBSEQUENTLY THE 43S COMPLEX
up 0.5 0.011
BIOCARTA ACTINY PATHWAY up 0.6 0.012
REACTOME POST TRANSLATIONAL PROTEIN MODIFICATION up 0.4 0.012
REACTOME TRANSLATION up 0.4 0.012
REACTOME SIGNALING BY NOTCH3 up 0.74 0.012
REACTOME N GLYCAN TRIMMING IN THE ER AND CALNEXIN 
CALRETICULIN CYCLE
up 0.69 0.012
REACTOME ACTIVATION OF THE MRNA UPON BINDING OF THE CAP 
BINDING COMPLEX AND EIFS AND SUBSEQUENT BINDING TO 43S
up 0.48 0.012
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PID P38 ALPHA BETA PATHWAY up 0.54 0.013
KEGG PENTOSE PHOSPHATE PATHWAY up 0.58 0.013
KEGG B CELL RECEPTOR SIGNALING PATHWAY up 0.43 0.013
KEGG VIBRIO CHOLERAE INFECTION up 0.48 0.013
REACTOME CALNEXIN CALRETICULIN CYCLE up 0.71 0.013
REACTOME DNA STRAND ELONGATION up 0.61 0.013
REACTOME LYSOSOME VESICLE BIOGENESIS up 0.6 0.013
BIOCARTA EDG1 PATHWAY up 0.57 0.013
REACTOME SPHINGOLIPID METABOLISM up 0.46 0.014
KEGG PATHOGENIC ESCHERICHIA COLI INFECTION up 0.48 0.014
PID TCR PATHWAY up 0.47 0.014
PID TOLL ENDOGENOUS PATHWAY up 0.59 0.014
BIOCARTA CDC42RAC PATHWAY up 0.64 0.014
REACTOME GLYCOLYSIS up 0.58 0.014
REACTOME UNWINDING OF DNA up 0.72 0.015
KEGG OTHER GLYCAN DEGRADATION up 0.64 0.015
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Chapter 5
Supplementary Table S5.1 – Canonical pathways (from Ingenuity Pathway Analysis) regulated in the calcifediol 
group
Ingenuity Canonical Pathways  -log(p-value) Ratio
CCR5 Signaling in Macrophages 2.03 0.143
OX40 Signaling Pathway 1.98 0.136
Guanine and Guanosine Salvage I 1.67 1
Methylglyoxal Degradation VI 1.67 1
Autoimmune Thyroid Disease Signaling 1.67 0.182
Graft-versus-Host Disease Signaling 1.67 0.182
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 1.67 0.182
UVA-Induced MAPK Signaling 1.6 0.0755
Superpathway of Cholesterol Biosynthesis 1.53 0.154
Allograft Rejection Signaling 1.47 0.143
Myc Mediated Apoptosis Signaling 1.43 0.0857
STAT3 Pathway 1.4 0.0833
Hematopoiesis from Pluripotent Stem Cells 1.38 0.5
Histidine Degradation III 1.38 0.5
Adenine and Adenosine Salvage III 1.38 0.5
S-adenosyl-L-methionine Biosynthesis 1.38 0.5
Type I Diabetes Mellitus Signaling 1.34 0.0789
Retinoic acid Mediated Apoptosis Signaling 1.31 0.118
Regulation of eIF4 and p70S6K Signaling 1.24 0.0505
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Supplementary Table S5.2 – Upstream regulators (from Ingenuity Pathway Analysis) regulated in the calcifediol 
group
Upstream Regulator Molecule Type Activation z-score p-value of overlap
CD247 transmembrane receptor -1 0.00117
HOXA10 transcription regulator -1.633 0.00187
SLC4A1 transporter  0.00252
DIRAS3 enzyme  0.00414
MYB transcription regulator  0.00698
SREBF2 transcription regulator  0.0102
PRDM1 transcription regulator -1 0.0109
PARP9 enzyme  0.0111
SIRT2 transcription regulator  0.0111
PTP4A3 phosphatase  0.0141
B2M transmembrane receptor  0.0174
TR-RXR complex  0.0208
HLA-B27 complex  0.0208
PARG enzyme  0.0208
CHFR enzyme  0.0208
HSPE1 enzyme  0.0208
PAM enzyme  0.0208
FUT4 enzyme  0.0208
MPG enzyme  0.0208
Ryr group  0.0208
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Chapter 6
Importance
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Supplementary Figure S6.1 – Variable importance for sPLS model using common atrophy genes. 
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Supplementary Table S6.1 – Top 50 genesets enriched during knee immobilization. Ranking is based on 
absolute normalized enrichment score (NES). ES: Enrichment score. NES: Normalized enrichment score. NOM 
p-val: nominal p-value. FDR q-val: P-value adjusted using Benjamini-Hochberg False Discovery Rate. 
NAME SIZE ES NES
NOM 
p-val
FDR 
q-val
REACTOME TCA CYCLE AND RESPIRATORY 
ELECTRON TRANSPORT
116 -0.54408 -2.54447 0 0
REACTOME GLUCONEOGENESIS 29 -0.71399 -2.52042 0 0
PID IL8 CXCR2 PATHWAY 33 -0.66926 -2.50223 0 0
REACTOME RESPIRATORY ELECTRON 
TRANSPORT ATP SYNTHESIS BY 
CHEMIOSMOTIC COUPLING AND HEAT 
PRODUCTION BY UNCOUPLING PROTEINS 
80 -0.55314 -2.42203 0 0
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS 115 -0.50963 -2.387 0 2.73E-04
REACTOME PYRUVATE METABOLISM AND 
CITRIC ACID TCA CYCLE
40 -0.60776 -2.33714 0 7.21E-04
REACTOME PEPTIDE CHAIN ELONGATION 73 -0.54813 -2.32228 0 6.18E-04
KEGG OXIDATIVE PHOSPHORYLATION 115 -0.50111 -2.30176 0 5.41E-04
KEGG RIBOSOME 76 -0.53375 -2.29167 0 4.81E-04
REACTOME SIGNAL AMPLIFICATION 31 -0.64852 -2.26112 0 5.84E-04
REACTOME SRP DEPENDENT 
COTRANSLATIONAL PROTEIN TARGETING TO 
MEMBRANE
94 -0.50862 -2.25438 0 5.31E-04
KEGG HEMATOPOIETIC CELL LINEAGE 83 -0.52008 -2.25351 0 4.86E-04
REACTOME ADP SIGNALLING THROUGH P2RY1 25 -0.66627 -2.25214 0 4.49E-04
PID ALPHA SYNUCLEIN PATHWAY 33 -0.60485 -2.24982 0 4.17E-04
PID TXA2PATHWAY 57 -0.55088 -2.24324 0 3.89E-04
REACTOME DNA STRAND ELONGATION 30 -0.64397 -2.24163 0 3.65E-04
REACTOME UNWINDING OF DNA 11 -0.83358 -2.2385 0 3.43E-04
REACTOME GLUCOSE METABOLISM 61 -0.54726 -2.22856 0 4.10E-04
KEGG PARKINSONS DISEASE 111 -0.47853 -2.21041 0 4.67E-04
REACTOME PYRUVATE METABOLISM 18 -0.72889 -2.19492 0 6.75E-04
PID IL8 CXCR1 PATHWAY 27 -0.64607 -2.19158 0 6.43E-04
REACTOME TRANSPORT OF MATURE 
TRANSCRIPT TO CYTOPLASM
50 0.610673 2.191445 0 6.91E-04
REACTOME FORMATION OF ATP BY 
CHEMIOSMOTIC COUPLING
13 -0.77339 -2.16842 0 8.89E-04
KEGG GLYCOLYSIS GLUCONEOGENESIS 59 -0.52751 -2.16788 0 8.51E-04
REACTOME INFLUENZA VIRAL RNA 
TRANSCRIPTION AND REPLICATION
89 -0.49011 -2.15837 0 0.001004
REACTOME THROMBIN SIGNALLING 
THROUGH PROTEINASE ACTIVATED 
RECEPTORS PARS
32 -0.61208 -2.15799 0 9.64E-04
BIOCARTA PROTEASOME PATHWAY 28 0.684648 2.150185 0 0.001067
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KEGG PENTOSE PHOSPHATE PATHWAY 26 -0.62511 -2.1495 0 0.001043
REACTOME IMMUNOREGULATORY 
INTERACTIONS BETWEEN A LYMPHOID AND A 
NON LYMPHOID CELL
59 -0.51203 -2.13955 0 0.001117
REACTOME THROMBOXANE SIGNALLING 
THROUGH TP RECEPTOR
23 -0.66108 -2.13288 0 0.001244
KEGG ALZHEIMERS DISEASE 154 -0.44412 -2.12922 0 0.001253
PID TCR PATHWAY 66 -0.50954 -2.11823 0 0.001414
BIOCARTA SRCRPTP PATHWAY 11 -0.80383 -2.1043 0 0.002058
REACTOME PROSTACYCLIN SIGNALLING 
THROUGH PROSTACYCLIN RECEPTOR
19 -0.66988 -2.09827 0 0.002272
REACTOME G BETA GAMMA SIGNALLING 
THROUGH PLC BETA
20 -0.6722 -2.09201 0 0.002488
REACTOME DEPOSITION OF NEW CENPA 
CONTAINING NUCLEOSOMES AT THE 
CENTROMERE
55 -0.50423 -2.09116 0 0.002415
REACTOME PYRIMIDINE METABOLISM 23 -0.63739 -2.08683 0 0.002473
KEGG GRAFT VERSUS HOST DISEASE 36 -0.56536 -2.07124 0 0.002959
KEGG STEROID BIOSYNTHESIS 16 -0.69675 -2.05679 0.002364 0.003783
KEGG GLYCOSPHINGOLIPID BIOSYNTHESIS 
GLOBO SERIES
14 -0.72102 -2.05459 0 0.003723
REACTOME RESPIRATORY ELECTRON 
TRANSPORT
64 -0.49993 -2.03772 0 0.004484
REACTOME TRANSPORT OF 
RIBONUCLEOPROTEINS INTO THE HOST 
NUCLEUS
26 0.666511 2.035447 0 0.012914
REACTOME ADP SIGNALLING THROUGH 
P2RY12
21 -0.62767 -2.01733 0 0.005873
KEGG LYSOSOME 119 -0.43433 -2.0069 0 0.00661
REACTOME G PROTEIN BETA GAMMA 
SIGNALLING
28 -0.58087 -2.00357 0 0.006738
REACTOME METABOLISM OF CARBOHYDRATES 226 -0.3909 -2.00255 0 0.006647
KEGG PROTEASOME 43 0.578985 2.001636 0 0.015836
KEGG COMPLEMENT AND COAGULATION 
CASCADES
67 -0.47893 -1.99819 0 0.006778
REACTOME G1 S SPECIFIC TRANSCRIPTION 16 -0.66605 -1.9956 0 0.006798
REACTOME RNA POL I PROMOTER OPENING 49 -0.50684 -1.99001 0 0.007043
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Supplementary Table S6.2 – Top 50 upstream regulators from Ingenuity Pathway Analysis, based on genes 
differentially expressed after 7 days of knee immobilization. Ranking based on p-value of overlap.
Upstream Regulator Expr 
Log 
Ratio
Molecule Type Predicted 
Activation 
State
Activation 
z-score
p-value of 
overlap
ID2 -0.614 transcription regulator  0.302 1.82E-04
ID3 -0.276 transcription regulator  -0.56 7.22E-04
Insulin  group  -1.502 2.16E-03
ALKBH5 -0.033 enzyme   2.19E-03
IFI16 -0.448 transcription regulator  0.81 2.80E-03
CBS/CBSL  enzyme  1 3.32E-03
dihydrotestosterone  
chemical - endogenous 
mammalian  0.908 3.67E-03
SPIB  transcription regulator  0.378 5.06E-03
MAP2K5 0.247 kinase   5.07E-03
cobalt  chemical toxicant   6.95E-03
FSH  complex  -0.322 7.11E-03
adenosine dialdehyde  chemical reagent   7.72E-03
HDAC4 1.677 transcription regulator  0.861 8.01E-03
COL6A1 -0.395 other  -1.342 8.31E-03
mir-223  microrna  -0.118 9.04E-03
FOXO3  transcription regulator Activated 2.084 1.17E-02
dactolisib  chemical drug  1.951 1.25E-02
2-amino-5-phosphonovaleric acid  chemical - other  1.437 1.27E-02
NRL  transcription regulator  0 1.58E-02
clofibrate  chemical drug  1.963 1.59E-02
C8  complex   1.66E-02
glemanserin  chemical drug   1.66E-02
WISP3  growth factor   1.66E-02
GH2  other   1.66E-02
NKX6-1  transcription regulator   1.66E-02
C9  other   1.66E-02
C7  other   1.66E-02
KLK5  peptidase   1.66E-02
dimaprit  chemical drug   1.66E-02
quetiapine  chemical drug   1.66E-02
FOXP3  transcription regulator   1.72E-02
LAMTOR5 -0.008 other   1.74E-02
curcuminoids  chemical drug   1.74E-02
WNT11  other  1.342 1.86E-02
AK1 -0.739 kinase   2.02E-02
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NFATC2 -0.06 transcription regulator  0.664 2.10E-02
RRP1B  other   2.47E-02
olanzapine  chemical drug  -0.895 2.48E-02
histamine  
chemical - endogenous 
mammalian  0.885 2.59E-02
deoxycholate  
chemical - endogenous 
mammalian  -0.394 2.59E-02
10E,12Z-octadecadienoic acid  
chemical - endogenous 
mammalian  -1.698 2.64E-02
2,3,4,7,8-pentachlorodibenzofuran  chemical toxicant  0.478 2.76E-02
thiazolidinedione  chemical drug  -1.131 3.03E-02
BCL11B  transcription regulator   3.16E-02
MAP2K7  kinase   3.42E-02
PIAS1 0.23 transcription regulator  -0.447 3.48E-02
mir-25  microrna  -0.882 3.48E-02
tetrachlorodibenzodioxin  chemical toxicant  1.412 3.59E-02
Cg  complex  0.246 3.59E-02
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Supplementary Table S6.3 – Top 50 genesets enriched during bed rest. Ranking is based on absolute normalized 
enrichment score (NES). ES: Enrichment score. NES: Normalized enrichment score. NOM p-val: nominal p-value. 
FDR q-val: P-value adjusted using Benjamini-Hochberg False Discovery Rate. 
Name Size ES NES NOM 
p-val
FDR 
q-val
REACTOME TCA CYCLE AND RESPIRATORY 
ELECTRON TRANSPORT 116 -0.72647 -3.38487 0 0
REACTOME RESPIRATORY ELECTRON TRANSPORT 
ATP SYNTHESIS BY CHEMIOSMOTIC COUPLING AND 
HEAT PRODUCTION BY UNCOUPLING PROTEINS 80 -0.73657 -3.23365 0 0
REACTOME RESPIRATORY ELECTRON TRANSPORT 64 -0.75913 -3.18785 0 0
KEGG PARKINSONS DISEASE 111 -0.64511 -3.03839 0 0
REACTOME SRP DEPENDENT COTRANSLATIONAL 
PROTEIN TARGETING TO MEMBRANE 94 0.623695 3.000525 0 0
KEGG LYSOSOME 119 0.586164 2.967007 0 0
KEGG OXIDATIVE PHOSPHORYLATION 115 -0.63241 -2.95886 0 0
REACTOME PEPTIDE CHAIN ELONGATION 73 0.616106 2.882654 0 0
KEGG RIBOSOME 76 0.602861 2.8164 0 0
REACTOME PYRUVATE METABOLISM AND CITRIC 
ACID TCA CYCLE 40 -0.71285 -2.72647 0 0
REACTOME NONSENSE MEDIATED DECAY 
ENHANCED BY THE EXON JUNCTION COMPLEX 94 0.54543 2.701495 0 0
KEGG LEISHMANIA INFECTION 66 0.590432 2.68391 0 0
REACTOME TRANSLATION 129 0.509645 2.642031 0 0
REACTOME 3 UTR MEDIATED TRANSLATIONAL 
REGULATION 91 0.533291 2.602906 0 0
REACTOME INFLUENZA VIRAL RNA TRANSCRIPTION 
AND REPLICATION 89 0.537578 2.594616 0 0
REACTOME INFLUENZA LIFE CYCLE 122 0.510243 2.57867 0 0
KEGG ALZHEIMERS DISEASE 154 -0.50725 -2.49155 0 0
KEGG HUNTINGTONS DISEASE 169 -0.49907 -2.47711 0 0
PID CXCR4 PATHWAY 102 0.500613 2.459188 0 1.63E-04
PID INTEGRIN A4B1 PATHWAY 33 0.630807 2.458056 0 1.49E-04
KEGG CITRATE CYCLE TCA CYCLE 30 -0.69513 -2.4298 0 0
PID IL8 CXCR2 PATHWAY 33 0.640461 2.426467 0 1.38E-04
REACTOME GENERATION OF SECOND MESSENGER 
MOLECULES 26 0.665985 2.415338 0 1.28E-04
REACTOME GPVI MEDIATED ACTIVATION CASCADE 31 0.634178 2.393021 0 3.63E-04
REACTOME INTERFERON GAMMA SIGNALING 57 0.538127 2.389887 0 3.41E-04
REACTOME OLFACTORY SIGNALING PATHWAY 297 -0.45242 -2.38508 0 0
KEGG FC GAMMA R MEDIATED PHAGOCYTOSIS 92 0.490054 2.378169 0 3.21E-04
REACTOME CITRIC ACID CYCLE TCA CYCLE 19 -0.76068 -2.36828 0 0
PID PI3KCI PATHWAY 49 0.554782 2.326147 0 5.00E-04
REACTOME PHOSPHORYLATION OF CD3 AND TCR 
ZETA CHAINS 15 0.734603 2.325055 0 4.74E-04
REACTOME PYRUVATE METABOLISM 18 -0.74499 -2.31748 0 0
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REACTOME MITOCHONDRIAL FATTY ACID BETA 
OXIDATION 14 -0.7961 -2.29614 0 0
PID IL8 CXCR1 PATHWAY 27 0.628558 2.28687 0 8.01E-04
PID INTEGRIN1 PATHWAY 66 0.501866 2.284304 0 7.63E-04
REACTOME METABOLISM OF MRNA 195 0.416486 2.275443 0 8.10E-04
REACTOME P75 NTR RECEPTOR MEDIATED 
SIGNALLING 79 0.477519 2.273325 0 7.75E-04
REACTOME ASPARAGINE N LINKED GLYCOSYLATION 80 0.480908 2.273279 0 7.42E-04
REACTOME SIGNALING BY RHO GTPASES 110 0.453769 2.272689 0 7.13E-04
KEGG PRIMARY IMMUNODEFICIENCY 35 0.563493 2.264446 0 6.85E-04
REACTOME CYTOKINE SIGNALING IN IMMUNE 
SYSTEM 256 0.398189 2.251344 0 8.60E-04
KEGG OLFACTORY TRANSDUCTION 365 -0.41234 -2.24977 0 3.58E-05
KEGG CARDIAC MUSCLE CONTRACTION 72 -0.52381 -2.24287 0 6.74E-05
REACTOME REGULATION OF PYRUVATE 
DEHYDROGENASE PDH COMPLEX 12 -0.82535 -2.23817 0 9.49E-05
BIOCARTA NKCELLS PATHWAY 20 0.668843 2.234647 0 8.92E-04
KEGG INTESTINAL IMMUNE NETWORK FOR IGA 
PRODUCTION 45 0.534629 2.233325 0 9.22E-04
REACTOME MHC CLASS II ANTIGEN PRESENTATION 88 0.463759 2.229342 0 9.52E-04
REACTOME INFLAMMASOMES 16 0.701081 2.227516 0 9.79E-04
SA B CELL RECEPTOR COMPLEXES 24 0.618634 2.224591 0 0.001006
PID FCER1 PATHWAY 62 0.488736 2.215382 0 0.001083
PID TCR PATHWAY 66 0.485929 2.214418 0 0.001051
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Supplementary Table S6.4 – Top 50 upstream regulators from Ingenuity Pathway Analysis, based on genes 
differentially expressed after 7 days of bed rest.Ranking based on p-value of overlap.
Upstream Regulator
Expr Log 
Ratio Molecule Type
Predicted 
Activation State
Activation 
z-score
p-value of 
overlap
KDM5A 0.112 transcription regulator Activated 3.671 4.96E-09
KLF15 -0.794 transcription regulator Inhibited -3.711 4.31E-08
rosiglitazone  chemical drug Inhibited -4.104 6.72E-08
RXRA -0.292 ligand-dependent 
nuclear receptor
 -1.854 8.75E-08
PPARA -0.694 ligand-dependent 
nuclear receptor
Inhibited -3.315 1.18E-07
mono-(2-ethylhexyl)
phthalate
 chemical toxicant Inhibited -4.845 2.47E-07
TNF  cytokine Activated 2.567 3.35E-07
PPARGC1A -0.681 transcription regulator Inhibited -3.496 2.37E-06
INSR -0.197 kinase Inhibited -4.265 3.00E-06
MAP4K4 0.458 kinase Activated 4.375 5.36E-06
PPARD  ligand-dependent 
nuclear receptor
Inhibited -2.393 8.57E-06
LEP  growth factor  -0.645 1.24E-05
Esrra  transcription regulator Inhibited -2.579 1.53E-05
calcitriol  chemical drug  -0.042 1.81E-05
dexamethasone  chemical drug  -1.161 1.93E-05
RB1 0 transcription regulator Inhibited -3.318 2.11E-05
sirolimus  chemical drug Inhibited -2.753 2.20E-05
RICTOR 0.027 other Activated 3.796 6.44E-05
alitretinoin  chemical drug  -0.927 6.46E-05
Rxr  group Activated 2.213 6.89E-05
ESRRA  ligand-dependent 
nuclear receptor
Inhibited -3.052 7.94E-05
LIPG  enzyme  0.816 1.05E-04
OMA1 -0.245 peptidase  -1.633 1.05E-04
cholesterol  chemical - endogenous 
mammalian
 1.44 1.12E-04
LPL -0.82 enzyme  -0.578 1.16E-04
NR3C1 -0.146 ligand-dependent 
nuclear receptor
 1.328 1.80E-04
MYOCD  transcription regulator  -0.957 1.87E-04
PGR  ligand-dependent 
nuclear receptor
 -0.688 1.98E-04
CREB1 0.052 transcription regulator  0.831 2.07E-04
gemfibrozil  chemical drug  -1.367 2.36E-04
HDAC5 -0.287 transcription regulator  0 2.75E-04
TP73  transcription regulator  0.161 2.92E-04
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SPI1  transcription regulator Activated 2.424 2.96E-04
troglitazone  chemical drug Inhibited -2.7 2.98E-04
Rar  group   3.10E-04
IL13  cytokine Inhibited -2.371 3.34E-04
CEBPA  transcription regulator  0.927 4.59E-04
NCOR-LXR-Oxysterol-
RXR-9 cis RA
 complex  0 4.74E-04
RXRG -0.502 ligand-dependent 
nuclear receptor
  4.74E-04
VDR  transcription regulator  0.231 4.75E-04
guanidinopropionic acid  chemical - endogenous 
non-mammalian
Inhibited -3.29 4.94E-04
PIAS1 0.121 transcription regulator  -1.604 5.28E-04
KLF11  transcription regulator  -1.934 5.28E-04
IGF1R -0.032 transmembrane receptor Inhibited -3.192 5.29E-04
Insulin  group  -0.498 5.61E-04
oleic acid  chemical - endogenous 
mammalian
 -0.598 5.87E-04
NOTCH1  transcription regulator  -1.525 6.30E-04
FABP1  transporter  0.655 6.45E-04
galactosylceramide-alpha  chemical reagent  0.152 6.45E-04
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Supplementary Table S6.5 – Top 50 genes across 8 datasets. Q-value is for the p-value derived using Fisher’s 
method, corrected using Benjamini-Hochberg False Discovery Rate. Ranking based on Q-value. 
Gene
ULLS 
(21 days)
Bed Rest 
(9 days)
Bed Rest 
(7 days)
KI 
(7 days)
Prot. Def. 
(7 days)
KI 
(2 days)
ULLS 
(2 days)
ULLS 
(1 day) Q-value
CHRNA1 0.000 0.005 0.000 0.023 0.000 0.005 0.003 0.002 0.000
COL4A3 0.001 0.005 0.619 0.001 0.841 0.000 0.000 0.004 0.000
CALM1 0.002 0.001 0.001 0.000 0.756 0.002 0.033 0.026 0.000
COL4A4 0.006 0.001 0.776 0.004 0.775 0.042 0.000 0.000 0.000
PAQR9 0.000 0.000 0.000 0.716 0.778 0.002 0.000 0.000
COQ10A 0.000 0.000 0.005 0.000 0.068 0.111 0.005 0.000
COQ3 0.004 0.000 0.008 0.070 0.002 0.237 0.030 0.001 0.000
LSMEM2 0.008 0.000 0.003 0.006 0.001 0.130 0.015 0.000
ALPK3 0.001 0.006 0.001 0.046 0.003 0.678 0.002 0.015 0.000
GLRX 0.008 0.001 0.001 0.001 0.656 0.075 0.045 0.006 0.000
TSPAN8 0.241 0.008 0.876 0.141 0.001 0.000 0.001 0.001 0.000
MEGF10 0.002 0.002 0.001 0.002 0.003 0.076 0.579 0.000
RASL12 0.005 0.005 0.001 0.002 0.127 0.693 0.020 0.003 0.000
CNNM4 0.000 0.000 0.000 0.095 0.008 0.027 0.108 0.019 0.000
CDC42EP3 0.000 0.000 0.009 0.000 0.011 0.040 0.023 0.256 0.000
TFRC 0.000 0.854 0.019 0.000 0.010 0.002 0.000 0.209 0.000
CHRND 0.000 0.000 0.000 0.366 0.095 0.062 0.301 0.003 0.000
XPO4 0.000 0.001 0.000 0.025 0.720 0.008 0.060 0.104 0.000
TWF2 0.000 0.000 0.000 0.317 0.050 0.001 0.338 0.080 0.000
SMCO1 0.000 0.007 0.000 0.053 0.011 0.002 0.000
ACSS1 0.000 0.000 0.000 0.656 0.527 0.074 0.005 0.000
SLC7A6 0.008 0.033 0.090 0.000 0.108 0.000 0.010 0.014 0.000
CA14 0.000 0.000 0.010 0.008 0.881 0.109 0.275 0.189 0.000
PPIF 0.000 0.001 0.000 0.001 0.079 0.020 0.553 0.786 0.000
SLC16A10 0.007 0.055 0.315 0.001 0.154 0.002 0.014 0.000 0.000
TP53INP2 0.004 0.001 0.012 0.170 0.344 0.000 0.000 0.000
RORA 0.001 0.008 0.344 0.000 0.120 0.036 0.008 0.025 0.000
LPL 0.000 0.002 0.000 0.823 0.042 0.006 0.576 0.190 0.000
DCXR 0.001 0.000 0.000 0.396 0.001 0.694 0.876 0.156 0.000
HINT2 0.000 0.000 0.000 0.199 0.188 0.802 0.002 0.000
ITGB1BP2 0.000 0.001 0.283 0.003 0.016 0.043 0.199 0.005 0.000
FAM210A 0.005 0.001 0.003 0.036 0.023 0.008 0.034 0.000
KLHL40 0.002 0.002 0.321 0.001 0.000 0.117 0.354 0.000
C1orf54 0.271 0.734 0.051 0.032 0.004 0.009 0.000 0.007 0.000
TYRP1 0.005 0.000 0.000 0.044 0.330 0.225 0.058 0.010 0.000
ANKRD12 0.118 0.035 0.145 0.000 0.979 0.010 0.007 0.000 0.000
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ZFC3H1 0.127 0.078 0.018 0.009 0.802 0.000 0.001 0.004 0.000
MYADML2 0.002 0.001 0.004 0.003 0.079 0.038 0.000
GOT1 0.002 0.000 0.002 0.006 0.247 0.191 0.261 0.109 0.000
PERM1 0.001 0.006 0.003 0.061 0.283 0.010 0.004 0.000
BCO2 0.002 0.002 0.002 0.058 0.947 0.033 0.001 0.000
DHTKD1 0.001 0.001 0.003 0.185 0.020 0.004 0.069 0.772 0.000
MRPL12 0.002 0.001 0.003 0.001 0.062 0.131 0.421 0.092 0.000
PFKFB3 0.016 0.067 0.274 0.002 0.108 0.002 0.008 0.002 0.000
CCDC39 0.002 0.008 0.000 0.007 0.407 0.078 0.208 0.000
PPP1R1C 0.005 0.008 0.000 0.531 0.036 0.021 0.005 0.000
DLST 0.005 0.001 0.003 0.208 0.107 0.139 0.005 0.014 0.000
TACO1 0.002 0.002 0.006 0.101 0.081 0.088 0.132 0.003 0.000
MRPL34 0.010 0.003 0.012 0.220 0.004 0.007 0.113 0.042 0.000
COL1A1 0.001 0.064 0.009 0.327 0.004 0.002 0.015 0.644 0.000
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Prolonged lifespan and decreased fertility will lead to an increased proportion of older adults 
in the world population (population aging). An important strategy to deal with population 
aging has been to promote healthy aging; not only to prevent mounting health care costs, 
but also to maintain independence and quality of life of older populations for as long as 
possible. Close to the opposite of the healthy aging is frailty. A major component of (physical) 
frailty is sarcopenia: age-related loss of muscle mass. Decreased muscle size and strength 
has been associated with a wide variety of negative health outcomes, including increased 
risk of hospitalization, physical disability and even death. Therefore, maintaining muscle size 
and strength is very important for healthy aging. Nutrition and physical activity are possible 
strategies to maintain or even improve muscle function with age. 
 The effect of nutrition, age, frailty and physical activity on the function of skeletal 
muscle is complex. A better understanding of the molecular mechanisms involved can 
provide new insights in potential strategies to maintain muscle function over the life course. 
This thesis aims to investigate these mechanisms and processes that underlie the effects 
of age, frailty and physical activity by leveraging the sensitivity and comprehensiveness of 
transcriptomics and metabolomics.
 Chapter 2 and 3 describe the effects of age, frailty and resistance-type exercise 
training on the skeletal muscle transcriptome and metabolome. Both the transcriptome 
and metabolome show significant differences between frail and healthy older adults. 
These differences are similar to the differneces between healthy young men and healthy 
older adults, suggesting that frailty presents itself as a more pronounced form of aging, 
somewhat independent of chronological age. These age and frailty related differences in 
the transcriptome are partially reversed by resistance-type exercise training, in accordance 
with the observed improvement in muscle strength. Regression analysis revealed that 
the protocadherin gamma gene cluster may be important to skeletal muscle function. 
Protocadherin gamma is involved in axon guidance and may be upregulated due to the 
denervation-reinnervation cycles observed in skeletal muscle of older individuals. The 
metabolome suggested that resistance-type exercise training led to a decrease in branched-
chain amino acid oxidation, as shown by a decrease in amino acid derived carnitines. Lastly, 
the blood metabolome showed little agreement with the metabolome in skeletal muscle, 
indicating that blood is a poor read-out of muscle metabolism. 
 We assessed the effect of knee immobilization with creatine supplementation 
or placebo on the skeletal muscle transcriptome and metabolome in chapter 4. Knee 
immobilization caused muscle mass loss and strength loss in all participants, with no 
differences between creatine and placebo groups. Knee immobilization appeared to induce 
the HDAC4-myogenin axis, which is primarily associated with denervation and motor neuron 
diseases. The metabolome showed changes consistent with the decreased expression 
of energy metabolism genes. While acyl-carnitine levels tended to decrease with knee 
immobilization, one branched-chain amino acid-derived acyl carnitine was increased after 
knee immobilization, suggesting increased amino acid oxidation. 
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 Vitamin D deficiency is common among older adults and has been linked to muscle 
weakness. Vitamin D supplementation has been proposed as a strategy to improve muscle 
function among older populations. In chapter 5, supplementation with vitamin D (calcifediol, 
25(OH)D) is investigated as nutritional strategy to improve muscle function among frail older 
adults. However, we observed no effect of vitamin D on the muscle transcriptome. These 
findings indicate the effects of vitamin D supplementation on skeletal muscle may be either 
absent, weak, or limited to a small subset of muscle cells. 
 Transcriptomic changes due to different forms of muscle disuse are compared 
in chapter 6 (primarily knee immobilization and bed rest). The goal was to determine the 
similarities and differences among various causes of muscle atrophy in humans (primarily 
muscle disuse). Both knee immobilization and bed rest led to significant changes in the muscle 
transcriptome. However, the overlap in significantly changed genes was relatively small. 
Knee immobilization was characterized by ubiquitin-mediated proteolysis and induction of 
the HDAC4/Myogenin axis, whereas bed rest revealed increased expression of genes of the 
immune system and increased expression of lysosomal genes. Knee immobilization showed 
the highest similarity with age and frailty-related transcriptomic changes. This finding 
suggests that knee immobilization may be the most suitable form of disuse atrophy to assess 
the effectiveness of strategies to prevent age-related muscle loss in humans.
 The transcriptome and metabolome are incredibly useful tools in describing the 
wide array of biological systems within skeletal muscle. These systems can be modulated 
using physical activity (or lack thereof) as well as nutrition. This thesis describes some of 
these processes and highlights several unexplored genes and metabolites that may be 
important for maintaining or even optimizing muscle function. In the future, it may be 
possible to optimize both exercise and nutrition for each individual using these techniques; 
or even better, cheaper and less invasive alternatives.
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of Groningen. After a year in Groningen, Roland moved to Wageningen in 2006 to study 
Voeding & Gezondheid, a Bachelor course that was more catered to his increased interest 
in nutrition. The highlight of his bachelor was his literature review of Fat Loss Supplements, 
which introduced Roland to the joy scientific writing. 
 In 2010, his beard becoming a more frequent presence on his cheeks, he chose 
to continue his studies in Wageningen with a master in Nutrition and Health with the 
specialization, Molecular Nutrition and Toxicology. He also broadened his horizon by 
following a minor in Marketing & Management and qualifying as a fitness instructor. In 2013 
Roland received the Diploma in Sports Nutrition from the International Olympic Committee, 
a two year course that he successfully completed alongside his studies in Wageningen. 
 Triggered by the social relevance of research into nutrition and muscle health, 
Roland started his PhD on muscle health and nutrigenomics. For the first time, Roland’s 
beard had become a permanent feature. During his PhD he was able to work on a subject 
with tangible use in society that interested him and allowed him to further develop skills he 
had honed in his free time. A combination that he found both motivating and captivating. 
 After his PhD Roland started work as data scientist at Vitens. He is continuing to 
learn and develop, while working on new big data puzzles. And his beard? His beard will 
continue adorn his visage. 
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Propositions 
 
 
1. Steady state gene expression can be used as a read-out of 
muscle function  
(this thesis) 
 
2. Leg immobilization and bed rest have distinct effects on the 
skeletal muscle transcriptome  
(this thesis) 
 
3. Psychedelic drugs have therapeutic potential in the 
treatment of mental disorders 
 
4. Self-control is not a finite mental resource 
 
5. Computer programming should be a required subject in 
high school 
 
6. Contrary to popular belief, cats prefer social interaction 
over food 
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